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Abstract 
Arsenic trioxide is a clinically effective treatment for the disease acute 
promyelocytic leukaemia (APL) which is caused by the chromosomal translocation 
t(15;17) which fuses the promyelocytic leukaemia (PML) protein to the retinoic 
receptor alpha (RARα). The PML-RARα oncoprotein disrupts normal retinoic acid 
signalling and the function of PML nuclear bodies (PML-NBs), subnuclear protein 
complexes with roles in control of apoptosis and cellular senescence. Treatment with 
arsenic induces rapid post translational modification of PML and with the small 
ubiquitin like modifier (SUMO). SUMO modification of PML recruits the SUMO 
targeted ubiquitin E3 ligase RNF4 via four SUMO interaction motifs within the N-
terminal region of RNF4. PML is then ubiquitylated and targeted for proteasomal 
degradation. In APL, these events trigger degradation of PML-RARα, curing the 
disease. 
To further investigate the process of arsenic induced degradation of PML, a high 
content siRNA screen was designed to monitor the fate of a YFP linked version of PML 
after siRNA mediated knockdown of components of the ubiquitin system and arsenic 
treatment. RNF4 depletion prior to arsenic treatment prevented PML degradation and 
resulted in accumulation of PML in large, bright PML-NBs. This was used as a positive 
control. A library of siRNAs targeting 1067 gene products were screened to identify 
those which perturbed the process of arsenic mediated degradation of PML, and those 
which affected the stability of PML in untreated cells. A number of putative hits were 
identified. Depletion of the cullin RING ligase scaffold CUL3, and the NEDD8 E3 
ligase DCUN1D1 resulted in striking accumulation of PML, suggesting PML may be a 
substrate of a CUL3 RING ligase complex. Further experiments using the inhibitor of 
neddylation, MLN4924 support this hypothesis. 
20 
 
PML is expressed as  various isoforms which encode a unique C-terminal 
region, due to alternative splicing. The second part of this study investigated the role of 
this variable C-terminal region in the response of the six major PML isoforms to arsenic 
treatment. Using a system in which only a single eYFP-linked PML isoform is 
expressed, differences in the localisation of PML isoforms following arsenic treatment 
were identified, with PML I, II and VI found to accumulate in the cytoplasm following 
arsenic treatment, whereas PML III, IV and V did not. A high content imaging assay 
identified PML V as the isoform most readily degraded following arsenic treatment, and 
PML IV as relatively resistant to degradation. Using siRNA it was demonstrated that 
arsenic induced degradation of all PML isoforms is dependent on the ubiquitin E3 ligase 
RNF4. Intriguingly, depletion of RNF4 resulted in marked accumulation of PML V, 
suggesting this isoform is an optimal substrate for RNF4. Thus the variable C-terminal 
domain influences the rate and location of degradation of PML isoforms following 
arsenic treatment. 
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1 Introduction 
1.1 Ubiquitin 
1.1.1 Ubiquitin like proteins 
The founding member of the family of ubiquitin like proteins is ubiquitin itself, 
a 76 amino acid protein which is responsible for the post translational modification of a 
vast array of substrate proteins (Kim et al., 2011). The covalent attachment of ubiquitin 
to a substrate protein, a process named ubiquitylation, is best characterised in the 
targeting of modified proteins for degradation by the 26S proteasome, a large multi-
protein protease responsible for the regulated degradation of ubiquitylated proteins 
(Bedford et al., 2010). 
Ubiquitin has a characteristic three dimensional structure, the β grasp fold, 
which is the hallmark structure of members of the ubiquitin like protein family, though 
the degree of sequence similarity to ubiquitin varies between family members 
(Hochstrasser, 2009). Other ubiquitin like proteins include Small Ubiquitin Like 
Modifier (SUMO), NEDD8, ISG15, FAT10 and ATG8. Like ubiquitin, SUMO is 
conjugated to hundreds of substrate proteins (Golebiowski et al., 2009). Each of these 
ubiquitin like proteins is conjugated to a target protein via a similar pathway, but each 
uses its own specific set of enzymes. 
1.1.2 Ubiquitin conjugation 
Ubiquitin is conjugated to target proteins via an enzymatic cascade involving 
three key enzymes (Figure 1.1.1.). The first step in this process involves the activation 
of the C- terminal glycine motif of ubiquitin by an E1 activating enzyme. Ubiquitin is 
then conjugated to a cysteine residue in an E2 conjugating enzyme via a thioester bond, 
22 
 
thus the E2 enzyme is ‘charged’ with ubiquitin. The charged E2 is subsequently bound 
by an E3 ligase enzyme, which also binds the target substrate, and ubiquitin is 
covalently linked to an amino group, most commonly the ε- amino group of a  target 
lysine residue, in the substrate via an isopeptide bond. In humans, there are two 
ubiquitin E1 enzymes, approximately 30 E2 enzymes and more than 600 E3 ligases 
(Komander, 2009). There are two main classes of E3 enzyme: RING (Really Interesting 
New Gene) domain containing, and those with a HECT (Homologues to E6-AP C-
terminus) domain. The mechanism of catalysis of ubiquitylation differs for the two 
classes of enzyme. E3 ligases with a HECT domain form a covalent intermediate with 
ubiquitin, whereas those with a RING domain catalyse the direct transfer of ubiquitin 
from the charged E2 enzyme to substrate. 
 
Figure 1.1.1. Ubiquitin conjugation cascade 
Initially, ubiquitin is activated by the formation of a thioester bond between 
ubiquitin and the E1 activating enzyme, a process which is dependent on ATP. 
Ubiquitin is then transferred to an E2 conjugating enzyme. The final step in the 
ubiquitylation cascade is facilitated by a ubiquitin E3 ligase which recruits both 
substrate and ubiquitin charged E2 enzyme, and results in the formation of an 
isopeptide bond between the C- terminus of ubiquitin and the ε-amino group of 
a lysine side chain of the substrate protein. Deubiquitylating enzymes (DUBs) 
reverse this process. 
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1.1.3 Ubiquitin chains 
The manner of ubiquitin modification modulates the effects of this modification 
on the substrate protein. A single ubiquitin molecule may be conjugated to a single 
lysine residue on the substrate protein, a process called monoubiquitylation, or single 
ubiquitin molecules may be conjugated to many lysine residues on the substrate protein: 
multiple monoubiquitylation. Monoubiquitylation is involved various cellular processes 
including endocytosis of membrane receptors (Haglund et al., 2003), the DNA damage 
response and the subcellular localisation of substrate proteins. (Haglund and Dikic, 
2005). Monoubiquitylation may also serve as a starting point for polyubiquitin chain 
formation, with different E2 enzymes catalysing the initial and subsequent 
ubiquitylation events (Rodrigo-Brenni and Morgan, 2007; Windheim et al., 2008). 
Ubiquitin itself has seven lysine residues (Lys6, 11, 27, 29, 33, 48 and 63), each 
of which can be modified with another ubiquitin moiety to form polymeric ubiquitin 
chains. Alternatively, linear ubiquitin chains are formed by the fusion of another 
ubiquitin molecule to the ubiquitin N terminus. The physiological role of some of these 
chain types is better characterised than of others. The most abundant of these are Lys48 
linked chains, which comprise approximately one third of all ubiquitin chains (Xu et al., 
2009). Lys48 linked ubiquitin chains are the best characterised ubiquitin chain, with a 
minimum of four Lys48 linked ubiquitin moieties functioning to target the substrate 
protein for degradation by the 26S proteasome (Thrower et al., 2000). Lys11 chains are 
almost as abundant as Lys48 chains (Xu et al., 2009), and also function as a signal for 
proteasomal degradation (Wickliffe et al., 2011). In contrast, Lys63 chains do not 
function as a signal for degradation. Rather, they have been implicated in endocytosis, 
the DNA damage response and cell signalling (Chen and Sun, 2009).  
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The process of ubiquitylation is reversible, through the action of 
deubiquitylating enzymes (DUBs). There are approximately 90 DUBs encoded by the 
human genome, which are attributed to five different families, classified by their 
protease domains (Ventii and Wilkinson, 2008). The majority are cysteine proteases 
which attack the lysine- glycine isopeptide bonds present in ubiquitylated proteins and 
ubiquitin chains (Sowa et al., 2009). DUBs can counteract the activity of E3 ligases by 
removing ubiquitin from substrates, or by editing ubiquitin chains and are also found at 
the proteasome where they are involved in the recycling of ubiquitin (Ventii and 
Wilkinson, 2008). 
1.2 SUMO 
The Small Ubiquitin like Modifier (SUMO) is a member of the family of 
ubiquitin like proteins, though it shares only 20% sequence identity with ubiquitin 
(Geoffroy and Hay, 2009; Hay, 2005). Like ubiquitin, SUMO is reversibly conjugated 
to ε- amino groups of a lysine residue of a substrate protein. There is one SUMO gene 
expressed in lower eukaryotes but three paralogues in vertebrates, termed SUMO1, 
SUMO2 and SUMO3. All three of these paralogues are expressed as larger, precursor 
molecules which are processed by proteases to reveal the diglycine motif which forms 
the isopeptide link to substrate (Hay, 2005; Melchior et al., 2003). The processed forms 
of SUMO2 and SUMO3 differ by only three amino acids at the N- terminus, and are 
difficult to functionally differentiate, and are therefore often referred to as SUMO2/3. 
SUMO1 shares only 50% sequence identity with SUMO2/3, but the proteins have both 
shared and distinct substrates (Vertegaal et al., 2006). There is redundancy between 
SUMO1 and SUMO2/3, because SUMO1 deficient mice are viable (Evdokimov et al., 
2008; Zhang et al., 2008), but mice deficient in the SUMO conjugating enzyme UBC9 
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are not (Nacerddine et al., 2005), suggesting SUMO2/3 can take over at least some of 
the functions of the absent SUMO1.  
SUMO modification has been implicated in the control of many cellular 
functions, including control of gene expression, maintenance of genome integrity, 
protein stability and intracellular transport (Hay, 2005; Melchior et al., 2003). More 
recently, SUMO has been characterised as a signal to recruit ubiquitin E3 ligases 
(Lallemand-Breitenbach et al., 2008; Tatham et al., 2008; Yin et al., 2012). Post 
translational modification with SUMO, as for modification with other Ubls, creates 
additional surfaces for protein- protein interactions. 
1.2.1 SUMO conjugation 
The process of SUMO conjugation to a substrate, termed sumoylation, proceeds 
through an enzymatic cascade similar to that for ubiquitin, but using a discrete set of 
enzymes (Hay, 2005). SUMO precursors are first processed to reveal the C terminal 
diglycine motif which is subsequently conjugated to the ε- amino group of a target 
lysine residue in the substrate protein. There is one SUMO E1 activating enzyme, a 
heterodimer of SAE1 and SAE2 (Desterro et al., 1999). Unlike the ubiquitin system, 
there is only one SUMO E2 enzyme, UBC9 (Desterro et al., 1997), which is often 
capable of transferring SUMO to the substrate in the absence of an E3 ligase, but the 
process is made more efficient in the presence of an E3 ligase (Johnson and Gupta, 
2001; Pichler et al., 2002).  
In general, the lysine residues modified with SUMO lie within a SUMO 
consensus motif, which most commonly consists of the sequence ψ-K-X-E, where ψ is a 
bulky hydrophobic residue, and X is any residue (Matic et al., 2010; Rodriguez et al., 
2001). This consensus motif is recognised by UBC9, with residues within the motif 
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stabilising the interaction between UBC9 and substrate, thus facilitating sumoylation 
(Bernier-Villamor et al., 2002). 
Like ubiquitylation, modification with SUMO can take several forms: a single 
SUMO molecule may be conjugated to a single lysine residue, or to multiple lysine 
residues within the same substrate proteins. Polymeric SUMO chains may be formed 
because SUMO2 and SUMO3 encode a SUMO consensus motif within the flexible N- 
terminal region, and can therefore be modified with further SUMO moieties to form 
SUMO2/3 chains (Tatham et al., 2001). Though SUMO1 lacks the SUMO consensus 
motif, there is evidence it can also be incorporated into polymeric SUMO chains, 
probably as a chain terminator (Matic et al., 2008).  
SUMO modification is a dynamic, reversible process, which is modified by the 
action of six SUMO specific cysteine proteases, SENP1, 2, 3, 5, 6 and 7 (Hay, 2007; 
Melchior et al., 2003). SENPs function at different stages of SUMO conjugation. Prior 
to conjugation, SENPs use C- terminal hydrolase activity to process precursor SUMO 
molecules, revealing the C- terminal diglycine motif required for conjugation to 
substrate. Following SUMO conjugation, SENPs can modify the process in two ways. 
Firstly, SENP activity can edit polymeric SUMO chains by removing SUMO molecules 
from the chain.  Secondly, SUMO specific protease activity can function to deconjugate 
SUMO from the substrate (Gareau and Lima, 2010; Hay, 2007; Melchior et al., 2003). 
The different SENP family members exhibit differences in SUMO paralogue 
specificity, subcellular localisation and response to cell stress, and thus regulate the 
modification of discrete substrates (Gareau and Lima, 2010; Hay, 2007; Melchior et al., 
2003).  
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1.2.2 SUMO interaction motif 
In addition to covalent modification of substrate proteins with SUMO, non- 
covalent protein- SUMO interactions may be mediated by a SUMO interaction motif 
(SIM). SIMs consist of a stretch of four hydrophobic residues, (V/I/L)-X-(V/I/L)-
(V/I/L), often flanked by acidic residues, and insert into a hydrophobic groove on 
SUMO (Hecker et al., 2006; Song et al., 2005). Many proteins have been demonstrated 
to have SIMs, for example promyelocytic leukaemia protein (PML) and other PML 
body constituents such as DAXX and SP100, and enzymes of the SUMO conjugation 
pathway (Kerscher, 2007). The class of SUMO targeted ubiquitin E3 ligases (STUbLs) 
contain a number of SIM domains as well as a RING domain, and are thus recruited to 
SUMO modified proteins, which are then ubiquitylated (Geoffroy and Hay, 2009). 
SIMs therefore serve to recruit effector proteins to SUMO modified substrates, and thus 
mediate the effects of SUMO modification.  
1.3 PML 
The promyelocytic leukaemia protein (PML) was first identified in the disease 
Acute Promyelocytic Leukaemia (APL), in which it is fused to the retinoic acid receptor 
alpha (RARα) (De The et al., 1991; Kakizuka et al., 1991). PML is a member of the 
tripartite motif (TRIM) family of proteins, and as such contains three cysteine rich zinc 
binding domains, a RING and two B Boxes, and a coiled- coil domain at its N- terminus 
(Jensen et al., 2001b). The coiled- coil domain mediates protein- protein interactions, 
and in the case of PML facilitates homodimerisation of PML and heterodimerisation of 
PML with PML-RARα in APL (Kastner et al., 1992). PML is predominantly a nuclear 
protein which localises to punctate nuclear structures called PML nuclear bodies (PML-
NBs) (Bernardi and Pandolfi, 2007). The molecular function of PML remains poorly 
understood, though it has been implicated in a many biological processes including the 
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control of apoptosis, response to viral infection and regulation of transcription (Bernardi 
and Pandolfi, 2007) 
1.3.1 PML Isoforms 
The PML gene consists of nine exons, which undergoes alternative splicing, 
resulting in the expression of six major nuclear PML isoforms, and one cytoplasmic 
isoform (Jensen et al., 2001b). Each of the nuclear isoforms share a common N- 
terminus, encoded by exons 1-6, but differ at the C- terminus due to the expression of 
various combinations of exons 7-9 (Figure 1.3.1., panel A). The TRIM motif is 
encoded within the common N- terminus (Figure 1.3.1., panel B), as is a nuclear 
localisation signal encoded within exon 6, which suggests that any functions related to 
these elements should be common to all isoforms, with isoform specific interactions or 
functions dependent on the varying C- terminal region. 
1.3.2 PML and SUMO modification 
PML was one of the first identified SUMO substrates (Boddy et al., 1996), and 
was further characterised to have three sumoylation sites: Lys65, Lys160 and Lys490 
(Kamitani et al., 1998). Each of these sumoylation sites lies within the common N- 
terminal region of all the PML isoforms (Figure 1.3.1., panel B), and two, Lys160 and 
Lys490, lie within SUMO consensus motifs. In addition to these sites of covalent PML- 
SUMO modification, exon 7a of the primary PML transcript encodes a SUMO 
interaction motif (Shen et al., 2006). PML isoforms I-V therefore contain a SIM 
enabling non- covalent PML- SUMO interactions, whereas PML VI does not. 
29 
 
 
Figure 1.3.1. The exon assembly of PML (Adapted from Jensen et al., 
2001) 
A. Schematic representation of the exon structure of the six nuclear PML 
isoforms. All isoforms encode exons 1-6, but alternative splicing of exons 7-9 
result in varying C-termini as shown. The length of each isoform is shown on 
the right. Asterisk indicates a retained intron.  
B. All components of the PML TRIM are encoded within exons 1-6: RING 
domain (R), B Boxes 1 and 2 (B1 and B2) and the coiled coil motif (CC). The 
nuclear localisation signal (NLS) is also encoded by all six isoforms. 
Sumoylation sites are found at Lys65 within the RING domain, Lys160 in B box 
1 and Lys490 in the nuclear localisation signal.   
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There is some evidence to suggest that PML itself may function as a SUMO E3 
ligase: PML has a RING domain, and expression of human PML in yeast stimulates 
SUMO conjugation, a process dependent on its RING domain, suggesting that the 
RING has SUMO E3 ligase activity (Quimby et al., 2006); the RING domain of PML 
has been demonstrated to interact with the SUMO E2 conjugating enzyme UBC9 
(Duprez et al., 1999); PML was also noted to enhance SUMO modification of the 
known SUMO substrates p53 and MDM2, primarily using mammalian overexpression 
systems, a process again noted to be dependent on its RING domain (Chu and Yang, 
2011).  
1.3.3 PML nuclear bodies 
PML nuclear bodies are discrete nuclear foci (Figure 1.3.2), of approximately 
0.2-1µm in diameter which are present in mammalian cells, and represent multiprotein 
complexes. Typically, there are between 1 and 20 PML-NBs per nucleus (Bernardi and 
Pandolfi, 2007; Salomoni and Pandolfi, 2002), but this varies under different cellular 
conditions. PML is required for the formation of PML nuclear bodies, because in cells 
derived from PML-/- mice, PML-NBs do not form (Ishov et al., 1999). Moreover, 
SUMO modification of PML is required for formation of mature PML bodies (Ishov et 
al., 1999; Lallemand-Breitenbach et al., 2001), as is the SIM domain present in exon 7a 
(Shen et al., 2006), indicating that both covalent and non covalent PML-SUMO 
interactions are required to form PML-NBs. Many other proteins are associated with 
PML-NBs, either constitutively or transiently, and many of these proteins are SUMO 
substrates. DAXX and SP100 are two well characterised PML-NB associating proteins. 
Both are SUMO substrates and contain SIM domains (Jang et al., 2002; Knipscheer et 
al., 2008; Lin et al., 2006; Sternsdorf et al., 1997). These observations regarding the 
requirement for SUMO modification of PML from PML-NB formation, the presence of 
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multiple other sumoylated proteins at PML-NBs, and the potential for PML to function 
as SUMO E3 ligase discussed above have led to a hypothesis that PML-NBs may 
function as sites of protein sumoylation, possibly through the action of PML as a 
SUMO E3 ligase. Alternatively, PML-NBs may act as ‘depots’ for SUMO modified 
proteins (Bernardi and Pandolfi, 2007). 
 
Figure 1.3.2. PML nuclear bodies are punctate nuclear structures 
HeLa cells were fixed and immunolabelled with antibodies specific for PML and 
SUMO1, and appropriate fluorescently labelled secondary antibodies. DNA 
was stained with DAPI. PML is shown in green, SUMO1 in red and DAPI in 
blue. The top image shows four PML nuclear bodies (PML-NBs) in a cell 
nucleus; the lower panels are magnified images of the PML-NB indicated. 
Images represent maximal intensity projections of multiple z sections. 
 
 
1.3.3.1 Cell cycle variation  
As cells progress through S phase, the number of PML bodies increases 
(Dellaire et al., 2006a), but the most striking changes are seen when cells enter mitosis, 
when PML accumulates in fewer, larger aggregates termed MAPPs ( mitotic 
accumulations of PML protein), which lack normal PML-NB components (Dellaire et 
al., 2006b; Everett et al., 1999). The formation of MAPPs coincides with a decrease in 
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sumoylation of PML, suggesting that cell cycle related regulation of SUMO 
modification of PML plays a role in the control of PML body formation, and therefore 
potentially PML-NB function throughout the cell cycle. The PML contained in MAPPs 
is then recycled from the cytoplasm into PML-NBs during G1 (Dellaire et al., 2006b). 
1.3.3.2 Antiviral response 
PML transcription is increased in response to interferon which leads to a marked 
increase in the number and size of PML bodies (Bernardi and Pandolfi, 2007; Everett 
and Chelbi-Alix, 2007), implicating PML-NBs in host antiviral defence. Indeed, some 
viruses target PML and PML-NB components to subvert their anti- viral effects: PML 
depletion increases Herpes simplex virus 1 (HSV-1) infection efficiency (Everett et al., 
2006) and HSV-1 expresses a SUMO targeting ubiquitin E3 ligase which targets SUMO 
modified PML for degradation (Boutell et al., 2011). Interestingly, a study of the role of 
the individual PML isoforms in restriction of HSV-1 replication demonstrated though 
expression of PML I or PML II partially reverses the increase in HSV-1 replication 
observed in PML depleted cells, no individual isoform completely rescued the 
phenotype (Cuchet et al., 2011). This suggests that PML-NBs comprised of all PML 
isoforms are required for the antiviral response. 
1.3.3.3 Apoptosis control 
The study of PML-/- mice suggests a role for PML in tumour suppression. PML-/- 
cells grow faster than control cells (Gang Wang et al., 1998), whereas PML 
overexpression slows cell growth (Koken et al., 1995). PML-/- mice were more 
susceptible to tumours, in particular lymphomas (Gang Wang et al., 1998). PML 
expression is often lost in human cancers, and its loss correlates with tumour 
progression, again supporting the role of PML as a tumour suppressor (Gurrieri et al., 
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2004).  The response to apoptotic stimuli is altered in PML-/- cells, which are more 
resistant to caspase induced apoptosis than control cells (Wang et al., 1998). PML 
exerts these effects both via interactions with the tumour suppressor p53, and 
independently of p53 (Bernardi and Pandolfi, 2007).   
1.3.3.4 Control of transcription 
PML has been identified as both a transcriptional co activator and a corepressor. 
Many transcription factors localise to PML-NBs, including CREBBP and p300. There is 
some suggestion that PML and PML-NBs may regulate the activity of such 
transcription factors, either by sequestering them within PML-NBs or by controlling 
post translational modification of transcription factors, thus controlling their function 
(Zhong et al., 2000). 
1.3.3.5 Cellular senescence 
Cellular senescence describes the state of irreversible growth arrest which cells 
enter in response to various stimuli, for example DNA damage, oncogenic signalling or 
loss of telomeric integrity. This growth arrest prevents the proliferation of potential 
cancer cells and is therefore a mechanism for tumour suppression (Rodier and Campisi, 
2011). Both PML expression and the number of PML-NBs are increased in response to 
oncogenic ras overexpression, a potent inducer of senescence, and overexpression of 
PML induces senescence via interactions with p53 and Rb (Bischof et al., 2002; 
Ferbeyre et al., 2000). PML triggered senescence promotes localisation of Rb and E2F 
transcription factors to PML-NBs, thus inhibiting the transcriptional activation activities 
of E2F proteins. E2F targets include many genes responsible for cell proliferation,  and 
therefore PML induced suppression of transcription results in cell growth arrest 
(Vernier et al., 2011).  PML-NBs also regulate the formation of senescence associated 
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heterochromatin foci, an important early event in cells approaching senescence (Zhang 
et al., 2005). 
1.4  Acute promyelocytic leukaemia 
Acute promyelocytic leukaemia (APL) is a rare but distinct subtype of acute 
myeloid leukaemia characterised by the accumulation of myeloid progenitor cells, 
promyelocytes, in the bone marrow and peripheral blood, a severe bleeding tendency 
and the balanced t(15;17) chromosomal translocation which results in the fusion of 
PML with the retinoic receptor α (RARα) (Lallemand-Breitenbach et al., 2012; Wang 
and Chen, 2008). The t(15;17) translocation is present in the vast majority of cases of 
APL, but less than 2% have variant chromosomal translocations involving chromosome 
17, the most common being t(11;17) encoding the PLZF-RARα fusion. APL is now an 
eminently curable disease, with approaching 90% of patients achieving cure with 
treatments which target the PML-RARα fusion for degradation: all-trans retinoic acid 
(ATRA) and arsenic trioxide (Ablain and de The, 2011; de Thé and Chen, 2010). 
Sequential monitoring of patient bone marrow or peripheral blood samples for PML-
RARα transcripts by RT-qPCR allows both assessment of treatment response and early 
identification of patients undergoing disease relapse, and enables reinstitution of anti-
leukaemia therapy prior to frank relapse (Grimwade et al., 2009). 
1.4.1 Pathogenesis of APL 
The t(15;17) translocation and formation of PML-RARα fusion is the causative 
genetic lesion in APL, because expression of PML-RARα in mouse myeloid precursors 
causes development of a disease which closely resembles APL (Brown et al., 1997; 
Grisolano et al., 1997; He et al., 1997; Westervelt et al., 2003). Variation in the 
breakpoint in the PML gene leads to the formation of one of three PML-RARα isoforms 
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(Figure 1.4.1.): bcr1, the commonest, long isoform with the PML breakpoint within 
intron 6; bcr2, the variant isoform, with the breakpoint in exon 6; and bcr3, the short 
isoform with the breakpoint in PML intron 3 (Melo et al., 2006). The RARα breakpoint 
is consistently in intron 2, leading to the fusion of exons 3-9 to PML. The resulting 
PML-RARα isoforms therefore encode all components of the PML TRIM, of which the 
coiled- coil domain has been shown to be essential for the transforming potential of 
PML-RARα, allowing both PML-RARα homodimerisation and interaction of PML-
RARα with PML (Occhionorelli et al., 2011).  PML-RARα also encodes the functional 
elements of RARα, including the DNA binding, hormone binding and RXR binding 
domains. APL incidence is increased in patients previously treated with the 
topoisomerase II targeting agents etoposide, mitoxantrone and epirubicin for diseases 
such as multiple sclerosis and breast cancer. Interestingly, these agents predispose to 
specific breakpoint hot spots within both the PML and RARα genes, which correspond 
to regions of DNA preferentially cleaved by the DNA damaging agents in vitro (Hasan 
et al., 2008; Mays et al., 2010; Mistry et al., 2005).  
Under normal circumstances, RARα interacts with RXR to act as a retinoic acid 
responsive transcription factor. PML-RARα forms heterotetramers with RXR, which 
bind RARα-RXR targets as well as DNA sequences not usually targeted by RARα-RXR 
complexes, leading to widespread deregulation of transcription (Martens et al., 2010). 
This deregulation of transcription leads to the block in myeloid progenitor 
differentiation demonstrated by the accumulation of promyelocytes, and also to 
increased self renewal properties (de Thé and Chen, 2010).  
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Figure 1.4.1. PML-RARα isoforms  
The chromosomal translocation t(15;17) results in fusion of PML and RARα. 
Different breakpoints in chromosome 15 result in three PML-RARα isoforms, 
indicated by arrowheads. The breakpoint in bcr1 is within PML intron 6, bcr2 
within exon 6 and bcr3 within intron 3. The breakpoint in chromosome 17 is 
invariably in RARα intron 2, thus all PML-RARα isoforms encode RARα exons 
3-9. 
 
PML-RARα also interferes with the normal functions of PML. PML-NBs are 
disrupted in APL due to PML- PML-RARα interactions, and are observed as 
characteristic nuclear speckles rather than punctate PML-NBs when assessed by 
immunofluorescence (de Thé and Chen, 2010; de The et al., 2012; Koken, 1994). This 
disrupts PML pro-apoptotic functions in leukaemic cells, leading to enhanced survival. 
1.4.2 Treatment of APL 
APL is an excellent example of a disease with molecularly targeted treatments.  
Initial treatment with conventional chemotherapeutic agents such as anthracyclines was 
complicated by the severe bleeding tendency conferred by APL cell overexpression of 
activators of coagulation and fibrinolysis (Breen et al., 2012), and cure rates were in the 
range of 35-45% (Wang and Chen, 2008). The identification of all trans retinoic acid 
(ATRA) as an agent which stimulated differentiation of leukaemic promyelocytes was a 
major breakthrough in the treatment of APL, and its use in combination with 
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conventional chemotherapy increased survival rates to approaching 90% (Wang and 
Chen, 2008). 
PML-RARα is insensitive to physiological levels of retinoic acid which would 
normally stimulate dissociation of RARα-RXR co-repressor complexes and the 
recruitment of co-activator complexes. However, treatment with pharmacological 
concentrations of ATRA leads to proteasomal degradation of PML-RARα, allowing 
release of PML-RARα induced transcriptional repression, with a marked increase in 
histone acetylation observed at PML-RARα binding sites after ATRA treatment 
(Martens et al., 2010). This leads to activation of genes required for myeloid 
differentiation, and induces differentiation of leukaemic cells (de Thé and Chen, 2010).  
ATRA induced degradation of PML-RARα also abolishes PML-RARα interactions with 
PML and allows the reformation of normal PML-NBs (de The et al., 2012). It seems 
ATRA induced differentiation alone is insufficient for cure of APL, because despite 
complete differentiation, cure of leukaemia is rarely observed in the absence of other 
chemotherapeutic agents, or arsenic trioxide therapy (Ablain and de The, 2011). 
 Arsenic trioxide was first identified as an active agent in the treatment of APL 
through its use in traditional Chinese medicine, and is probably the single most active 
agent in treating the disease (Chen et al., 2011). Its clinical efficacy in APL was first 
reported in the 1990s, with striking response rates even in patients refractory to 
treatment with ATRA and chemotherapy (Shen et al., 1997). It is administered 
intravenously, and is well tolerated in the majority of patients, with little in the way of 
myelosuppression, or other toxicities (Chen et al., 2011). Arsenic induces degradation 
of PML-RARα by targeting the PML moiety for proteasomal degradation, the 
mechanism of which will be discussed in detail below. Having confirmed the efficacy 
of arsenic trioxide in the treatment of relapsed APL, clinical trials are now addressing 
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the role of arsenic treatment in newly diagnosed APL, and indeed assessing treatment 
regimens consisting of only ATRA and arsenic, thus abrogating the side effects of 
conventional chemotherapeutic agents (Lengfelder et al., 2012).  
1.5 Mechanism of arsenic induced degradation of PML 
Studies using the APL derived NB4 cell line (Lanotte et al., 1991) which 
expresses PML-RARα, as well as engineered mammalian cells have delineated the early 
effects of arsenic treatment on PML and PML-RARα. Shortly after arsenic treatment, 
PML is redistributed from the nucleoplasm to PML-NBs (Geoffroy et al., 2010; Zhu et 
al., 1997). PML is also rapidly sumoylated after arsenic treatment (Lallemand-
Breitenbach et al., 2001), though recruitment of PML to PML-NBs is not SUMO 
dependent, because PML mutants which cannot be sumoylated are also redistributed to 
PML-NBs after arsenic treatment (Lallemand-Breitenbach et al., 2001). This may 
however be due to interaction of these mutants with SUMO modified PML-NB 
components.  SUMO modification of PML is essential for the process of arsenic 
mediated degradation: mutational analyses demonstrate that sumoylation of PML 
Lys160 is required for degradation to take place (Lallemand-Breitenbach et al., 2001). 
Two recent studies have investigated the mechanism of PML targeting to PML-
NBs, and suggest that both direct arsenic binding and arsenic induced oxidative stress 
induce crosslinking of PML molecules which are targeted to PML-NBs (Jeanne et al., 
2010; Zhang et al., 2010). Zhang and colleagues have demonstrated that the organic 
arsenical ReAsh, which fluoresces when bound to a tetracysteine motif, labels PML 
bodies, implying that arsenic binds directly to PML or another PML body component 
via cysteine residues. Using deletion mutants, ReAsH fluorescence at PML-NBs is 
demonstrated to be dependent on the RING domain and B2 domain of the PML TRIM, 
both of which are cysteine rich, zinc binding domains. The authors propose direct 
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binding of arsenic to these cysteine rich domains results in multimerisation of PML. 
Using a variety of techniques, for example nuclear magnetic resonance and circular 
dichroism, to examine the effects of arsenic on the secondary structure of a zinc 
depleted, isolated RING domain of PML, the authors conclude that arsenic binds 
directly to the PML RING in place of zinc atoms, and that this binding promotes 
multimerisation of PML and PML-RARα which in turn promotes SUMO modification. 
Zinc atoms stabilise the structure of the RING domain (Zheng et al., 2000), and these 
experiments may therefore be confounded by misfolding and subsequent aggregation of 
the zinc depleted PML RING, which may mimic multimerisation.  
The second paper, by Jeanne and colleagues focusses on the role of PML 
oxidation in its targeting to PML-NBs. It is demonstrated PML accumulates in nuclear 
matrix associated, high molecular weight species under non- reducing conditions 
following arsenic treatment, and that the addition of the reducing agent DTT abrogates 
this multimerisation, implicating the formation of intermolecular disulfide bridges in the 
targeting of PML to the nuclear matrix. The direct binding of arsenic and PML is 
demonstrated using similar techniques to Zheng et al, but a dicysteine motif within the 
PML B2 domain is implicated as the site of binding. PML mutants in which one of 
these cysteine residues are mutated, C212 or C213, demonstrate decreased arsenic 
binding, decreased sumoylation under basal conditions, are predominantly 
nucleoplasmic and fail to form normal PML-NBs. Following arsenic treatment, these 
mutants are not sumoylated and are not degraded. Since these mutants fail to form 
normal PML-NBs under basal conditions and are not targeted to PML-NBs after arsenic 
treatment, the mutation of these cysteine residues themselves are likely to interfere with 
PML sumoylation in response to arsenic which takes place at PML-NBs, regardless of 
whether or not the cysteine residues directly bind arsenic.  
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The SUMO E3 ligase responsible for PML sumoylation triggered by arsenic 
therapy is yet to be confirmed. A single study reports the SUMO E3 ligase PIAS1 to be 
required for arsenic mediated degradation of PML (Rabellino et al., 2012).  shRNA 
mediated depletion of PIAS1 impaired degradation of PML-RARα in NB4 cells, 
whereas overexpression of PIAS1 plus SUMO1 or 2 enhanced arsenic induced 
degradation of overexpressed PML-RARα in HEK293T cells. The overexpression 
experiments were performed using a system in which both PIAS1 and SUMO were 
overexpressed, Further confirmation of these findings is required. Given the evidence 
that PML itself may have SUMO E3 ligase function, another possibility is that arsenic 
activates autosumoylation activity of PML (Chu and Yang, 2011; Quimby et al., 2006). 
Alternatively, arsenic induced inhibition of SUMO proteases, for example SENP6 of 
which PML is a substrate (Hattersley et al., 2011), could result in the increased 
sumoylation of PML observed after arsenic treatment.  
1.5.1 The role of RNF4 
Ring finger protein 4 (RNF4) is a ubiquitin E3 ligase which encodes four SUMO 
interaction motifs in its N-terminal region, and a C-terminal RING domain, and thus 
targets SUMO modified proteins for ubiquitylation (Tatham et al., 2008). Arsenic 
treatment of cells depleted of RNF4 results in the accumulation of high molecular 
weight PML species, demonstrating that RNF4 is essential for arsenic mediated 
degradation of PML and PML-RARα (Lallemand-Breitenbach et al., 2008; Tatham et 
al., 2008). Under basal conditions, RNF4 is predominantly distributed in the 
nucleoplasm, but following arsenic treatment it is rapidly recruited to PML-NBs in a 
SUMO dependent manner, because RNF4 mutants lacking the N- terminal SIM 
domains do not relocalise to PML-NBs following arsenic treatment (Geoffroy et al., 
2010), nor does wild type RNF4 colocalise with PML mutants which cannot be 
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sumoylated following arsenic treatment (Lallemand-Breitenbach et al., 2008). Indeed, 
PML modified with polymeric SUMO2 chains, but not unmodified PML is efficiently 
ubiquitylated by RNF4 in vitro (Tatham et al., 2008). These data demonstrate that 
sumoylation of PML in response to arsenic treatment recruits RNF4 to PML-NBs, 
where it subsequently ubiquitylates PML, targeting it for proteasomal degradation 
(Figure 1.5.1.) (Lallemand-Breitenbach et al., 2008; Tatham et al., 2008). It is 
established that inhibition of the proteasome prevents arsenic induced degradation of 
PML (Lallemand-Breitenbach et al., 2001). PML accumulates in PML bodies following 
combined arsenic treatment and proteasome inhibition, and after RNF4 depletion 
followed by arsenic treatment, suggesting that arsenic induced PML degradation by the 
proteasome takes place in PML-NBs (Geoffroy et al., 2010; Lallemand-Breitenbach et 
al., 2008; Tatham et al., 2008).  In the case of APL, the PML-RARα oncoprotein is 
degraded via the same, SUMO dependent, ubiquitin mediated proteolytic pathway as 
PML, leading to cure of the disease. 
 
Figure 1.5.1. A model of the role of RNF4 
Following arsenic treatment, PML is modified with polymeric SUMO chains 
which recruit RNF4 via its SIM domains. RNF4 then ubiquitylates the SUMO 
chains, targeting PML for degradation by the proteasome. 
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1.5.2 Resistance to arsenic therapy 
The vast majority of patients who receive arsenic trioxide as a first line 
treatment reach a complete remission (Ghavamzadeh et al., 2011; Ravandi et al., 2009). 
There are therefore few reports detailing investigation of the mechanism of resistance to 
therapy. One report details the investigation of one patient in whom clinical resistance 
developed after prolonged arsenic treatment, and one patient who was primarily 
refractory to arsenic treatment (Goto et al., 2011). Studies revealed missense mutations 
in the B2 domain of the PML moiety of the PML-RARα fusion. Functional studies were 
then performed using PML-RARα constructs containing the two mutations, A216V and 
L218P. These revealed impaired SUMO modification and degradation of PML-RARα 
in the presence of these mutations, and notably both constructs localised to the 
cytoplasm (Goto et al., 2011). The mutated residues are close to the dicysteine motif 
proposed to directly bind arsenic (Jeanne et al., 2010), and it is suggested mutations 
may interfere with this arsenic binding. Alternatively, these mutations may disrupt the 
structure of the B2 domain of PML-RARα, interfering with PML-RARα interactions 
with, for example, the sumoylation machinery.   
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2 Materials and methods 
2.1 DNA and RNA techniques 
2.1.1 Constructs used in this study 
The pGD-EYFP-C1 is a vector for mammalian expression, and was a kind gift 
from Professor Roger Everett, University of Glasgow.  
2.1.2 DNA sequencing 
Plasmid DNA was submitted for sequencing to the DNA Sequencing Service, 
University of Dundee. 
2.1.3 Transformation of competent E coli cells 
50ng of plasmid DNA was added to 50µl of competent DH5α E. coli cells which 
were then incubated on ice for 30 minutes. Cells were then subjected to heatshock at 
42ºC in a water bath for 1 minute 15 seconds. Cells were incubated on ice for a further 3 
minutes and then 1ml of LB medium was added. This cell suspension was incubated at 
37ºC for 1 hour with constant shaking at 220 rpm. 100-900µl of this cell suspension was 
then spread on agar plates with appropriate antibiotic selection and incubated at 37ºC 
overnight.   
2.1.4 Small scale preparation of plasmid DNA (miniprep) 
5ml of LB medium with appropriate antibiotic (ampicillin was used at a final 
concentration of 100µg/ml, kanamycin at a final concentration of 50µg/ml) was 
inoculated with a single colony from an agar plate and incubated overnight at 37ºC with 
constant rotation at 220 rpm. The bacteria were then pelleted by centrifugation at 2800 x 
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g for 10 minutes at room temperature, and plasmid DNA purified from the cell pellet 
using the QIAprep Spin Miniprep Kit (Qiagen) according to manufacturer’s 
instructions. 
2.1.5 RNA preparation 
Mammalian cells were cultured in triplicate wells in 6 well plates. Cells were 
washed once with PBS and lysed using RNA lysis buffer from the SV Total RNA 
Isolation System (Promega). RNA was then extracted from lysates using the SV Total 
RNA Isolation System (Promega) according to manufacturer’s instructions, and stored 
at -80ºC. 
2.1.6 Reverse transcription of RNA 
RNA was prepared as in section 2.1.5 and the concentration determined using a 
NanoVue spectrophotometer (GE Healthcare). 1µg of RNA and 4µl of qScript cDNA 
Supermix (Quanta Biosciences) were added to an eppendorf tube, with the final reaction 
volume made up to 20µl with nuclease free water.  
• Reverse transcription reaction 
25ºC for 5 minutes 
42ºC for 50 minutes 
85ºC for 5 minutes 
Resulting cDNA was diluted 1:4 by the addition of 60µl of nuclease free water 
and stored at -20ºC. 
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2.1.7 RT qPCR 
Triplicate samples were lysed and RNA extracted as described in section 2.1.5, 
and reverse transcribed as described in 2.1.6.  
Specific primer pairs for each gene of interest were designed using Primer3 
software, ordered from MWG Eurofins and reconstituted to a stock concentration of 
100µM. A 2µM, working aliquot of forward and reverse primers was prepared by 
mixing 2µl of forward and reverse primers, with 96µl of nuclease free water.  
Primer tests were performed by creating a 2 fold dilution curve (undiluted, 1/2, 
1/4, 1/8, 1/16, 1/32) of cDNA which was assayed with each of the primer pairs to be 
tested. Duplicate reactions were performed in 96 well plates. The cDNA concentration 
resulting in a threshold cycle of 24 was selected for each primer, and subsequently 
cDNA was diluted by this factor for use with the primers.  
RT qPCR reactions were performed in duplicate. Mastermixes of SYBR green, 
ROX reference dye and primer were prepared for each primer pair to be tested, and 9µl 
of this mix was pipetted into 96 well reaction plates. 6µl of each cDNA, diluted to the 
concentration required for the primer pair was then added. Plates were then sealed and 
centrifuged for 1 minute at 1000rpm before assaying using an ABI7500 real-time PCR 
machine. 
• 1 X RT qPCR reaction  
7.5µl Perfecta SYBR Green Fastmix (Quanta Biosciences) 
0.03 µl ROX reference dye (Invitrogen) 
1.5µl forward/ reverse primer 2µM mix 
6µl cDNA 
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• Reaction protocol 
95ºC for 2 minutes 
95ºC for 10 seconds/ 60ºC for 30 seconds, for 40 cycles 
Dissociation step 
Results were processed using Applied Biosystems sequence detection system 
software and analysed using the ddCT method. Samples transfected with non- targeting 
control siRNA were used as the reference samples, and actin expression as the 
housekeeping gene.  
2.1.7.1 RT qPCR primer sequences (5’→ 3’) 
• PML  F- GGAACATCCTCGGCAGTAGA  
R- AGTCGGTGCGTGAGTTCC 
• RNF4   F- GTGAGCAGTGACGATGA  
R- GGAGGCACTGGCTACAG 
• LZTR1 F- GACCGCCACCTCTATGTGTT 
R- CCAAACACATCTCGGGACTT 
• KCNC1 F- GAGGACGAGCTGGAGATGAC   
R- AAGGTGGTGATGGAGACCAG 
• ABTB2 F- GAGGACAGCTATGCGGAGAC   
R - TGGCTGAAGCAGTTCATGTC 
• ANKFY1 F- GCTCCTCAGGGAGAGATGTG  
R- ATCCTCCTTCCTCAGGTCGT 
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• KLHL25 F- CACAAGGCCAAGGAGATCAT 
R- TACGGTGTCGTACACCCAGA 
• actin  F- CAACTCCATCATGAAGTGTGACG 
R- CAGGGCAGTGATCTCCTTCTG 
2.2 Protein techniques 
2.2.1 SDS-PAGE 
Samples for sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) were separated in NuPAGE Novex Bis-Tris 4-12% gels using MOPS buffer. 
Gels were run at a constant voltage of 150V until adequate separation of proteins was 
achieved (usually 90 minutes). 
2.2.2 Coomassie Blue staining 
After electrophoretic separation, gels were incubated in Coomassie blue staining 
solution for 30 minutes with constant rocking. Gels were then incubated in destaining 
solution I for 1 hour, and destaining solution II overnight. 
• Coomassie blue staining solution 
Coomassie brilliant blue R-250 (1 g) was dissolved in 400 ml of methanol. 
Subsequently, distilled water and 70 ml of acetic acid were added to the final 
volume of 1 litre. The solution was filtered through a filter paper. 
• Destaining solution I 
40% (v/v) methanol 
7% (v/v) acetic acid 
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• Destaining solution II 
5% (v/v) methanol 
7% (v/v) acetic acid 
2.2.3 Western blot analysis 
Proteins were separated by SDS-PAGE and transferred to PVDF membrane 
(Immobilon-P Transfer Membrane, Millipore). Gel- sized pieces of PVDF membrane 
were incubated for 5 minutes in methanol before equilibration for 10 minutes in 
Transfer buffer. A wet transfer was performed using the Mini Trans-Blot Cell (Bio-Rad) 
system, at 25mA overnight, or 300mA for 1.5 hours. 
• Transfer buffer 
 
24 mM Tris 
 
193 mM glycine  
 
20% methanol 
 
 
Following protein transfer, membranes were blocked in 5% Marvel non-fat milk 
powder in PBS/ 0.1% Tween 20 (milk/ PBST) for 30 minutes. Primary antibodies were 
diluted in milk/ PBST and membranes incubated for 2 hours at room temperature, or 
4ºC overnight. Following 3 washes with PBST, membranes were incubated with 
secondary antibodies diluted in milk/ PBST for 1 hour at room temperature. Membranes 
were washed a further 3 times with PBST, twice with PBS and then incubated with ECL 
and exposed to x-ray film.  
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2.2.4 Antibodies used in this study 
• anti PML (chicken polyclonal; raised in house) 1:5000 in milk/PBST for 
western blotting, 1:1000 in BSA/PBST for immunofluorescence 
• anti PML 5E10 (mouse, monoclonal, from Roel van Driel, Amsterdam) 1:20 in 
BSA/PBST for immunofluorescence.  
• anti SUMO 1 (sheep, polyclonal; raised in house) 1:1000 in milk PBST for 
western blotting, 1:100 in BSA/ PBST for immunofluorescence 
• anti SUMO 2 (sheep, polyclonal; raised in house) 1:1000 in milk/ PBST for 
western blotting, 1:100 in BSA/ PBST for immunofluorescence 
• anti SUMO 2 (rabbit, polyclonal; Zymed) 1:2000 in milk/ PBST for western 
blotting 
• anti ubiquitin (rabbit, polyclonal; DAKO) 1:1000 in BSA/ PBST for western 
blotting 
• anti RNF4 (chicken, polyclonal, generated in house) 1:5000 in milk/ PBST for 
western blotting 
• anti RARα 115 (rabbit, polyclonal, gift from Cecily Egly) 1:1000 in milk/ 
PBST for western blotting 
• anti GFP ( mouse, monoclonal, Roche) 1:1000 in BSA/ PBST for western 
blotting 
• anti actin ( mouse, monoclonal; Sigma) used 1:25 000 in milk/ PBST for 
western blotting 
• anti CUL3 (rabbit, polyclonal, kind gift from Matthias Peter, ETH Zurich) 
1:1000-1:2000 in BSA/ PBST for western blotting 
• anti tubulin ( mouse, ) used 1:5000 in milk/ PBST for western blotting 
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• anti chicken, HRP conjugated (Sigma) 1:10 000 in milk/ PBST for western 
blotting 
• anti sheep, HRP conjugated (Sigma) 1:4000 in milk/ PBST for western 
blotting 
• anti rabbit, HRP conjugated (Sigma) 1:3000 in milk/ PBST for western 
blotting 
• anti mouse, HRP conjugated (Sigma) 1:3000 in milk/ PBST for western 
blotting 
• anti sheep, Dylight594 conjugated (Jackson) 1:150 in BSA/PBST for 
immunofluorescence 
• anti sheep, Cy5 conjugated (Jackson) 1:150 in BSA/ PBST for 
immunofluorescence 
• anti chicken, Alexafluor488 conjugated (Invitrogen) 1:300 in BSA/ PBST for 
immunofluorescence 
• anti chicken, Dylight594 conjugated (Jackson) 1:150 in BSA/ PBST for 
immunofluorescence 
• anti sheep, FITC conjugated (Jackson) 1:300 in BSA/ PBST for 
immunofluorescence 
• anti mouse, Alexafluor594 conjugated (Invitrogen) 1:300 in BSA/ PBST for 
immunofluorescence 
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2.3 Cell culture and lysates 
2.3.1 Cell lines 
All cell lines were maintained in culture at 37ºC in 5% CO2. 
HeLa and U2OS cells were from Hay lab stocks, and maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM) medium plus Glutamax (Invitrogen) supplemented 
with 10% fetal bovine serum (FBS) and 100U/ml penicillin and streptomycin. 
 HeLa cells stably expressing YFP-PML (Geoffroy et al., 2010) were maintained 
in DMEM plus Glutamax with 10% FBS, 100U/ml penicillin and streptomycin plus 
blasticidin 1µg/ml. 
HeLa cells stably expressing eYFP were generated as described in Section 2.3.2 
and maintained in DMEM plus Glutamax with 10% FBS, 100U/ml penicillin and 
streptomycin plus 250µg/ml G418. 
NB4 leukaemia cells were from Hay lab stocks and maintained in RPMI 
medium (Invitrogen) supplemented with 10% FBS, 2mM glutamine and 100U/ml 
penicillin and streptomycin. 
HL60 (Gallagher et al., 1979) and P39 (Nagai et al., 1984)  leukaemia cells were 
a kind gift from Mary Hepburn and Sudhir Tauro, University of Dundee. Cells were 
maintained in RPMI medium (Invitrogen) supplemented with 10% FBS, 2mM 
glutamine and 100U/ml penicillin and streptomycin. 
HepaRG hepatocytes expressing enhanced yellow fluorescent protein (eYFP) 
linked PML isoforms were a kind gift from Professor Roger Everett, University of 
Glasgow (Cuchet et al., 2011). Cells were cultured in Williams Medium E (Gibco), with 
10% fetal bovine serum gold (PAA), 2mM glutamine, 5μg/ml insulin, 0.5μM 
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hydrocortisone and 100U/ml penicillin and streptomycin. Cells were maintained under 
antibiotic selection with G418 and puromycin. Parental HepaRG hepatocytes were 
cultured under the same conditions, without antibiotic selection. 
2.3.2 Generation of eYFP HeLa cell line 
HeLa cells were transfected with the pGD-EYFP-C1 vector, a kind gift from 
Professor Roger Everett, University of Glasgow, as described in Section 2.3.3. 24 hours 
after transfection, antibiotic selection was commenced with 500µg/ml G418. Medium 
containing G418 was replaced every 24 hours and stable colonies were selected 
approximately two weeks later. Colonies were then screened by fluorescence 
microscopy and western blotting to identify those stably expressing eYFP.  
2.3.3 DNA transfections 
Cells were seeded in 6 well plates and transfected the following day at 70% 
confluency. 1µg of plasmid DNA was added to 50µl of OptiMEM serum free medium 
(Invitrogen) and vortexed briefly. 3µl of Fugene HD (Roche) transfection reagent was 
then added and vortexed briefly. This mixture was incubated at room temperature for 15 
minutes before it was added to 2 ml of complete DMEM medium on the cells. 
2.3.4 siRNA transfections 
Cells were seeded in 6 well plates and transfected the following day at 20% 
confluency. 2.5µl of Lipofectamine RNAiMAX transfection reagent (Invitrogen) was 
diluted in 200µl of opti-MEM serum free medium (Invitrogen), and 1µl of 20µM stock 
siRNA diluted separately in 200µl of opti-MEM. These two solutions were mixed, and 
incubated at room temperature for 15 minutes, then added to 1.6mls of antibiotic free 
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DMEM medium on cells, giving a final siRNA concentration of 10nM and final volume 
of 2ml. Cells were then incubated for at least 48 hours prior to analysis. 
2.3.5 Cell treatments 
Cells were treated with drugs diluted in DMEM culture medium. Arsenic 
trioxide (Sigma) was used at 1µM final concentration. MG132 was used at a final 
concentration of 5 or 10µM. MLN 4924 was obtained from SCILLS, and used at 
various concentrations as documented in the text.   
• Preparation of arsenic stock solution 
110mg arsenic trioxide was dissolved in 2ml 1M sodium hydroxide to give 
280mM stock 
35.7µl of this 280mM stock was then diluted in 10ml TBS to give 1mM working 
stock 
1mM stock was then filter sterilised, aliquoted and stored at -20ºC.  
2.3.6 Cell lysis 
For whole cell lysis, cells were washed twice with PBS, and then lysed in 2 X 
SDS lysis buffer. Samples were then sonicated to shear DNA, incubated at 100ºC for 5 
minutes and cleared by centriguation at 17 000 x g for 10 minutes. Protein concentration 
of the lysate was estimated using the DC Assay (Biorad). Β- mercaptoethanol was 
added to samples at a final concentration of 0.5M after protein concentration estimation 
for samples to be separated by SDS-PAGE. 
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• 2 X SDS lysis buffer 
50mM Tris pH6.8 
2% (v/v) SDS 
10% (v/v) glycerol  
0.005% (w/v) bromophenol blue 
2.3.7 Lysis of NB4 cells 
Western blotting analysis of NB4 cells lysed in 2 X SDS lysis buffer using the 
anti RARα-115 antibody demonstrated poor PML-RARα extraction. NB4 cells were 
therefore lysed in 8M urea containing lysis buffer which resulted in enhanced PML-
RARα extraction, as previously reported (Isakson et al., 2010). Cells were washed twice 
in PBS and lysed in urea lysis buffer. Protein concentration of lysates was measured 
using the Biorad Protein Assay (Bio-Rad)according to manufacturer’s instructions. 
• Urea lysis buffer 
8M urea 
0.5% triton 
0.1M DTT 
 
Lysates were diluted 1:3 with 2 X SDS lysis buffer for SDS-PAGE and western 
blotting analysis. 
2.3.8 ATP based survival assay 
This protocol relies on the ATP-dependent action of firefly luciferase and the 
direct correlation between the obtained luminescence values and ATP levels in the 
reaction. A buffer containing the required components for the reaction except ATP is 
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used. The reaction rate is therefore dependent on ATP levels, which are directly 
proportional to the number of live cells in the assay. 
Cells were cultured in white, flat bottomed 96 well plates (Greiner). Typically 
1x105  HL60 or P39 cells were cultured per well in 100µl of culture medium. For drug 
treatment, identical aliquots of cells were centrifuged at 1000rpm to pellet cells, and 
resuspended in culture medium containing the appropriate concentration of drug. A 
multichannel pipette was then used to dispense 100µl of the well mixed cell suspension 
into 8 replicate wells.  
72 hours later, cells were lysed by pipetting 100µl of 2 X ATP lysis buffer into 
each well using a multichannel pipette. Plates were then sealed with an adhesive plate 
seal and incubated at room temperature on an optical shaker at 750rpm for 10 minutes. 
Luminescence signal was then assayed using an EnVision Multilabel reader (Perkin-
Elmer). 
• 2 X ATP lysis buffer 
50 mM Tris/Phosphate pH 7.8 
16 mM MgCl2 
2 mM DTT 
2% v/v Triton-X-100 
30% v/v (37.8% w/v) Glycerol 
1% w/v BSA 
0.25 mM D-Luciferin 
8 μM Sodium Pyrophosphate Tetra-basic Decahydrate 
500 ng/ml Luciferase 
 
The average luminescent signal for each drug concentration was calculated from 
replicate wells, and calculated as a surviving fraction of untreated control cells.  
Dissolved completely in distilled 
water before addition of Luciferin. 
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2.4 Immunoprecipitation 
2.4.1 GFP-IP of YFP-PML isoforms 
PML isoform expressing HepaRG cells were cultured in 10cm plates and treated 
with arsenic as described in section 2.3.5 prior to harvesting by scraping after 2 washes 
with PBS/ 100mM iodoacetamide on ice. Typically, two 10cm plates were cultured for 
each time point. Cells were pelleted by centrifugation at 400 x g and lysed in ice cold 
RIPA buffer (see below) with 100mM iodoacetamide with end over end rotation for 20 
minutes at 4 °C. Lysates were clarified by centrifugation at 17 000 x g for 10 minutes 
and precleared by incubation with sepharose beads for one hour, followed by overnight 
incubation with agarose beads coupled to a recombinant, single chain, camelid anti GFP 
antibody (a kind gift from the Division of Signal Transduction Therapy, University of 
Dundee) with constant end over end mixing at 4°C. Beads were then washed three times 
with RIPA buffer and bound proteins eluted in 2x SDS lysis buffer, and analysed by 
SDS- PAGE and western blotting. 
• RIPA buffer 
50mM Tris pH7.5 
150mM NaCl 
1% NP-40 
0.5% deoxycholate 
 
2.4.2 GFP-IP of YFP-PML for mass spectrometry 
HeLa cells stably expressing either eYFP or YFP-PML were each cultured in 10, 
15 cm tissue culture plates. When cells reached confluency, cells were harvested by 
scraping after 2 washes with PBS/ 100mM iodoacetamide on ice. Cells were pelleted by 
centrifugation at 400 x g and lysed in ice cold lysis buffer (see below) with 100mM 
57 
 
iodoacetamide with end over end rotation for 20 minutes at 4 °C. Lysates were clarified 
by centrifugation at 17 000 x g for 10 minutes and incubated with agarose beads 
coupled to a single chain anti-GFP antibody (a kind gift from the DSTT, University of 
Dundee) for 2 hours with constant end over end mixing at 4ºC. Beads were then washed 
twice in lysis buffer without NP40 and bound proteins eluted in 2X SDS lysis buffer. 
• Lysis buffer 
50mM Tris pH7.5 
150mM NaCl 
0.5% NP-40 
 
All material eluted was loaded into a single lane of a pre-cast bis-tris gel for 
each cell line. Proteins were then separated by SDS-PAGE, and the gel Coomassie 
stained as described in Section 2.2.2. At all stages, contamination was minimised by 
using sterile, single use equipment, and commercially prepared reagents, for example 
MOPs running buffer. 
Microwave assisted, in- gel tryptic digestion of peptides for mass spectrometry 
was performed by Dr Mike Tatham, as was mass spectrometric analysis. 
2.5 Microscopy techniques 
2.5.1 Cell culture on coverslips 
Adherent cells were cultured on 13mm glass coverslips in individual wells of six 
well plates. DNA or siRNA transfections were performed as described in Sections 2.3.3 
and 2.3.4. 
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2.5.2 Cytospin preparations 
Suspension cells were cultured in 6 well plates, then centrifuged at 400 x g and 
resuspended in 1ml of media. 100µl of cell suspension was then loaded into disposable 
sample chambers and centrifuged at 300rpm on a Cytospin3 centrifuge (Shandon), to 
distribute cells onto glass microscope slides. Slides were then air dried and stored at 
room temperature prior to fixation. 
2.5.3 Cell fixation and immunolabelling 
• 4% paraformaldehyde (PFA) (10ml) 
0.4g PFA    
0.2mM NaOH  
8.6ml H2O 
1ml 10 x PBS added after PFA dissolved 
• Blocking buffer 
5% BSA 
0.1% Tween 20 
PBS   
• Washing buffer 
1% BSA 
0.1% Tween 20 
PBS 
2.5.3.1 Adherent cells 
Cells were washed twice with PBS and then fixed in 4% paraformaldehyde for 
10 minutes at 37ºC. Cells were washed a further three times with PBS, and at this point 
may have been temporarily stored at 4ºC. Cells were permeabilised by incubation with 
0.2% triton in PBS for 10 minutes at room temperature and then washed a further three 
times in PBS. Cells were then blocked in blocking buffer for 30 minutes at room 
Heated to 70ºC until dissolved 
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temperature before coverslips were transferred to a Saran wrap ‘wet room’ on the 
benchtop.  
Primary antibody was diluted in washing buffer, and coverslips incubated for 1 
hour at room temperature. Cells were washed three times with wash buffer, and 
incubated with secondary antibody, also diluted in wash buffer, for 45 minutes at room 
temperature. After three further washes, cells were incubated with DAPI, 0.1µg/ml to 
stain DNA for 5 minutes before five further washes. Cells were aspirated dry and 
mounted onto glass microscopy slides using Vectashield mounting media (Vector labs), 
and the edges sealed with nail varnish. Slides were then stored at -20ºC until imaging. 
2.5.3.2 Suspension cells 
A hydrophobic pen was used to circle the area of microscope slides with the 
cytospin cell preparations. Cells within the area marked were rehydrated by incubation 
with PBS for 10 minutes at room temperature, then fixed, permeabilised and 
immunolabelled as described for adherent cells. 
Cells were aspirated dry and mounted with Vectashield mounting media, 
covered with a 20mm glass coverslip, and the edges sealed with nail varnish. 
2.5.4 Imaging 
Immunofluorescence samples were imaged by widefield microscopy using a 
Deltavision DV3 microscope (Applied Precision). Typically, images of multiple z-
sections were captured using a Coolsnap HQ2 camera (12 bit, Roper scientific) and 40x 
and 60x oil immersion lenses. 
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2.5.5 Image analysis 
Images were deconvolved using the Spinlock deconvolution cluster. 
Deconvolved images were analysed using Softworx software (Applied precision). For 
analysis of PML body fluorescence, the 2D polygon finder tool was used to identify 
pixel clusters above a given fluorescence threshold in maximal intensity projections of 
multiple z-sections. This threshold was maintained for the analysis of all images in a 
given experiment.  
2.6 Structured illumination imaging 
Cells were cultured on coverslips, fixed and antibody stained as described in 
section 2.5. Imaging was performed using the OMX version 2 system (Applied 
Precision). Images were acquired using a 100X, 1.4NA, oil immersion objective lens 
(Olympus, Center Valley,PA) and back-illuminated Cascade II 512 ⋅ 512 electron-
multiplying charge-coupled device (EMCCD) camera (Photometrics, Tucson,AZ) on 
the OMX version 2 system (Applied Precision) equipped with 405-, 488-, and 593-nm 
solid-state lasers. Samples were illuminated by a coherent scrambled laser light source 
that had passed through a diffraction grating to generate the structured illumination by 
interference of light orders in the image plane to create a 3D sinusoidal pattern, with 
lateral stripes approximately 0.2 μm apart. The pattern was shifted laterally through five 
phases and through three angular rotations of 60’ for each Z-section, separated by 0.125 
μm. Exposure times were typically between 200 and 500 ms, and the power of each 
laser was adjusted to achieve optimal intensities of between 2,000 and 4,000 counts in a 
raw image of 16-bit dynamic range, at the lowest possible laser power to minimize 
photo bleaching. Raw images were processed and reconstructed to reveal structures with 
greater resolution (Gustafsson, 2008 ). The channels were then aligned in x, y, and 
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rotationally using predetermined shifts as measured using a target lens and the Softworx 
alignment tool (Applied Precision). 
2.7 High content imaging 
2.7.1 Tissue culture 
Cells for high content imaging were cultured in black, clear bottomed 96 well 
plates (Corning CellBIND) under standard tissue culture conditions. Typically, cells 
were cultured in 100µl of medium per well. 
2.7.2 siRNA transfection in 96 well plates 
For transfection of up to five 96 well plates, transfections were performed 
manually using multichannel pipettes. siRNA was diluted to 200nM in 1X siRNA 
buffer (Dharmacon). 10µl of this solution was pipetted into the desired wells of a 96 
well plate. Lipofectamine RNAiMAX transfection reagent (Invitrogen) was diluted 1:50 
in optiMEM serum free medium (Invitrogen) and 10ul of the resulting solution added to 
the 96 well plate using a multichannel pipette. This mixture of siRNA and transfection 
reagent was mixed by gently pipetting up and down three times. The plate was 
incubated at room temperature, with a sterile lid in place to prevent evaporation, for 
twenty minutes. Cells were trypsinised and typically 5000- 7500 cells were seeded to 
each well in 100µl of culture medium. 
2.7.3 Cell treatments 
For arsenic treatment, 10µl of 11µM arsenic trioxide dilute in culture medium 
was added to wells using a multichannel pipette, to give a final concentration of 1µM. 
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2.7.4 Cell fixation and staining 
At the desired time point, culture medium was aspirated from wells using a 
benchtop aspirator. Cells were washed twice in 100µl per well of PBS and fixed with 
40µl per well 4%PFA/PBS as described in section 2.5.3. Following fixation, cells were 
washed three times with 100µl per well of PBS, and then permeabilised with 40µl per 
well of 0.2% triton/PBS. Cells were washed a further three times with PBS prior to 
incubation with 40µl per well of 0.1µg/ml DAPI for 3 minutes. Cells were washed a 
further 5 times with PBS and 100µl of PBS left in each well. Plates were then sealed 
using adhesive microplate seals and plates stored at 4ºC prior to imaging. 
2.7.5 Imaging 
Cells in 96 well plates were imaged using an INCell 1000 automated 
microscope, or an INCell 2000 automated microscope (GE Healthcare) in the Drug 
Discovery Unit, University of Dundee. Robotics were used to enable automated, 
sequential analysis of multiple 96 well plates, which were loaded and unloaded from the 
microscope by a robotic arm. 
Imaging protocols were developed using INCell analyser software to capture 
YFP and DAPI fluorescence with a 10x/0.45 plan Apo lens or a 20x/0.45 lens. At least 
two fields of view were captured per well, using laser autofocus before each image to 
ensure images were in focus. Exposure times for each wavelength were adjusted to 
provide optimal signal strength of 1000-1500 pixel intensity units. Individual images 
were saved as tif files onto a dedicated server, with images from a single plate stored in 
a folder labelled with the date and time of imaging. 
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2.7.6 Image analysis 
Images were analysed using INCell Investigator software (GE healthcare). 
Protocols were developed according to the desired features to be analysed. For analysis 
of PML nuclear body fluorescence, cell nuclei were first identified in the DAPI channel 
using multi-scale top hat transformation. PML nuclear body fluorescence was then 
identified in the YFP channel, again using a multi-scale top hat transformation to 
identify pixel clusters above a specified threshold. The number of, size and location 
(nuclear or cytoplasmic, based on nuclear DAPI staining) of PML bodies was then 
reported for each cell analysed. Plates could be analysed in batches if required, for 
example when multiple plates formed one experiment.  
The results of the analysis for each plate was exported as an Excel file. Thus, the 
number of Excel files generated corresponded to the number of plates analysed.  These 
contained a summary document which contained a well by well summary of all cells 
analysed within the wells. Cell by cell data for each cell analysed was also available 
within the document. Raw images were reviewed using OMERO software, which 
allowed upload of images in a 96 well plate format. 
2.8 siRNA screening 
2.8.1 Screen setup 
2.8.1.1 siRNA library 
The ubiquitome siRNA library was purchased from Dharmacon, and consisted 
of 15, 96 well plates. Each well contained a pool of four siRNAs targeting a single gene. 
A total of 1067 genes were targeted in the library. The siRNA within the library plates 
was at a concentration of 200nM, and plates were thermally sealed and stored at -20ºC. 
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Each plate had a unique barcode, which allowed tracking of the number of freeze- thaw 
cycles for each plate, and the volume remaining in each well using a spreadsheet 
managed by Amit Garg, data manager and updated by each user.  
2.8.1.2 Quality control 
Where possible, the various steps undertaken in the siRNA screen were 
automated to increase precision. Prior to setup of the siRNA screen, quality control 
checks were performed for each piece of liquid handling equipment to be used. The 
Fluid X liquid handling robot which has 96 pipette tips was arranged to aspirate from, 
or dispense into a 96 well plate. This was programmed to aspirate and dispense 10µl of 
10mM Orange G into triplicate clear 96 well plates. The WellMate (Thermo scientific) 
liquid handling device which dispenses liquid into the eight wells which make up one 
column of a 96 well plate at one time, was programmed to dispense both 80µl of 1mM 
Orange G or 10µl of 10mM Orange G into triplicate clear 96 well plates. The plates 
were then sealed, and absorbance measured for each well of the plates. The resulting 
absorbance values for each well of three plates for each piece of equipment were then 
assessed. Equipment passed this quality control test if the average percentage coefficient 
of variation of the three plates was less than 5%. This indicated that the liquid handling 
equipment was accurately and reproducibly dispensing the desired volume.    
A quality control plate was to be assayed at the beginning and at the end of the 
assay plates containing the siRNA library in the siRNA screen. Each well of the QC 
plate was transfected with the positive control siRNA, in this case RNF4 siRNA. By 
assaying identical plates at the beginning and end of the screen, the consistency of the 
assay can be assessed. 
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2.8.1.3 Preparation 
The number of plates to be assayed was calculated and unique barcode labels 
printed for each plate. These allowed tracking of each plate and identification of which 
siRNAs produce interesting phenotypes in the screen. In this case there were 34 plates 
in all: an arsenic treated set consisting of 2 QC plates and 15 assay plates, and an 
identical vehicle treated set. 
Control siRNA was prepared as a batch to be used for all plates. RNF4 siRNA, 
PML siRNA and NT siRNAs were diluted from 20µM stock to 200nM working 
concentration in 1X siRNA buffer (Dharmacon). The siRNAs were pipetted into a 
reservoir 96 well plate in the layout which they would appear on each assay plate: 
filling columns 1 and 12 of each assay plate. A reservoir plate for the QC plates was 
also prepared with RNF4 siRNA in each well. 
2.8.1.4 Dispensing of siRNA 
The 15 siRNA library plates were thawed on the bench for one hour and then 
centrifuged at 3000rpm for 1 minute. 34 black, clear bottomed assay plates (Corning 
CellBIND) were labelled with the barcode stickers. Plates were moved into a laminar 
flow cabinet, and all subsequent steps took place under sterile conditions. Control 
siRNAs were dispensed using the Fluid X liquid handling device to aspirate siRNA 
from the reservoir plate and dispense 10µl of siRNA into the 30 assay plates. These 
control siRNAs occupy the outer-most columns of each 96 well plate, column 1 and 12. 
RNF4 siRNA was dispensed into each well of the 4 QC plates. 
The 200nM concentration library siRNAs were then dispensed using the Fluid X 
liquid handling device. 10µl of siRNA was aspirated from each well of each library 
plate (columns 1 and 12 are empty in the library plates) and dispensed into the two 
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corresponding assay plates which already contained the control siRNAs. Lids were 
placed onto the assay plates immediately to prevent siRNA evaporation. Pipette tips 
were changed between each library plate to prevent cross contamination of siRNAs. 
A 50:1 optiMEM serum free medium: lipofectamine RNAiMAX transfection 
reagent mix was prepared and gently mixed. This was then added to each plate using a 
multichannel pipette and gently pipetted up and down three times with fresh pipette tips 
for each well. This step was done in this way because siRNA transfection was 
unsuccessful when the transfection reagent was dispensed using the WellMate liquid 
handling device, probably due to siRNA binding the  CellBIND coating on the assay 
plates. Plates were then incubated at room temperature for 15 minutes.  
Tubing for the WellMate liquid handling device was flushed with first sterile 
water, then 70% ethanol, then finally further flushed with sterile water. Cells were 
trypsinised and a cell suspension prepared at a concentration of 6.25x104 cells per ml. 
80µl of this well mixed cell suspension was then dispensed  into each well of the assay 
plates using the WellMate liquid handling device, a total of 5000 cells per well. This 
resulted in a final siRNA concentration of 20nM in a volume of 100µl. Plates were then 
incubated at 37ºC for 48 hours, in a dedicated tissue culture incubator to avoid 
unnecessary changes in environment due to frequent opening of the incubator. 
2.8.1.5 Arsenic treatment 
48 hours after transfection, cells were treated with arsenic or vehicle. Arsenic 
trioxide stock solution (see section 2.3.5) was diluted in culture medium to a 
concentration of 11µM. Vehicle solution was diluted in the same way. The WellMate 
liquid handling device was then used to dispense 10µl of arsenic solution or vehicle to 
each well of the 17 corresponding assay and QC plates. Cells were then incubated at 
37ºC for a further 24 hours. 
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2.8.1.6 Cell fixation and staining 
Plates were taken from the tissue culture incubator in batches of four for 
fixation. Using the Fluid X liquid handling device, media was aspirated from each plate 
and replaced with 100µl of PBS from a reservoir plate. This was aspirated and replaced 
with fresh PBS once more to wash cells. PBS was then aspirated and replaced with 40µl 
of 4%PFA/PBS and incubated at room temperature for 10 minutes. Cells were washed 
three times with PBS and plates stored at 4ºC. While the first batch of plates were 
incubating with PFA, a second batch were removed from the incubator and the same 
procedure commenced. 
When all plates were fixed, the Fluid X liquid handling device was again used to 
aspirate PBS and dispense 0.2% triton to permeabilise cells. This was performed in 
batches of four plates. Following 10 minutes incubation, cells were washed three times 
before 5 minutes incubation with DAPI. Cells were then washed a final three times and 
100µl of PBS was dispensed into each well. Plates were then sealed using a thermal 
sealer and stored at 4ºC until imaging.  
2.8.1.7 Imaging and image analysis 
Imaging was performed as described in section 2.7.5, using an INCell 1000 
automated microscope with 10x/0.45 Plan apo lens. This took approximately 36 hours. 
Image analysis was performed using INCell Investigator software, as described 
in section 2.7.6. The resulting data files were saved on a dedicated high content imaging 
server. Raw images were reviewed using OMERO software, which allowed upload of 
images in a 96 well plate format. 
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2.9 Data analysis and hit identification 
Data analysis was performed by Amit Garg, SCILLS data manager using 
ActivityBase software (IDBS), and is discussed in detail in section 3.2.8.1. 
2.10 Follow up screen 
To follow up putative hits, the four individual siRNAs which made up the pool 
of siRNAs tested in the initial screen were ordered from Dharmacon, in 96 well plate 
format. Each siRNA occupied one well of a 96 well plate with, making a  total of two 
96 well plates. siRNAs were reconstituted to 200nM concentration and assayed using 
the same method as described in section 2.7. 
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3 Development of a high content siRNA screen 
3.1 Introduction 
The aim of this project was to investigate the mechanism of arsenic mediated 
degradation of PML. To do this a high content siRNA screen was developed to identify 
gene products which, when depleted using RNA interference, altered the fate of the 
PML protein in response to arsenic, implicating the gene product in the process. Initial 
steps in assay development involved characterisation of the reagents and cell lines 
required. Suitable controls were then identified, allowing development and validation of 
an assay suitable for use in high throughput screening. Ultimately, an siRNA screen was 
performed, and a number of putative hits identified and further validated. All steps in 
this process will be summarised in this chapter. 
3.1.1 RNA interference  
RNA interference is a conserved mechanism of post translational control of gene 
expression. Two types of short, non-coding RNAs, short interfering RNAs (siRNAs) 
and microRNAs induce silencing of target genes via the RNA interference machinery. 
siRNAs induce silencing by inducing degradation of target mRNA transcripts (Meister 
and Tuschl, 2004), while microRNAs effect silencing via translational inhibition and 
mRNA degradation (Huntzinger and Izaurralde, 2011).  
Long double stranded RNAs which may be endogenous or exogenously 
introduced into cells, for example during viral infection, are processed in the cytoplasm 
by the enzyme Dicer into short, 21-22 nucleotide siRNAs (Figure 3.1.1.). The two 
strands of the siRNA play different roles in the silencing process. The guide strand of 
the siRNA is loaded onto the RNA interference silencing complex (RISC) while the 
passenger strand is degraded following RISC binding.  
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Figure 3.1.1. Mechanism of siRNA induced gene silencing 
Long, double stranded RNA molecules are processed by the enzyme Dicer into 
21- 22 nucleotide short interfering RNAs (siRNAs). The guide strand of the 
siRNA duplex is loaded onto the RNA interference silencing complex (RISC) 
which guides the silencing complex to mRNA sequences which are 
complementary to the guide strand. Synthetic siRNAs do not require cleaveage 
by Dicer and are loaded directly onto the RISC. Complementary mRNAs are 
then cleaved by Argonaute, the catalytic element of the RISC.  
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The RISC complex is then guided to mRNAs with sequences complementary to the 
siRNA guide strand which are targeted for cleavage by Argonaute, the enzymatic 
component of the RISC (Figure 3.1.1.). Target gene expression is thus reduced in a 
sequence specific manner. The RNA interference machinery can be used to 
experimentally reduce expression of a target gene through the introduction of synthetic 
siRNAs. Work by Fire and Mello confirmed that in order to achieve maximal gene 
knockdown, these synthetic siRNAs should be double stranded (Fire et al., 1998). 
Further investigation confirmed optimal knockdown with siRNA duplexes of 21 
nucleotides in length (Elbashir et al., 2001). Synthetic siRNAs are now a widely used 
research tool, allowing examination of loss of function phenotypes on a large, even 
whole genome scale, through the use of libraries of siRNAs.  
microRNAs are endogenous, non coding RNAs which are expressed as long, 
double stranded RNAs. These are processed, first in the nucleus and then in the 
cytoplasm, by a series of enzymes. The guide strand of the resulting short, double 
stranded microRNA is loaded onto the RISC which guides the silencing complex to the 
3’ UTR of target mRNA, which may inhibit mRNA translation or induce mRNA 
degradation (Huntzinger and Izaurralde, 2011). In contrast to siRNA mediated 
silencing, microRNA induced silencing relies on only partial complementarity between 
microRNA and target mRNA sequences. Each microRNA therefore controls expression 
of multiple transcripts, each with 3’ UTR sequence similarity to the microRNA 
sequence.  The post transcriptional regulation enforced by microRNAs has functions in 
many physiological processes, for example control of developmental transitions (Ebert 
and Sharp, 2012). There is also increasing evidence of the involvement of microRNAs 
in disease processes, with some microRNAs functioning as biomarkers for diseases 
such as cancers and autoimmune disorders (Pritchard et al., 2012). 
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3.1.1.1 Off-target effects of siRNA 
Advances in the understanding of the mechanism of siRNA and microRNA 
induced silencing has allowed for greater understanding of the unintended side effects 
of siRNAs. These so called ‘off-target effects’ can be divided into two main groups: 
sequence specific off-target effects mediated by microRNA like activities and off-target 
effects due to an siRNA induced inflammatory response (Jackson and Linsley, 2010; 
Kassner, 2008; Sachse and Echeverri, 2004).  
In addition to the intended target of a given siRNA, each siRNA has a sequence 
specific profile of unintended targets. These microRNA- like off- target effects are 
mediated by sequence similarity between the 5’ region of the siRNA sequence and the 
sequence of the 3’ UTR of mRNAs. mRNAs with 3’ UTR sequences which display 
some, but not complete complementarity to the siRNA sequence may be targeted for 
cleavage in addition to the intended, perfectly complementary target. This process is 
similar to the targeting of multiple mRNAs by the seed region of a single microRNA 
(Birmingham et al., 2006; Jackson et al., 2006b). The repression of these off- target 
mRNAs tends to be less significant than those of the intended target (Birmingham et al., 
2006; Jackson et al., 2006b), but are still sufficient to cause false positive results in 
siRNA screens (Echeverri et al., 2006). siRNAs with different sequences targeting the 
same gene product will have a different profile of sequence specific off-target gene 
regulation. This difference in off target profile can be exploited to confirm that a 
phenotype observed following transfection of a single siRNA duplex is due to 
repression of the desired target mRNA. If the same phenotype is induced by multiple 
siRNAs with distinct sequences but the same target gene, it is likely that the phenotype 
is due to knockdown of the target gene, because the only mRNA target shared by the 
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individual siRNAs is the intended target (Echeverri et al., 2006; Jackson and Linsley, 
2010; Kassner, 2008; Sachse and Echeverri, 2004). 
The other classes of off-target effects of siRNAs tend to be less problematic. 
siRNAs can induce changes in gene transcription which are due to stimulation of the 
innate immune system by exogenous siRNA. Some siRNAs appear to stimulate the 
immune system to a greater extent than others, suggesting that some sequences are more 
immunogenic. There is also evidence that chemical modification of siRNAs can reduce 
the likelihood of immune stimulation, and that the likelihood of such stimulation can be 
minimised by using the lowest possible concentrations of reagents (Jackson and 
Linsley, 2010).  
3.1.2 Good practice in siRNA screening 
For an siRNA screen to produce meaningful data, siRNA must be transfected 
into cells with high efficiency, and such transfection must result in profound and 
specific knockdown of the intended gene product. To this end, there are a number of 
considerations to take into account when designing an siRNA screen or screening 
service.  
The siRNAs contained in libraries for screening should be designed in such a 
way that off target effects are minimised. Chemical modification by 2’-O-methyl 
ribosyl substitution at position 2 of the seed sequence of the guide strand of siRNA 
duplexes has been demonstrated to reduce off target transcriptional repression by 66% 
(Jackson et al., 2006a). siRNAs which have been modified in this way should therefore 
be used. The seed sequence of the guide strand of an siRNA duplex can also influence 
the likelihood of off target silencing via microRNA like mechanisms. A bioinformatics 
analysis of all possible six nucleotide seed sequences revealed wide variation in the 
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number of 3’UTR complementary regions in the genome for a given sequence 
(Anderson et al., 2008). Validation of this data confirmed significantly less off target 
silencing for siRNA seed sequences with low frequency seed region complementarity. It 
is therefore prudent to avoid siRNA sequences with high frequency seed region 
complementarity, which can be achieved using bioinfomatic tools (Anderson et al., 
2008). 
The use of a pool of siRNAs each with a distinct sequence enhances target gene 
silencing while reducing sequence specific off target effects (Echeverri and Perrimon, 
2006; Sharma and Rao, 2009). This is likely to allow a decrease in the total siRNA 
concentration required to achieve optimal silencing, which has been shown to decrease 
off target effects (Jackson and Linsley, 2010). The lowest effective siRNA 
concentration should therefore be used when performing siRNA screens (Hannon and 
Rossi, 2004). Optimisation of transfection protocols should be performed with the 
transfection reagents to be used, which are usually lipid based, to monitor for related 
cellular toxicity, as well as transfection efficiency (Echeverri and Perrimon, 2006). 
The SCILLS siRNA library consists of Dharmacon ON-TARGETplus siRNAs 
which are chemically modified and subject to the sequence design considerations 
mentioned above. The library consists of 1067 pools of siRNAs. Each is made up of 
four siRNAs with distinct sequences targeting the same gene product. These are 
transfected at a low concentration of 10-20nM to minimise off target effects. 
A number of approaches can be used to validate hits obtained in a primary 
siRNA screen. To confirm the phenotype obtained, replicates can be performed using 
the same pooled siRNAs as used in the primary screen. Subsequently, each of the 
siRNAs which constituted the pool can be assayed individually. It is generally accepted 
that the desired ‘hit’ phenotype should be reproduced by transfection of at least two 
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individual siRNAs targeting the gene of interest (Echeverri et al., 2006; Hannon and 
Rossi, 2004). This allows identification of off target effects of siRNAs, due to both 
microRNA like repression of genes other than the desired target and due to immune 
stimulation. Correlation between the phenotype obtained and the degree of gene product 
knockdown increases confidence that a hit is due to an on target effect of the siRNA. 
RT qPCR can be employed to assay target mRNA transcript expression levels and 
successful knockdown can also be confirmed at protein level by western blotting, 
though this requires the availability of good quality antibodies. 
 The gold standard approach for validation of siRNA mediated phenotypes is to 
demonstrate that the siRNA mediated phenotype can be rescued by the expression of a 
construct expressing the gene of interest that is resistant to the test siRNA (Echeverri et 
al., 2006; Hannon and Rossi, 2004). This can be performed by reintroduction of a 
construct expressing the target gene which has been rendered resistant to the siRNA by 
virtue of silent point mutations within the siRNA target sequence. An alternative 
approach is to design siRNAs which target the 3’UTR of the target gene, and then 
rescuing expression using a construct which lacks the 3’UTR and is therefore resistant 
to the siRNA. It may also be possible to confirm the specificity of a hit phenotype using 
a small molecule that confers the same effects as the test siRNA, for example use of a 
kinase inhibitor to confirm the phenotype observed with siRNA mediated knockdown of 
the kinase of interest (Mohr et al., 2010). In addition, if mice are available in which the 
gene of interest has been disrupted in the genome, experiments can be repeated in cells 
which lack the gene product identified in the siRNA screen (Sharma and Rao, 2009).  
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3.2 Results 
3.2.1 Characterisation of an affinity purified anti-PML 
antibody 
Initial experiments sought to confirm the reactivity and specificity of a newly 
generated anti-PML antibody. Until this point, the mouse monoclonal PML5E10 
antibody (Zhu et al., 1997) was used for immunofluorescence experiments, but was 
ineffective for western blotting. Chickens were therefore immunised with recombinant 
PML isoform VI (PML VI), the shortest PML isoform encoded by 560 amino acids, the 
sequence of which is shared by all the major PML isoforms(Jensen et al., 2001a) .  The 
polyclonal IgY anti-PML antibody was subsequently purified from egg yolk and affinity 
purified by Ellis Jaffray, and its sensitivity towards recombinant PML VI was initially 
confirmed by dot blots (data not shown).  
To assess the reactivity and specificity of the new anti- PML antibody, 
paraformaldehyde- fixed U2OS cells were incubated with either the purified antibody or 
IgY purified from the yolk of eggs laid prior to immunisation, followed by incubation 
with a fluorescently labelled anti chicken secondary antibody. Cells were then imaged 
by deconvolution microscopy. While the purified antibody identified punctate nuclear 
structures consistent with PML bodies, the preimmune IgY did not (Figure 3.2.1, panel 
A). Similarly, U2OS whole cell extracts were analysed by western blotting with the 
purified antibody or pre immune IgY. Western blotting with the purified antibody but 
not the preimmune IgY identified a series of PML species consistent with the various 
PML isoforms and their post-translationally modified forms (Figure 3.2.1, panel B). 
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Figure 3.2.1. Characterisation of a chicken anti PML antibody 
(A) U2OS cells were incubated with either preimmune IgY purified from egg 
yolk (top panels) or affinity purified chicken anti PML antibody (lower panels) 
followed by incubation with a fluorescently labelled anti chicken secondary 
antibody shown in red. DNA was stained with DAPI. Images presented are 
maximal projections of multiple z-sections. 
(B) U2OS whole cell extracts (four replicates) were analysed by western 
blotting with either preimmune IgY (left panel) or purified anti PML antibody 
(right panel). An anti actin antibody was used as a loading control. 
(C) U2OS cells were immunolabelled with mouse 5E10 anti PML antibody and 
purified chicken anti PML antibody, followed by fluorescently labelled 
secondary antibodies. DNA was stained with DAPI. Images presented are 
maximal projections of multiple z-sections. 5E10 PML is shown in red, chicken 
PML in green. 
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To investigate the specificity of the new antibody, U2OS cells cultured on 
coverslips were fixed in paraformaldehyde prior to double immunolabelling with the 
previously characterised monoclonal  PML 5E10 antibody (Zhu et al., 1997) and the 
new chicken anti PML antibody. As expected, the PML 5E10 antibody identified 
endogenous PML primarily in punctate PML-NBs (Figure 3.2.1, panel C, shown in 
red). The chicken anti PML antibody also labelled PML-NBs (Figure 3.2.1, panel C, 
shown in green), precisely colocalising with the PML 5E10 labelled structures, 
demonstrating that the chicken anti PML antibody is immunoreactive to endogenous 
PML in this cell line. 
To further confirm the specificity of the anti PML antibody, the effects of 
siRNA mediated depletion of PML on the pattern of species identified by western 
blotting were assessed. In cells depleted of PML by siRNA, the multiple species 
identified by the antibody in control, non- targeting siRNA treated cells all but 
disappeared (Figure 3.2.2, panel A). Immunofluorescence microscopy following PML 
siRNA demonstrates the disappearance of PML-NBs labelled by both the PML 5E10 
antibody and the new chicken anti PML antibody (Figure 3.2.2, panel B). 
These data confirm the newly generated antibody to be reactive to endogenous 
PML in both HeLa and U2OS cells, and the RNA interference data in Figure 3.2.2 
demonstrate the antibody to be specific for the PML protein. Thus the antibody is 
suitable for use in further immunoblotting and immunofluorescence experiments. 
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Figure 3.2.2. siRNA mediated depletion of PML confirms chicken anti 
PML antibody specificity 
(A) U2OS cells were transfected in duplicate with pools of 4 siRNA duplexes 
targeting RNF4, PML or a non- targeting (NT) control duplex. Cells were lysed 
48 hours after transfection and cell extracts analysed by western blotting with 
chicken anti PML and actin antibodies. 
(B) U2OS cells were transfected with a pool of 4 siRNA duplexes targeting 
PML or a non- targeting (NT) control duplex. Cells were fixed 48 hours after 
transfection and labelled with 5E10 PML and chicken anti PML antibodies and 
fluorescently labelled secondary antibodies. DNA was stained with DAPI. 
Images presented are maximal projections of multiple z-sections. 5E10 PML is 
shown in red, chicken anti PML in green. 
 
3.2.2 PML is degraded in response to arsenic treatment 
It is well established that PML is SUMO modified and then degraded by the 
proteasome in response to arsenic treatment (Lallemand-Breitenbach et al., 2001; 
Muller et al., 1998). To help plan the timing of analysis for the siRNA screen, a kinetic 
analysis of PML degradation in response to arsenic was performed. U2OS cells were 
treated with arsenic and cells harvested at various time points. Whole cell extracts were 
then resolved by SDS-PAGE and analysed by immunoblotting (Figure 3.2.3, panel A).  
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Figure 3.2.3. PML is degraded following arsenic treatment in an RNF4 
dependent manner 
(A) U2OS cells were treated with 1µM arsenic trioxide and lysed at the time 
points indicated. Cell extracts were then analysed by western blotting with 
chicken anti PML and actin antibodies. 
(B) U2OS cells were transfected with a pool of 4 siRNA duplexes targeting 
RNF4 or a non targeting (NT) control duplex. 48 hours after transfection, cells 
were treated with 1µM arsenic trioxide and cell lysates analysed by western 
blotting using chicken anti PML, chicken anti RNF4 and mouse anti actin 
anitbodies. 
 
After a short arsenic treatment of 1 to 4 hours, post translational modification of PML is 
demonstrated by the accumulation of high molecular weight PML species which 
represent the SUMO modification of the various PML isoforms (Figure 3.2.3, panel 
A). At later time points, a marked decrease in PML species is apparent, with near 
disappearance after 24 hours of treatment. This indicated arsenic induced degradation of 
PML was virtually complete after 24 hours of treatment. Some PML species appeared 
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to persist, indicating that some PML species are more susceptible to degradation than 
others (Figure 3.2.3, panel A, arrowhead).  
3.2.3 RNF4 is required for arsenic mediated degradation of 
PML 
The SUMO targeting ubiquitin E3 ligase RNF4 has been demonstrated to be 
essential for arsenic mediated degradation of PML (Lallemand-Breitenbach et al., 2008; 
Tatham et al., 2008). U2OS cells were transfected with either a non- targeting (NT) 
siRNA duplex or a pool of 4 siRNAs targeting RNF4. 48 hours later cells were treated 
with arsenic. Cells were harvested at various time points and whole cell extracts 
examined by western blotting (Figure 3.2.3, panel B). RNF4 depletion was confirmed 
by western blotting with an anti RNF4 antibody. Cells depleted of RNF4 express more 
PML than control cells prior to arsenic treatment, suggesting RNF4 may also regulate 
PML expression in the absence of arsenic (Figure 3.2.3, panel B). Following 1 hour of 
arsenic treatment, accumulation of high molecular weight PML species is observed in 
both control and RNF4 depleted cells. However, striking differences are noted 
following 24 hours of arsenic treatment. PML was almost completely degraded in 
control cells, whereas in RNF4 depleted cells there was accumulation of very high 
molecular weight PML species. These results confirmed that RNF4 is required for 
arsenic induced degradation of PML. 
The process of arsenic mediated degradation of PML can also be monitored by 
immunofluorescence. The siRNA screening assay was to be performed using fixed 
cells, because the automated microscope to be used did not have facilities for live cell 
imaging. Preliminary experiments were therefore performed using cells fixed at various 
time points. 
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Figure 3.2.4. Immunofluorescence demonstrates PML accumulates in 
PML bodies in cells depleted of RNF4 prior to arsenic treatment 
(A) HeLa cells were transfected with a pool of 4 siRNA duplexes targeting 
RNF4 or a non targeting control (NT) duplex. 48 hours after transfection cells 
were treated with 1µM arsenic for 0, 1 or 24 hours. Cells were fixed and 
stained with chicken anti PML (red) and sheep anti SUMO1 (green) antibodies. 
DNA was stained with DAPI. Immunofluorescence images presented are 
maximal projections of multiple z-sections. 
NT
siRNA
 RNF4
siRNA
 Hours of
arsenic PML
PML
PML
PML
PML
PML
SUMO1
SUMO1
SUMO1
SUMO1
SUMO1
SUMO1
MERGE
MERGE
MERGE
MERGE
MERGE
MERGE
DAPI
DAPI
DAPI
DAPI
DAPI
DAPI
0
1
24
0
1
24
10µm
A
83 
 
 
 
Figure 3.2.4. Immunofluorescence demonstrates PML accumulates in 
PML bodies in cells depleted of RNF4 prior to arsenic treatment 
(B) HeLa cells were transfected and treated with arsenic as in (A). Cells were 
fixed and stained with chicken anti PML (red) and sheep anti SUMO2/3 (green) 
antibodies. DNA was stained with DAPI. Immunofluorescence images 
presented are maximal projections of multiple z-sections 
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To investigate the effects of RNF4 depletion on the localisation and degradation 
of PML resulting from arsenic treatment, HeLa cells were transfected with either 
control NT siRNA or RNF4 siRNA and then treated with arsenic. Cells were fixed at 
various time points and immunostained with an anti PML antibody plus either anti 
SUMO1 (Figure 3.2.4, panel A) or anti SUMO2/3 (Figure 3.2.4, panel B) antibodies. 
In NT siRNA transfected control cells prior to arsenic treatment, there is a small amount 
of SUMO1 (Figure 3.2.4, panel A) and SUMO2/3 (Figure 3.2.4, panel B) associated 
with PML, as identified by colocalisation of the proteins by immunofluorescence. After 
1 hour of arsenic treatment, there is an increase in the number of PML-NBs and in the 
amount of associated SUMO1 and SUMO2/3. After 24 hours of treatment, there are 
virtually no PML-NBs remaining, and very little SUMO associated (Figures 3.2.4, 
panels A and B), indicative of SUMO modified PML having been degraded in 
response to arsenic. In cells depleted of RNF4, the initial response to arsenic treatment 
was similar to that of control cells, with an increase in the number of PML-NBs and in 
the amount of SUMO1 and SUMO2/3 associated. The striking differences identified 
between control and RNF4 depleted cells after 24 hours of arsenic treatment were 
confirmed in these immunofluorescence images. There was accumulation of PML and 
SUMO1 (Figure 3.2.4, panel A) and SUMO2/3 (Figure 3.2.4, panel B) in large, bright 
PML-NBs in RNF4 depleted cells, compared with the near complete absence of PML-
NBs in NT siRNA transfected cells.  
The striking difference in phenotype identified by immunofluorescence between 
cells transfected with NT siRNA and RNF4 siRNA suggested that it should be possible 
to screen for other proteins essential for the process of arsenic mediated degradation of 
PML by monitoring PML fluorescence. The aim of the siRNA screen would be to 
identify siRNAs which recreated the RNF4 siRNA phenotype after 24 hours of arsenic 
treatment. This suggested that RNF4 was likely to be an appropriate positive control for 
85 
 
a high content screening assay. Since NT siRNA did not interfere with arsenic mediated 
degradation of PML, it could be further employed as a negative control. 
3.2.4 Characterisation of YFP-PML HeLa cell line 
The aim of the siRNA screening experiment was to monitor the fate of the PML 
protein following siRNA mediated gene knockdown and arsenic treatment by 
immunofluorescence. This could be performed using the previously characterised anti-
PML antibody to immunostain endogenous PML in a cell line of choice. However, 
given the scale of the screening experiment, this was likely to be extremely laborious. In 
order to keep the screening assay as simple and reproducible as possible it would be 
ideal to use a cell line expressing a fluorescent version of PML. This would eliminate 
the need for two step antibody staining of PML and the associated potential variation in 
PML detection. For these reasons, a  HeLa cell line stably expressing PML isoform III- 
yellow fluorescent protein (YFP) fusion created by Marie-Claude Geoffroy (Geoffroy et 
al., 2010) was selected for characterisation. These cells express YFP-PML at close to 
endogenous levels, and the YFP-PML is efficiently incorporated into PML-NBs 
(Figure 3.2.5, panel A). When these cells are depleted of PML using siRNA, YFP 
fluorescence is abolished (Figure 3.2.5, panel B), confirming that all of the YFP is 
linked to PML. This experiment also confirms that these cells can be satisfactorily 
transfected with siRNA, another key characteristic of cells to be used in the screening 
experiment. 
The readout of the siRNA screen was to be measures of YFP-PML fluorescence. 
It was therefore important that cell to cell variation in YFP-PML expression was 
minimised in order to obtain a robust assay. To ensure the population of these cells used 
for further experiments, including the screening experiment was as homogeneous as 
possible, a population of cells expressing a low level of YFP-PML was obtained by 
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fluorescence-activated cell sorting, performed by Dr Rosie Clarke, University of 
Dundee. These cells were used in the studies which follow. 
 
 
Figure 3.2.5. Immunofluorescence characterisation of YFP-PML HeLa 
cells 
(A) YFP-PML HeLa cells were fixed and stained with chicken anti PML 
antibody. Cells were imaged by deconvolution microscopy. YFP-PML is shown 
in green, chicken anti PML antibody in red. DNA was stained with DAPI. 
Immunofluorescence images presented are maximal projections of multiple z-
sections. 
(B) YFP-PML HeLa cells were transfected with a pool of 4 siRNAs targeting 
PML or a control, non targeting (NT) duplex. Cells were fixed 48 hours after 
transfection and DNA was stained with DAPI. Images presented are maximal 
projections of multiple z- sections. 
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3.2.5 YFP-PML is degraded in an RNF4 dependent manner 
following arsenic treatment 
Endogenous PML is degraded in an RNF4 dependent manner, as described in 
section 3.2.3. The next experiments sought to characterise the response of YFP-PML in 
the YFP-PML HeLa stable cell to arsenic treatment.  Cells were transfected with a pool 
of four siRNAs targeting RNF4, and 48 hours later, treated with arsenic and lysed at 
various time points. Western blotting of whole cell extracts performed with an anti-
RNF4 antibody confirms that RNF4 can be successfully depleted in these cells (Figure 
3.2.6, panel A). The effects of this depletion on YFP-PML are similar to those observed 
when endogenous PML is assessed following RNF4 depletion and arsenic treatment. 
After a short 1 hour arsenic treatment, high molecular weight YFP-PML species 
accumulated, indicating that YFP-PML was post-translationally modified (Figure 3.2.6, 
panel A, anti-GFP blot). After 24 hours exposure to arsenic, in cells transfected with 
non-targeting (NT) control siRNA, YFP-PML was almost completely degraded. 
Conversley,  in cells transfected with RNF4 siRNA high molecular weight YFP-PML 
species accumulated (Figure 3.2.6, panel A, GFP blot, 24 hour time point). This 
experiment confirmed that in response to arsenic treatment YFP-PML is degraded in an 
RNF4 dependent manner. This experiment was repeated with cells cultured on 
coverslips to examine the effects of RNF4 depletion and arsenic treatment on the 
localisation and intensity of YFP-PML fluorescence by deconvolution microscopy. In 
cells transfected with NT siRNA, an increase in YFP-PML fluorescence at PML-NBs 
was noted after 1 hour of arsenic treatment. The marked decrease in YFP-PML 
fluorescence after 24 hours of arsenic exposure (Figure 3.2.6, panel B) indicated that 
YFP-PML has been degraded. Conversely, in cells depleted of RNF4, YFP-PML 
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accumulated in large, bright PML-NBs following arsenic treatment (Figure 3.2.6, panel 
B). 
 
Figure 3.2.6. YFP-PML is degraded in an RNF4 dependent manner in 
response to arsenic treatment 
(A) YFP-PML HeLa cells were transfected with a pool of siRNAs targeting 
RNF4 or a non-targeting (NT) control duplex. 48 hours after transfection, cells 
were treated with 1µM arsenic trioxide for the indicated periods of time prior to 
cell lysis. Cell lysates were analysed by western blotting with chicken anti PML, 
anti GFP (to detect YFP-PML only), anti RNF4 and actin antibodies. 
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(B) YFP-PML HeLa cells were transfected and arsenic treated as in (A), before 
fixation with paraformaldehyde. DNA was stained with DAPI and cells were 
imaged by deconvolution microscopy. YFP-PML is shown in green. 
Immunofluorescence images presented are maximal projections of multiple z-
sections. 
 
This demonstrated that, like endogenous PML (section 3.2.3.), the most marked 
differences in YFP-PML fluorescence between control and RNF4 depleted cells are 
identified following 24 hours of arsenic treatment (Figure 3.2.6, panel B, bottom 
panels). 
These results confirmed that HeLa cells stably expressing YFP-PML could be 
successfully transfected with siRNA, and that YFP-PML was degraded in an RNF4 
dependent manner in response to arsenic treatment. The phenotype observed in YFP-
PML HeLa cells depleted of RNF4 following 24 hours of arsenic treatment was the 
same as that observed for endogenous PML. YFP-PML HeLa cells were therefore a 
suitable system to use to investigate the effects of siRNA mediated gene knockdown on 
the process of arsenic mediated degradation of PML. The data also suggest that most 
appropriate time point at which to analyse cells in the screening assay would be after 24 
hours of arsenic treatment. 
3.2.6 Quantitation of YFP-PML fluorescence after RNF4 
depletion and arsenic treatment 
The images presented in Figures 3.2.4. and 3.2.6., panel B, demonstrated a 
marked difference in phenotype between cells transfected with control siRNA and cells 
transfected with RNF4 siRNA following 24 hours of arsenic treatment. This suggested 
that RNF4 siRNA may be an appropriate positive control to be used in the screening 
experiment. Knockdown of RNF4 prevented arsenic mediated degradation of PML, and 
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the aim of the screen was to identify siRNAs which perturbed this process. In order to 
transform this observation into an assay suitable for high content screening, a measure 
of YFP-PML fluorescence that characterised this difference was required, and the next 
experiments sought to identify such a measure.  
Quantitation of YFP-PML fluorescence was performed by imaging cells 
cultured on coverslips using deconvolution microscopy. Maximal intensity projections 
of multiple z sections of deconvolved images were prepared and YFP-PML 
fluorescence quantified using Softworx software. Initially, the mean YFP fluorescence 
of entire cell nuclei was calculated for NT siRNA and RNF4 siRNA transfected cells at 
three different time points after arsenic treatment (Figure 3.2.7, panel A). This 
identified a 1.3 fold difference between the mean nuclear YFP fluorescence of NT 
siRNA treated and RNF4 siRNA treated cells after 24 hours of arsenic treatment 
(Figure 3.2.7 panel A).  This small difference did not reflect the marked differences in 
phenotype identified in the images (Figure 3.2.6, panel B), and was unlikely to be 
sufficient to discriminate between siRNAs which perturbed the process of PML 
degradation and those which did not in a high content screening assay.  
Subsequently, attempts at quantification of YFP-PML fluorescence were 
focussed on quantification of fluorescence of PML-NBs, because it appeared from 
images (Figure 3.2.6, panel B) that the main difference in the phenotype of YFP-PML 
fluorescence following RNF4 depletion appeared to be in the intensity, number and size 
of PML-NBs present after arsenic treatment. Once again, maximal intensity projections 
were made of multiple z sections of images and PML-NBs were identified as clusters of 
pixels with a YFP intensity above a specified threshold using Softworx software. The 
threshold used was maintained across all time points and siRNA conditions to allow 
comparisons to be drawn. This semi- automated approach was used because eventually 
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the aim was to produce an assay suitable for automated analysis of thousands of images, 
and manual quantification of fluorescence of individual PML-NBs would not be 
possible. This method of quantification did not identify a difference in PML-NB 
intensity (Figure 3.2.7, panel B). 
 
Figure 3.2.7. Quantification of YFP-PML fluorescence following RNF4 
depletion and arsenic treatment 
YFP-PML HeLa cells were transfected with a pool of 4 siRNA duplexes 
targeting RNF4, or a non- targeting (NT) control duplex. 48 hours after 
transfection, cells were treated with 1µM arsenic trioxide for 0, 1 or 24 hours. 
Cells were stained with DAPI and imaged using deconvolution microscopy. 
YFP-PML fluorescence was then quantified from maximal projections of 
multiple z sections.  
(A) Comparison of YFP-PML fluorescence of whole cell nucleus. Data 
represents the average fluorescence of 50 cells analysed for NT or RNF4 
siRNA transfected cells at each timepoint. 
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(B) The average pixel intensity of YFP-PML bodies was analysed. Data 
represents the average pixel intensity of PML bodies in 100 cells per condition. 
(C) The number of YFP-PML bodies per nucleus was analysed for 100 cells 
per condition. Data represents the average number of PML bodies per nucleus 
for each condition. 
(D) The sum of the area of all PML bodies in each cell nucleus was calculated 
for 100 cells per condition. Data represents the average total area of the 
nucleus occupied by PML bodies. 
 
This is to be expected because in order to be identified as a PML-NB by the 
software, a cluster of YFP fluorescent pixels had to have a YFP intensity above the 
given threshold of YFP intensity. Thus, the mean intensity of very small pixel clusters 
with YFP intensity above the threshold identified in the NT siRNA treated cells is very 
similar to the mean intensity of the larger pixel clusters identified in RNF4 siRNA 
treated cells. More significant differences were identified in measures of PML-NB 
number and area (Figure 3.2.7, panel C and panel D). The average number of PML-
NBs identified per nucleus in RNF4 siRNA treated cells was 1.7 times higher than that 
identified in control cells after 24 hours of arsenic treatment (Figure 3.2.7, panel C). 
The most discriminatory measure between RNF4 depleted and control cells was found 
to be the sum of the area of PML-NBs attributed to one nucleus, with RNF4 depleted 
cells having PML-NBs twice the area of control cells after 24 hours of arsenic treatment 
(Figure 3.2.7, panel D). 
These experiments demonstrated that, in principle, a high content siRNA screen 
using NT siRNA as a negative control and RNF4 siRNA as a positive control, and the 
measure of the sum of the area of all PML-NBs in one cell, hereafter referred to as 
‘PML body total area’, as the assay parameter, should be capable of identifying gene 
products which, when knocked down, influence the process of arsenic mediated 
degradation of PML.  
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3.2.7 Development of an assay suitable for high content 
screening 
3.2.7.1 High content imaging and image analysis 
The next experiments aimed to recreate the results summarised in sections 3.2.5 
and 3.2.6  in an experimental format suitable for high throughput screening, and by 
doing so develop an assay suitable for use in a high content screen. A method was 
developed to perform reverse siRNA transfection of YFP-PML HeLa cells in black, 
clear bottomed 96 well plates which were suitable for automated microscope imaging. 
First the siRNA duplex, then transfection reagent and finally cells in culture medium 
were added to each well of the plate, and the cells incubated for 48 hours. Arsenic 
trioxide diluted in culture medium was then added to the plates, and cells incubated for 
a further 24 hours. Cells were then washed, fixed with paraformaldehyde and stained 
with DAPI.  
Imaging of cells in 96 well plates was performed using an IN Cell 1000 
automated microscope, using a 10x lens to obtain images of sufficient resolution to 
identify PML bodies, while maximising the number of cells imaged per field. Two 
fields of view were captured per well. 
To analyse YFP-PML fluorescence in the images obtained, a protocol was 
designed using IN Cell Investigator software (GE Healthcare) which, like the semi-
automated quantification of fluorescence described in section 3.2.6, identified PML-
NBs when the YFP-PML fluorescence of a pixel cluster exceeded a given threshold 
above background intensity (Figure 3.2.8). This threshold was maintained for all plates 
imaged and analysed in a given experiment.  
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Figure 3.2.8. Screenshot example of IN Cell Investigator software 
analysis of PML nuclear bodies 
YFP-PML HeLa cells were transfected with non targeting, control siRNA and 
cultured in 96 well plates prior to fixation and DAPI staining. Cells were imaged 
using the IN Cell 1000 automated microscope to capture YFP and DAPI 
fluorescence. Resulting images were analysed using a protocol designed to 
identify cell nuclei using DAPI fluorescence, and YFP-PML nuclear bodies 
within the nucleus. Left panels show raw images, and right panels the regions 
of interest selected by the analysis protocol: Blue lines encircle nuclei, green 
lines a cytoplasmic collar and yellow lines PML nuclear bodies. 
 
The protocol captured data regarding the PML body total area, mean nuclear 
YFP fluorescence, the number of PML-NBs per cell, the intensity of PML-NBs and the 
number of cells analysed per well. The output from this analysis was a summary file 
with a value for each of the parameters listed, which was an average of all the individual 
cells analysed in a well, for each well of the 96 well plate analysed. Cell by cell data 
was also available in a separate file. Data analysis was performed in the assay 
development phase using Microsoft Excel software. It was also possible to review the 
images to ensure the cells appeared healthy, and to compare the data obtained from the 
analysis protocol to the phenotype identified by eye. At each stage, analysis was 
YFP
DAPI
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discussed with Amit Garg, SCILLS Data Manager, who developed protocols in 
ActivityBase software (IDBS) which would be used to analyse siRNA screening data 
for hit identification. 
Using the procedure outlined above, YFP-PML HeLa cells were transfected in 
multiple replicates with either NT or RNF4 siRNA in 96 well plates and 48 hours later 
treated with arsenic for 24 hours. Cells were imaged and analysed, and the results are 
presented in Figure 3.2.9. Approximately 10 000 cells were analysed for each of the 
two conditions. Data were very similar to that reported in Figure 3.2.7. There was no 
difference found in mean nuclear YFP intensity or mean PML-NB intensity between 
NT siRNA or RNF4 siRNA transfected cells (Figure 3.2.9, panel A and panel B). A 
1.5 fold increase in the number of PML-NBs was noted for cells transfected with RNF4 
siRNA compared to NT siRNA (Figure 3.2.9, panel C), and a two fold increase in the 
PML body total area (Figure 3.2.9, panel D). 
The data obtained are very similar to that acquired from smaller scale 
experiments, and confirmed automation of this assay had been successful. Once again, 
the PML body total area was identified as the measure which best differentiated the 
control and RNF4 siRNA mediated phenotypes. These data confirm that the 96 well 
plate screening assay can discriminate between the phenotypes resulting from NT 
siRNA and RNF4 siRNA transfection prior to arsenic treatment, and are therefore 
encouraging in terms of using this assay to perform an siRNA screen searching for 
siRNAs which perturb the process of arsenic mediated degradation of PML.  
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Figure 3.2.9. Automated quantification of YFP-PML fluorescence 
following RNF4 depletion and arsenic treatment 
YFP-PML HeLa cells were transfected in 96 well plates with a pool of 4 siRNA 
duplexes targeting RNF4 or a non-targeting (NT) control duplex. 48 hours after 
transfection, cells were treated with 1µM arsenic for 24 hours. Cells were fixed 
and stained with DAPI. Imaging was performed using an IN Cell 1000 
automated microscope and YFP-PML fluorescence in the resulting images 
analysed using IN Cell Investigator software. 
(A) Average YFP-PML fluorescence of the cell nucleus was analysed for 
approximately 20 000 cells for NT and RNF4 siRNA transfected cells. Data 
were normalised to NT siRNA and represent the mean ± standard error of the 
mean. 
(B) The average YFP-PML fluorescence intensity of PML bodies was analysed 
for approximately 20 000 cells. Data were normalised to NT siRNA and  
represent the mean ± standard error of the mean. 
(C) The number of YFP-PML bodies per cell was analysed for 20 000 cells in 
each condition. Data were normalised to NT siRNA and represent the mean  
number of PML bodies per cell ± standard error of the mean. 
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(D) The total area of YFP-PML bodies per cell was analysed for 20 000 cells in 
each condition. Data were normalised to NT siRNA and represent the mean  
number of PML bodies per cell ± standard error of the mean. 
 
3.2.7.2 Z’ factor assessment of assay 
To assess whether an assay is suitable for high throughput siRNA screening, a 
number of statistical parameters can be calculated which give an indication of whether 
the assay is robust enough to allow confident identification of hits (Birmingham et al., 
2009).  One of these statistical parameters, the Z’ factor, is calculated using the mean 
and standard deviations of the positive and negative controls for a given parameter 
(Zhang et al., 1999), in this case each particular measure of YFP fluorescence.  Table I 
shows the Z’ factors calculated using the results obtained from arsenic treated, NT 
siRNA and RNF4 siRNA transfected cells analysed for the number of PML-NBs per 
cell, the average pixel intensity of PML-NBs and the PML body total area.  
Table I.  Z’ factor calculations 
Cells were transfected with either NT siRNA or RNF4 siRNA in 48 wells each 
of a 96 well plate. 48 hours after transfection, cells were treated with 1µM 
arsenic trioxide for 24 hours, and then fixed, DAPI stained and imaged using 
the automated high content screening assay. Z’ factors were calculated using 
the resulting data for number of PML bodies per cell, PML body intensity and 
total area of the nucleus occupied by PML bodies in cells transfected with NT 
or RNF4 siRNA. 
 
Z’ factor NT vs RNF4 siRNA 
PML body number 0.49 
PML body intensity -0.08 
PML body total area 0.56 
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Z' factor = 1 − 3(𝜎hc + 𝜎lc)|𝜇hc − 𝜇lc|  
Equation 3.1. Z’ factor calculation 
The Z’ factor is calculated using the means of the high and low controls (µhc and 
µlc respectively), and the standard deviation of the two control populations (σhc and  σlc) 
as demonstrated in Equation 3.1. 
A Z’ factor of greater than 0.5 identifies an assay which is statistically robust, in 
that there is sufficient separation of positive and negative controls to allow hit 
identification. A Z’ factor of >0 is adequate, and a Z’ factor of <0 demonstrating the 
assay is unsuitable for screening. Thus, the assay measurements of both PML- NB 
number and PML body total area produce statistically robust assays which should be 
suitable for use in a high content siRNA screen. Since the PML body total area had 
consistently yielded the best separation between negative and positive controls, it was 
selected as the primary measure to be used for siRNA screening. 
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3.2.7.3 Test plates 
Prior to commencing the large scale siRNA screen, a number of test plates were 
analysed using the assay described above. RNF4 siRNA was transfected in 17 wells of a 
96 well plate and NT siRNA in the remaining wells (Figure 3.2.10, panel A). Cells 
were treated with arsenic, fixed and stained before imaging and image analysis as 
previously described. The image analysis results were then interpreted by Amit Garg, 
data manager, without information as to which wells were transfected with RNF4 
siRNA. All 17 wells were correctly identified using the measure PML body total area 
(Figure 3.2.10, panel B), and once again the PML body total area in RNF4 depleted 
cells was approximately twice that found in control cells. 
At this stage, the high content screening assay had been tested on multiple 
occasions, all yielding similarly robust Z’ factors calculated using the positive and 
negative controls. It was therefore decided to proceed with the siRNA screen, using the 
assay as described. 
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Figure 3.2.10. Testing the high content screening assay 
(A) RNF4 siRNA was transfected in 17 wells of a 96 well plate, highlighted in 
red. The remaining wells were transfected with NT siRNA. 
(B) Cells transfected as in (A) were treated with 1µM arsenic 48 hours after 
transfection, and fixed with paraformaldehyde 24 hours later. Cells were then 
imaged and analysed using the automated assay. Data presented represent 
the mean total area of the nucleus occupied by PML bodies for all cells in the 
well. Approximately 4000 cells were analysed per well. Wells transfected with 
RNF4 siRNA are highlighted in orange. 
 
  
1 2 3 4 5 6 7 8 9 10 11 12
A 14.721 8.661 7.942 8.741 8.018 8.32 16.412 8.726 8.808 8.384 8.718 9.341
B 9.364 9.117 16.843 8.382 8.126 7.802 7.649 16.167 8.401 8.484 8.391 8.974
C 9.443 8.525 8.633 7.66 16.056 7.638 7.689 7.698 16.192 7.741 8.573 9.444
D 9.297 8.389 8.078 16.29 15.272 16.077 8.43 7.869 8.245 7.892 8.056 9.068
E 8.844 8.344 8.026 7.758 16.475 7.724 8.02 7.293 7.639 8.061 9.053 17.375
F 8.968 15.728 8.318 8.235 8.199 7.296 16.268 7.859 7.511 8.419 8.731 9.514
G 9.704 8.733 8.452 7.746 7.376 6.808 7.712 8.145 7.788 8.243 17.158 16.982
H 10.158 8.834 8.777 8.987 8.603 15.842 8.361 8.232 7.977 16.956 9.169 9.67
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3.2.8 Primary screen- ubiquitome siRNA library 
The first siRNA library to be used in the screening assay was a library consisting 
of 1067 pools of 4 siRNAs targeting elements of the ubiquitin system, for example 
ubiquitin E1, E2 and E3 enzymes, deubiquitylases, RING domain containing proteins, 
SUMO E1, E2 and E3 enzymes and SUMO specific proteases (Figure 3.2.11.). This 
library is owned by SCILLS, and is distributed over 15 96-well plates. 
 
Figure 3.2.11. Composition of the ubiquitome siRNA library 
The ubiquitome siRNA library is composed of siRNAs targeting proteins in the 
following categories: E1 enzymes, E2 enzymes, E3 enzymes, proteins with 
ubiquitin binding domains (UBD), deubiquitylating enzymes (DUBs) and SUMO 
specific proteases (SENPs). siRNAs targeting proteins not included in one of 
these categories are counted in ‘Others’. 
 
In order to identify siRNAs which influenced PML expression in the absence of 
arsenic, the screen was performed with and without arsenic treatment. Each assay plate 
contained both positive and negative siRNA controls (Figure 3.2.12, panel A) so the Z’ 
factor could be calculated for each assay plate for quality control. These plate controls 
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also allowed normalisation of data so the results for all test siRNAs could be compared, 
despite the siRNAs being assayed in a number of different plates.  
 
 
Figure 3.2.12. Plate layout and workflow for high content screening 
assay 
(A) Each 96 well plate in the high content screen contains the following 
controls: RNF4 siRNA (red), PML siRNA (yellow), non targeting siRNA (blue) 
and a transfection reagent plus cells control (green). Test siRNAs fill the 
remaining wells. 
(B) Schematic of workflow for high content screen. 
 
Prior to commencing the screen, quality control experiments were performed using all 
liquid handling devices to be used for dispensing reagents and cells to ensure accuracy, 
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to minimise error introduced by inaccurate dispensing. These tests were all satisfactory. 
All plates were transfected with siRNA at the same time (Figure 3.2.12, panel B). 48 
hours later, one set of 15 plates containing the siRNA library were treated with arsenic, 
and the other 15 plates were treated with vehicle solution at the same concentration. 24 
hours later, cells were fixed and stained with DAPI, using robotics for liquid handling. 
The plates were then imaged using the automated microscope, and the resulting images 
analysed using the protocol described in section 3.2.7.1, to measure the PML body total 
area for each test siRNA.  
3.2.8.1 Data analysis and quality control 
The output data from the IN Cell investigator software was further analysed by 
Amit Garg, SCILLS data manager, using ActivityBase software. The Z’ was calculated 
for each plate assayed to determine whether individual plates met quality control criteria 
(Figure 3.2.13). All plates in the arsenic treated dataset had Z’ score of greater than 0.5 
indicating they were suitable for further analysis. Six of the 15 plates in the vehicle 
treated dataset had Z’ score of less than 0.5, but all were greater than 0.25 which was 
deemed acceptable (Birmingham et al., 2009). This is likely to be because RNF4 siRNA 
does not produce a particular phenotype in the absence of arsenic treatment (Figure 
3.2.6., 0hr time point). All 30 plates were then analysed to identify potential hits. 
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Figure 3.2.13. Quality control for primary ubiquitome library siRNA 
screen  
The Z’ factor was calculated for each plate in the siRNA screen using results 
from wells containing the negative control, non targeting siRNA and the 
positive control, RNF4 siRNA. Red line denotes optimal Z’ threshold of 0.5. 
 
YFP-PML fluorescence was analysed for each test siRNA, and the parameter 
used for hit identification was PML body total area. Potential hits were identified using 
two parameters: ‘non target fold’ and ‘percent activity’. ‘Non target fold’ was calculated 
by dividing the PML body total area for a test siRNA by the result for NT siRNA 
control. ‘Per cent activity’ was derived by calculating the test siRNA PML body area as 
a percentage of that of the RNF4 positive control. Potential hits were selected as 
siRNAs with PML body total area greater than 2 standard deviations above or below the 
‘non target fold’ or ‘per cent activity’ average. This resulted in four lists of putative hits; 
siRNAs which decreased PML expression in the absence of arsenic, siRNAs which 
increased PML expression in the absence of arsenic, siRNAs which decreased PML 
expression in response to arsenic and siRNAs which increased PML expression in 
response to arsenic. 
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3.2.8.2 Results 
Tables II and III list the putative hits identified in the non- drug treated dataset, 
including the ‘non target fold’ value for each. In order to score as a hit in this dataset, 
the siRNA ‘non target fold’ was either less than 0.6 or greater than 1.32. The siRNAs 
included in the list with ‘non target fold’ values outside these limits were scored as hits 
because the ‘percent activity’ was outwith 2 standard deviations of the mean.  
The arsenic treated dataset yielded the following list of potential hits (Tables IV 
and V). In order to score as a hit in this dataset, the ‘non target fold’ was less than 0.5 
or greater than 1.175. ‘Percent activity’ thresholds for this dataset were 8.18 and 
48.86% of RNF4 activity. 
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Table II. Ubiquitome screen: putative hits in non drug treated dataset 
which increase PML expression 
Gene Symbol 
Fold change 
compared to NT 
siRNA control 
CUL3 2.40 
BAZ1B 1.81 
TRIM7 1.80 
VPS11 1.61 
DCUN1D1 1.55 
NICE-4 1.52 
COPS6 1.50 
LZTR1 1.48 
TRAF2 1.39 
MARK1 1.34 
UEVLD 1.33 
BRPF3 1.32 
CHD4 1.21 
UCHL3 1.43 
SHARPIN 1.38 
USP15 1.40 
UBQLN2 1.39 
FBXO34 1.38 
UFD1L 1.35 
UBASH3A 1.35 
USP18 1.34 
TRIM60 1.33 
TRIM62 1.33 
FBXL19 1.33 
RBX1 1.26 
LOC643904 1.23 
KRTAP5-9 1.20 
PDZRN3 1.17 
PHF11 1.15 
BAHD1 1.15 
PHF13 1.15 
BRPF1 1.14 
AIRE 1.13 
BRCA1 1.11 
CNOT4 1.11 
EEA1 1.09 
ANAPC11 1.09 
MARCH-IX 1.09 
LPXN 1.09 
WDR71 1.08 
C6ORF49 1.07 
IBRDC2 1.07 
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Table III. Ubiquitome screen: putative hits in non drug treated dataset 
which decrease PML expression 
Gene Symbol 
Fold change 
compared to NT 
siRNA control 
PML 0.24 
RBBP6 0.34 
SOCS2 0.38 
LOC200933 0.41 
DDB1 0.42 
FBXL3A 0.45 
PCF11 0.45 
KIAA1536 0.47 
DNAJB2 0.47 
RYBP 0.47 
TRIM33 0.49 
FBXO43 0.49 
CBLL1 0.50 
SPOP 0.50 
MGC10198 0.53 
LOC124402 0.59 
REV1L 0.60 
TRIM48 0.60 
FBXW12 0.48 
RAB40C 0.50 
FBXW7 0.52 
FBXW2 0.54 
SHFM3 0.54 
KIAA0644 0.57 
LMX1B 0.57 
KLHL15 0.64 
KIAA0363 0.65 
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Table IV. Ubiquitome screen: putative hits in arsenic treated dataset 
which increase PML expression 
Gene Symbol 
Fold change 
compared to NT 
siRNA control 
RNF4 1.69 
CHD4 1.59 
BAZ1B 1.55 
FBXO44 1.52 
UBE4B 1.51 
LOC644006 1.46 
VPS11 1.42 
ZNF364 1.40 
LZTR1 1.29 
MYO6 1.23 
STAM 1.19 
EPN3 1.09 
UBE2V2 1.29 
UEVLD 1.28 
RNF165 1.26 
NPL4 1.26 
LPXN 1.24 
SENP1 1.23 
TOPORS 1.23 
KCTD15 1.22 
LNX2 1.19 
UFD1L 1.19 
LMX1B 1.18 
LRRC29 1.26 
KIAA0804 1.23 
INTS12 1.22 
LOC200933 1.19 
TRIM45 1.19 
40245 1.18 
ANAPC2 1.17 
DKFZP761G2113 1.16 
USP37 1.13 
KIAA1536 1.13 
EIF2AK4 1.09 
EPN2 1.08 
CDC27 1.04 
DMRT3 1.03 
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Table V. Ubiquitome screen: putative hits in arsenic treated dataset 
which decrease PML expression 
Gene Symbol 
Fold change 
compared to NT 
siRNA control 
CNOT4 0.04 
RNF6 0.05 
FSD1L 0.10 
DTX3L 0.11 
PML 0.37 
CXXC1 0.49 
RBX1 0.49 
UBE1 0.50 
PCF11 0.46 
OTUD5 0.58 
IBRDC3 0.08 
EDD1 0.37 
TRIP12 0.44 
RAB40C 0.45 
DDB1 0.46 
RBBP6 0.46 
HUWE1 0.46 
SMURF1 0.48 
RYBP 0.50 
BRE 0.50 
USP20 0.53 
 
3.2.8.3 Hits selected for further follow up 
The raw images for each of the putative hits listed in tables Tables II, III, IV 
and V were examined to assess the YFP-PML fluorescence. In each case, the data 
analysis results corresponded to the phenotype seen in the images. 
The top hits, that is those producing the most pronounced phenotypes for each 
dataset, were selected for further analysis in the deconvolution screen. There was some 
crossover between the hits identified in the vehicle and arsenic treated datasets (Tables 
VI and VII). 
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Table VI. Ubiquitome screen follow up: putative hits in non drug 
treated dataset selected for further investigation in deconvolution 
screen 
Gene Symbol 
Fold change 
compared to NT 
siRNA control 
CUL3 2.40 
BAZ1B 1.81 
TRIM7 1.80 
VPS11 1.61 
DCUN1D1 1.55 
PML 0.24 
RBBP6 0.34 
SOCS2 0.38 
 
Table VII. Ubiquitome screen follow up: putative hits in arsenic treated 
dataset selected for further investigation in deconvolution screen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Symbol 
Fold change 
compared to NT 
siRNA control 
RNF4 1.69 
CHD4 1.59 
BAZ1B 1.55 
FBXO44 1.52 
UBE4B 1.51 
LOC644006 1.46 
VPS11 1.42 
ZNF364 1.40 
LZTR1 1.29 
STAM 1.19 
EPN3 1.09 
UBE2V2 1.29 
UEVLD 1.28 
RNF165 1.26 
TOPORS 1.23 
CNOT4 0.04 
RNF6 0.05 
FSD1L 0.10 
DTX3L 0.11 
PML 0.37 
CXXC1 0.49 
OTUD5 0.58 
IBRDC3 0.08 
USP20 0.53 
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3.2.9 Deconvolution screen- ubiquitome siRNA library 
The aim of the deconvolution screen was to identify siRNAs which give a true 
phenotype and to exclude those which produce a phenotype through an off target effect. 
In order to do this, four individual siRNAs for each target gene were assayed. When two 
or more of these duplexes produced the same phenotype, a true hit was identified, 
whereas if only one of the four produced a phenotype, this gene target was rejected as 
an off target effect of that individual siRNA. 
For each of the putative hits identified listed in tables VI and VII, the four 
individual siRNA duplexes making up the pool of siRNA tested in the primary screen 
were ordered. A screen was then performed in exactly the same way as described in 
section 3.2.4 using these 96 siRNA duplexes targeting 24 individual genes, distributed 
in two 96 well plates. Positive and negative controls were included in each plate. Once 
again, duplicate plates were treated with either arsenic or vehicle, and imaged and 
analysed using the automated microscopy system.  
The deconvolution experiments for CUL3 and DCUN1D1 were performed in 
the non-automated assay described in section 3.2.6, because siRNA duplexes were 
available in the lab, and were therefore not ordered in 96 well plate format. 
3.2.9.1 Data analysis and quality control 
Amit Garg, SCILLS data manager performed initial data analysis using 
ActivityBase software. The Z’ was calculated for each of the four plates assayed using 
the RNF4 and NT siRNA controls ( Figure 3.14), and for the arsenic treated plates, Z’ 
were highly satisfactory at 0.8, indicating the data were suitable for further analysis. The 
Z’ in the vehicle treated plates were once again lower, but deemed to be acceptable as 
they were greater than 0 in both cases.  
113 
 
 
Figure 3.2.14. Quality control for deconvolution ubiquitome siRNA 
screen 
The Z’ factor was calculated for each plate in the siRNA screen using results 
from wells containing the negative control, non targeting siRNA and the 
positive control, RNF4 siRNA. Red line denotes optimal Z’ threshold of 0.5. 
 
3.2.9.2 Results 
As mentioned previously, the purpose of this experiment was to investigate 
whether phenotypes identified in the primary siRNA screen were off target effects of 
the pools of siRNA tested. Once again, the data were allocated into four datasets: 
siRNAs which increased PML expression in the presence of arsenic, those which 
decreased PML expression in the presence of arsenic, those which increased PML 
expression in the absence of drug and those which decrease expression in the absence of 
drug. Twelve target genes were validated as potential regulators of PML in the presence 
of arsenic; nine raising PML expression (Table VIII) and three decreasing expression 
(Table IX). At least two oligosiRNAs targeting each of these genes reproduced the 
phenotype identified in the primary screen. All four oligosiRNAs targeting CUL3 and 
DCUN1D1 caused marked accumulation of PML in the absence of arsenic treatment 
(Table X), but no other targets were validated in this dataset. siRNAs targeting two of 
the genes identified to decrease PML expression in the presence of arsenic were also 
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validated to decrease PML expression in the absence of arsenic (Table XI). For the 
remaining target genes examined, only one siRNA recreated the phenotype identified in 
the primary screen and were therefore excluded from further follow up. 
Table VIII. Deconvolution screen: siRNAs confirmed to increase PML 
expression following arsenic treatment 
Gene Symbol 
Fold change compared to NT siRNA control 
Oligo 1 Oligo 2 Oligo 3 Oligo 4 
UEVLD 1.79 0.96 0.72 1.23 
FBXO44 1.36 0.79 1.07 1.52 
BAZ1B 0.96 1.14 1.80 1.05 
CHD4 0.91 1.45 1.04 2.01 
LOC644006 1.35 1.24 1.13 0.97 
TOPORS 1.18 0.83 1.25 1.32 
UBE4B 1.24 1.47 1.57 1.19 
VPS11 0.72 0.87 1.57 1.47 
EPN3 0.73 0.87 1.16 1.17 
 
Table IX. Deconvolution screen: siRNAs confirmed to decrease PML 
expression following arsenic treatment 
Gene Symbol 
Fold change compared to NT siRNA control 
Oligo 1 Oligo 2 Oligo 3 Oligo 4 
CXXC1 0.70 0.36 0.49 0.57 
RBBP6 0.34 0.39 0.34 0.42 
OTUD5 0.27 0.49 0.52 0.41 
 
Table X. Deconvolution screen: siRNAs confirmed to decrease PML 
expression in the absence of arsenic 
Gene Symbol 
Fold change compared to NT siRNA control 
Oligo 1 Oligo 2 Oligo 3 Oligo 4 
CXXC1 0.77 0.41 0.54 0.49 
RBBP6 0.35 0.41 0.19 0.41 
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Table XI. Deconvolution screen: siRNAs confirmed to increase PML 
expression in the absence of arsenic 
Gene Symbol 
Fold change compared to NT siRNA control 
Oligo 1 Oligo 2 Oligo 3 Oligo 4 
CUL3 8.11 5.16 4.89 5.65 
DCUN1D1 5.11 2.94 1.75 2.54 
 
3.2.9.3 Hits selected for further follow up 
The next step was to decide which of the validated gene targets to follow up 
with further experiments to attempt to characterise the role of the gene product in the 
regulation of PML. The phenotype induced by siRNAs targeting CUL3 and DCUN1D1 
were particularly striking and therefore they were selected for further investigation, 
detailed in Chapter 4.  
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3.2.10 Primary screen- kinome siRNA library 
There is evidence to suggest that phosphorylation of PML influences its stability 
(Gresko et al., 2008), and that PML is phosphorylated in response to arsenic treatment 
(Hayakawa and Privalsky, 2004). The screening assay was therefore repeated using a 
library of siRNAs targeting kinases, a subset of the Drug Discovery Unit whole genome 
siRNA library, to identify kinases involved in the process of arsenic mediated 
degradation of PML. This screen consisted of 12 assay plates which were tested with 
and without arsenic treatment using the same plate layout and controls as described in 
section 3.2.7.  
3.2.10.1 Data analysis and quality control 
Data were analysed by Amit Garg using ActivityBase software. The Z’ for each 
assay plate was calculated using RNF4 and NT siRNA controls. The Z’ for the arsenic 
treated datasets were highly satisfactory with all scoring approximately 0.7 (Figure 
3.2.15). The Z’ for the non- drug treated dataset were lower, with values ranging from 
0.2 to 0.7. Hits were identified using the parameters of ‘non target fold’ and ‘percent 
activity’ as in the primary screen, and siRNAs giving a PML body total area of greater 
or less than two standard deviations from the mean for either or both of these 
parameters were determined to be hits. 
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Figure 3.2.15. Quality control for primary kinome library siRNA screen 
The Z’ factor was calculated for each plate in the siRNA screen using results 
from wells containing the negative control, non targeting siRNA and the 
positive control, RNF4 siRNA. Red line denotes optimal Z’ threshold of 0.5. 
 
3.2.10.2 Results 
Data were grouped into hits in the presence (Table XIII) or absence (Table 
XII) of arsenic treatment. Three siRNAs were hits in both datasets, NLK, PMVK and 
MGC26597, though the latter is a pseudogene.  
The lists of hits were reviewed and links with PML sought from the literature. 
There were no clear links with PML, and therefore follow up experiments were 
concentrated on hits generated from the ubiquitome siRNA screen. 
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Table XII. Kinome screen: putative hits from non drug treated dataset 
Gene Symbol 
Fold change 
compared to NT 
siRNA control 
CDK5RAP1 0.32 
MGC26597 0.40 
SGKL 0.40 
TTBK1 0.44 
CDK9 1.40 
PCK1 1.57 
EPHA6 1.66 
GFRA2 1.66 
PMVK 1.69 
BLNK 1.73 
MAP4K5 1.78 
CAMKK2 1.85 
APEG1 2.04 
NLK 2.04 
AKAP3 2.40 
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Table XIII. Kinome screen: putative hits from arsenic treated dataset  
Gene Symbol 
Fold change 
compared to NT 
siRNA control 
MGC26597 0.24 
AGTR2 0.26 
PANK4 0.31 
AKT2 0.31 
ITPKA 0.38 
CKB 1.26 
CLK1 1.27 
NRBP2 1.28 
MAP3K1 1.29 
MYLK 1.32 
PIP5K2B 1.32 
FGFR4 1.32 
TAO1 1.34 
CHKB 1.36 
CALM3 1.37 
AMHR2 1.39 
PIK3CA 1.39 
NLK 1.47 
STK23 1.54 
MAP2K7 1.56 
PMVK 1.59 
 
3.2.11 Conclusions 
The aim of this project was to investigate the mechanism of arsenic induced 
degradation of PML using a high content siRNA screen. Initial experiments 
characterised the various reagents required. A new, chicken anti-PML antibody was 
demonstrated to identify endogenous PML by both western blotting and 
immunofluorescence. The kinetics of arsenic mediated degradation of PML were then 
assessed and demonstrated to be near complete after 24 hours of arsenic treatment. 
siRNA mediated depletion of RNF4 prior to arsenic treatment prevented PML 
degradation, which resulted in accumulation of PML within PML-NBs demonstrated by 
immunofluorescence. This suggested other siRNAs which influence the pathway of 
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arsenic induced degradation of PML may be identified by monitoring PML-NBs by 
immunofluorescence. 
An assay suitable for high content siRNA screening was then developed, using 
RNF4 siRNA as a positive control. A YFP linked version of PML stably expressed in 
HeLa cells was demonstrated to degrade in an RNF4 dependent manner as for 
endogenous PML. These cells were selected for use in the siRNA screen as two step 
antibody staining of endogenous PML was not then required. Quantitation of YFP 
fluorescence was performed following transfection with RNF4 siRNA and arsenic 
treatment and PML body total area was noted as the measure which best discriminated 
between control cells and those depleted of RNF4.  
A high content siRNA screen was then performed, using the YFP PML HeLa 
cell line and a library of 1067 pools of siRNA targeting components of the ubiquitin 
system. The screen was performed with and without arsenic treatment. Cells were 
transfected with siRNA and 48 hours later treated with arsenic or vehicle for 24 hours 
before fixation. Cells were imaged using an automated microscope and YFP PML 
fluorescence quantified using a protocol developed to quantify the size of PML-NBs. 
Data was then analysed and a number of potential hits identified. Putative hits were 
further validated in a deconvolution screen in which 4 individual siRNAs targeting each 
putative hit were assayed. A number of hits were validated in this way. The most 
striking phenotypes were noted in the absence of arsenic treatment when CUL3 and 
DCUN1D1 were depleted. Further follow up experiments are discussed in the chapter 
which follows. 
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3.3 Discussion 
3.3.1 Rationale for use of a high content screen  
Despite the widespread clinical use of arsenic trioxide in the treatment of acute 
promyelocytic leukaemia, the mechanism of its action has only recently been 
elucidated, and unanswered questions remain. Arsenic treatment induces proteasomal 
degradation of PML and PML-RARα (Lallemand-Breitenbach et al., 2008; Lallemand-
Breitenbach et al., 2001; Tatham et al., 2008). Shortly after arsenic treatment, PML is 
recruited to PML-NBs, where it is SUMO modified. This SUMO modification recruits 
the SUMO targeted ubiquitin E3 ligase, RNF4 to PML-NBs (Geoffroy et al., 2010). 
RNF4 ubiquitylates SUMO modified PML targeting it for degradation by the 26S 
proteasome (Lallemand-Breitenbach et al., 2008; Tatham et al., 2008). A number of 
questions remain regarding this process: what is the SUMO E3 ligase responsible for 
SUMO modification of PML?; do SUMO specific proteases modify the process of 
arsenic induced sumoylation of PML and if so which ones?; which deubiquitylating 
enzymes counteract the actions of RNF4?; are there other ubiquitin mediated regulators 
of PML? This project set out to investigate this process using siRNA screening to 
identify components of the ubiquitin system that influence the process of arsenic 
mediated degradation of PML. 
High content screening refers to the use of automated microscopy to capture 
images of intact cells as the read out of a high throughput assay (Giuliano et al., 1997). 
Assays may use live or fixed cells, and often capture images of multiple fluorescently 
labelled cellular structures or proteins. The advantage of using such an assay is that 
various parameters can be quantitavely assessed to define the effect of a given 
treatment. For example, the intensity, distribution and size of regions of fluorescent 
signal can be assayed. The morphology of cells can also be evaluated, which may allow 
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identification of drugs or siRNAs which have particularly toxic effects. Thus, a huge 
amount of data can be gleaned from a single assay. Advances in the quality of 
automated microscopy equipment have allowed interrogation of various cellular 
processes using this technology. High content screening can be used for drug discovery, 
for example previous screens have identified compounds with efficacy against the 
tropical disease Leishmaniasis (Siqueira-Neto et al., 2012), and compounds which 
induce mitotic arrest (Wilson et al., 2006). The use of siRNA coupled with high content 
screening allows examination of loss of function phenotypes on a genome wide scale, 
which can help define key proteins in cellular processes (Adamson et al., 2012; Lipinski 
et al., 2010; Orvedahl et al., 2011).  
Arsenic induced degradation of PML can be monitored using fluorescence 
microscopy (Figures 3.2.4., 3.2.6). Disruption of this pathway induced by depletion of 
RNF4 results in a striking phenotype, with accumulation of PML in PML-NBs (Figures 
3.2.4., 3.2.6.) (Geoffroy et al., 2010; Lallemand-Breitenbach et al., 2008; Tatham et al., 
2008). This suggested that it may be possible to identify other gene products involved in 
this process by monitoring the appearance of PML-NBs after siRNA mediated gene 
knockdown and arsenic treatment. A cell line expressing a YFP linked version of PML 
isoform III was characterised. Experiments confirmed YFP PML degraded in an RNF4 
dependent manner in response to arsenic, recapitulating the phenotype identified for 
endogenous PML. This cell line was selected for use in further experiments because 
YFP PML fluorescence could be directly visualised, thus removing the need for two 
step antibody labelling of PML. The difference in whole cell YFP fluorescence was not 
significantly altered in cells depleted of RNF4 following arsenic treatment compared to 
control cells (Figure 3.2.7., panel A) Measuring whole cell fluorescence using a plate 
reader was therefore unlikely to be sensitive enough to detect small changes in whole 
cell PML fluorescence induced by blocking arsenic mediated degradation of PML in 
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this way. High content siRNA screening was therefore an attractive option to investigate 
the role of a large number of gene products in the process of arsenic mediated 
degradation of PML, because the size, number and location of PML-NBs could be 
monitored allowing identification of siRNAs which perturbed the process of PML 
degradation. 
3.3.2 Appraisal of the screening assay 
The aim of this assay was to identify gene products which influenced PML 
degradation in response to arsenic treatment. To assess whether gene products were 
associated with changes in PML-NB stability exclusively in the presence of arsenic 
treatment, the assay was also performed without arsenic. The majority of assay 
development was performed using arsenic treated cells, and in particular, the positive 
control siRNA RNF4 only produces a pronounced PML phenotype in cells treated with 
arsenic (Figure 3.2.6.) The Z’ quality control measure was calculated for all plates 
using the positive (RNF4) and negative (non targeting) siRNA controls. Because there 
was not a significant difference between the positive and negative controls in the 
absence of arsenic, plates assayed in the absence of arsenic had lower Z’ scores 
(Figures 3.2.12., 3.2.13. and 3.2.14.). The Z’ of arsenic treated plates was consistently 
very good at approximately 0.75, indicating the assay was robust. RNF4 siRNA was 
included within the siRNA library and was identified as the top hit in the arsenic treated 
data set (Table IV). This confirmed the ability of the assay to robustly identify the 
phenotype of PML-NB accumulation of PML following arsenic treatment induced by 
RNF4 depletion. To increase confidence in the assay in the absence of arsenic, the 
screen could be repeated using CUL3 siRNA as the positive control, which was 
identified to induce marked accumulation of PML in the absence of arsenic (discussed 
in detail in Chapter 4 of this thesis). 
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PIAS1, the SUMO E3 ligase reported to be required for arsenic induced 
degradation of PML (Rabellino et al., 2012) was not identified as a hit in this screen. If 
one assumes PIAS1 is indeed the ligase required, there are a number of technical 
reasons why this may not have been identified. These reasons also apply to the reporting 
of other potential false negatives. siRNA transfection efficiency may not have been 
optimal in the well containing the pool of siRNAs targeting PIAS1. The quality control 
plates performed at the beginning and end of the screen have positive control siRNA 
transfected in each well of the 96 well plate. By assaying these, any well specific 
transfection problems, for example due to a blocked pipette tip on the liquid handling 
device, should have been identified. This does not however exclude a problem with 
transfection in a single well. This could be investigated by performing further replicates 
of the primary siRNA screen to increase confidence in the hits identified and to confirm 
siRNAs which do not produce a phenotype. This assay was performed at one time point 
only, with the end point of the assay 72 hours after siRNA transfection. The efficiency 
of siRNA mediated knockdown at a protein level depends on the half life of the protein 
translated from the targeted mRNA. Therefore, if the half life of the targeted protein is 
longer than 72 hours, the effects of siRNA mediated knockdown are unlikely to be 
identified as a hit by this assay. This could be avoided by performing the screen at 
different time points.  Where multiple proteins contribute to a cellular process, 
redundancy between these proteins may mean that siRNA mediated depletion of a 
single factor does not cause a phenotype sufficient for hit identification in the screening 
assay. Finally, the screen was performed using a cell line expressing YFP linked PML 
isoform III in HeLa cells which also express endogenous PML (Geoffroy et al., 2010). 
It is possible that PML isoform III specific effects may be identified using this cell line, 
though interactions between YFP PML III and endogenous PML may preclude this. The 
screen could be repeated using the cell lines employed in Chapter 5 of this thesis, which 
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express only a single PML isoform (Cuchet et al., 2011) to identify isoform specific 
phenotypes. Alternatively immunofluorescence labelling of endogenous PML could be 
employed to assess the effects of siRNA knockdown on the degradation of endogenous 
protein. 
3.3.3 Other applications of the HCS assay 
Yip and colleagues developed a high content screen to identify compounds 
which induced formation of PML-NBs, using a measure of the number of PML-NBs 
present within the cell nucleus as the read out, and interferon stimulation as a positive 
control (Yip et al., 2011). The assay described in this thesis could be used to identify 
compounds which induce degradation of PML-NBs, using arsenic as a positive control. 
Compounds identified by such a screen may be clinically useful in patients with APL 
for whom arsenic treatment is contraindicated. Compounds identified in this way would 
not necessarily act via the same mechanism as arsenic, and therefore may be useful in 
the treatment of patients whose disease has become refractory to arsenic therapy. It 
would also be possible to identify compounds which induce PML accumulation in 
PML-NBs using this assay. Though such compounds would not be useful in the 
treatment of APL, they be useful in other cancers in which PML expression is lost, as 
the loss of PML is associated with increased tumour invasion (Gurrieri et al., 2004). 
Compounds which increase PML expression may therefore help to rescue this 
phenotype, and be useful as anti- cancer treatments.  
3.3.4 Selection of hits for further follow up 
The first step after the screen had been performed and data analysed was to 
decide which putative hits to follow up in the deconvolution screen. In the main, these 
were siRNAs which had induced the most pronounced phenotypes either in the presence 
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or absence of arsenic treatment. There were some siRNAs which scored as hits in both 
datasets, suggesting that the gene product targeted exerted effects on PML independent 
of arsenic treatment. 
Hits were validated in the deconvolution screen when 2 of more siRNAs with 
distinct sequences targeting the same gene induced the same PML phenotype. This was 
the case for 14 target gene products (Tables VIII, IX, X, and XI), the vast majority of 
which were not previously reported to influence PML stability or the process of arsenic 
mediated degradation of PML. Of the gene products noted to impair arsenic mediated 
degradation of PML, LOC644006 is an RNF4 pseudogene. The sequence of 
LOC644006 and RNF4 are very similar, and it is therefore likely that siRNAs designed 
to target the sequence of LOC644006 also targeted RNF4 mRNA for degradation. 
Western blotting analysis of cell extracts transfected with the pool of siRNAs targeting 
LOC644006 confirmed reduced RNF4 expression (data not shown), and thus explain 
the phenotype detected in the screen.  
3.3.4.1 CHD4 and BAZ1B 
Depletion of the transcription factors CHD4 and BAZ1B was noted to impair 
arsenic mediated degradation of PML (Table VIII). Both are implicated in disease 
processes. A proportion of patients with dermatomyositis have autoantibodies to CHD4 
(Seelig et al., 1995), and BAZ1B (also known as WSTF)  is commonly deleted in 
patients with William’s syndrome (Lu et al., 1998). CHD4 is part of a large multi-
protein complex which has both chromatin remodelling effects and histone deacetylase 
function, and maintains gene repression. BAZ1B is a member of three chromatin 
remodelling complexes, which have diverse roles in transcriptional control of a number 
of processes. Cells derived from BAZ1B deficient mice were obtained (Yoshimura et 
al., 2009), however unfortunately the chicken anti PML antibody was not reactive to 
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endogenous PML in these cells, precluding further investigations. The mechanism of 
how these transcription factors and related complexes may regulate arsenic mediated 
degradation of PML is not immediately clear. The phenotype identified in the screen 
may be due to a direct effect on PML expression, or via regulation of one or more 
intermediates. Initial steps in follow up for these siRNA phenotypes would include the 
use of RT qPCR to assess the effects of depletion of CHD4 or BAZ1B on PML 
expression. It would also be useful to quantify expression of other known components 
of the pathway of arsenic mediated degradation of PML, for example RNF4. 
3.3.4.2 UBE4B 
The ubiquitin fusion degradation (UFD) pathway is a ubiquitin mediated 
proteolytic pathway first identified in yeast. The yeast homologue of UBE4B, UFD2 
was identified in a screen searching for mutations which impaired degradation of a 
ubiquitin- glutathione S-transferase (ubi-GST) fusion (Johnson et al., 1995). UFD2 is a 
RING domain containing protein which functions as a so called ubiquitin E4 enzyme. 
UFD2 is not required for the initiation of ubiquitylation of ubi-GST, but its addition 
greatly enhances the formation of polyubiquitin chains (Koegl et al., 1999). It has been 
further demonstrated that UFD2 functions in a pathway which escorts ubiquitylated 
proteins to the proteasome for degradation (Richly et al., 2005). p97 (CDC48 in yeast) 
is a member of the AAA ATPase family which has been demonstrated to have roles in 
multiple cellular processes including the degradation of misfolded proteins, 
autophagosome maturation (Ju et al., 2009; Tresse et al., 2010), and membrane transport 
(Ye et al., 2001). p97/ CDC48 exerts functions to remodel ubiquitylated substrate 
proteins to facilitate downstream events, and binds to UFD2 and recruits 
oligoubiquitylated substrates for further ubiquitylation by UFD2 (Richly et al., 2005). 
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The E4 activity of UBE4B has been demonstrated to enhance MDM2 mediated 
ubiquitylation and degradation of p53 (Wu and Leng, 2011; Wu et al., 2011).  
Depletion of UBE4B in the siRNA screen impaired degradation of PML in 
response to arsenic treatment. This is consistent with a model in which UBE4B 
mediated ubiquitylation of PML following arsenic treatment enhances proteasomal 
degradation of PML via a CDC48 mediated pathway. Thus, depletion of UBE4B would 
impair PML ubiquitylation and degradation, leading to the phenotype identified in the 
screen. This may be an additional mechanism by which PML is degraded in response to 
arsenic treatment. A specific inhibitor of p97 ATPase activity, DBeQ, has recently been 
reported (Chou et al., 2011). Preliminary experiments performed using this compound 
demonstrated accumulation of PML after treatment with DBeQ suggesting PML may be 
a substrate of a p97 mediated degradative pathway (data not shown). Attempts to use 
this compound to investigate the role of p97 in arsenic mediated degradation of PML 
were limited by toxicity of the combination of DBeQ and arsenic trioxide treatments. 
An alternative approach to investigate this process would be to use an in vitro system to 
investigate whether PML is a substrate of UBE4B/ p97. It would be interesting to 
investigate whether any ubiquitylation activity of UBE4B/ p97 toward PML was 
dependent on SUMO modification of PML, as is true for RNF4 (Lallemand-
Breitenbach et al., 2008; Tatham et al., 2008). 
3.3.4.3 OTUD5 
OTUD5 (also known as DUBA) is a member of the ovarian tumour domain 
class of deubiquitylase enzymes. OTUD5 activity is regulated by phosphorylation, and 
phosphorylated OTUD5 undergoes marked structural changes on ubiquitin binding 
(Huang et al., 2012). OTUD5 was previously identified as a negative regulator of the 
innate immune system (Kayagaki et al., 2007), where it suppresses type 1 interferon 
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production. Depletion of OTUD5 was noted to enhance arsenic mediated degradation of 
PML (Table IX). If PML were a substrate of the deubiquitylating activity of OTUD5, it 
would be anticipated that depletion of OTUD5 would lead to enhanced PML 
degradation, as was observed in the screen. Some preliminary follow up experiments 
were performed to test this hypothesis. It was noted however that depletion of OTUD5 
resulted in accumulation of RNF4 (data not shown). This increase in RNF4 expression 
is likely to account for the phenotype identified in the screen. The mechanism by which 
OTUD5 depletion results in increased RNF4 expression is unclear, but cannot be 
explained by an increase in Lys48 linked ubiquitin chains attached to RNF4. It is 
possible that OTUD5 depletion leads to destabilisation of an intermediate which in turn 
leads to stabilisation of RNF4. OTUD5 was previously reported to have specificity for 
Lys63 linked ubiquitin chains (Kayagaki et al., 2007). Therefore OTUD5 depletion may 
lead to accumulation of ubiquitin chains of different linkage type attached to RNF4 or 
an intermediate which in turn stabilises the protein. 
3.3.4.4 CUL3 and DCUN1D1 
CUL3 depletion resulted in marked accumulation of PML in the primary screen. 
This phenotype was confirmed in the deconvolution screen (Table XI). DCUN1D1, a 
NEDD8 E3 ligase responsible for activation of cullin RING ligase complexes was also 
identified as a hit in the siRNA screen. Both phenotypes were identified in the absence 
of arsenic treatment, however accumulation was so striking that it was decided to follow 
up these hits further. This will be discussed in detail in chapter 4 of this thesis.  
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4 A CUL3 ubiquitin ligase complex regulates PML 
4.1 Introduction 
4.1.1 Cullin RING ligases 
The cullin family of proteins, which in humans consists of six members, form 
the scaffold of multi subunit ubiquitin E3 ligase complexes called cullin RING ligases 
(CRL). The CRL complexes formed by different cullin proteins, denoted CUL1, 2, 3, 
4a, 4b,  and 5, contain the cullin protein as a central scaffold which binds a RING 
domain containing protein, RBX1 or RBX2, at the C terminus and a substrate adaptor 
protein at the N terminus (Zheng et al., 2002). The RING domain of RBX1 or 2 recruits 
ubiquitin charged E2 enzyme to the complex, and promotes ubiquitin transfer to the 
substrate. CRL complexes regulate a variety of cellular processes, by targeting substrate 
proteins for ubiquitylation and subsequent proteasomal degradation (Petroski and 
Deshaies, 2005).  
Each cullin protein binds a distinct substrate adaptor protein which in turn binds 
substrate receptor proteins which confer substrate specificity to the complexes (Petroski 
and Deshaies, 2005; Zimmerman et al., 2010). CUL1 binds to the adaptor protein SKP1 
which in turn binds to various F- box protein substrate receptors responsible for 
recruiting substrate (Bai et al., 1996). CUL2 binds the adaptor protein Elongin C, which 
in turn binds suppressor of cytokine signalling/ elongin- BC (SOCS/BC) box substrate 
receptor proteins (Kamura et al., 1998). CUL3 binds proteins which confer both CUL3 
substrate adaptor and receptor function in a single polypeptide (Geyer et al., 2003; 
Pintard et al., 2003). These proteins consist of an N terminal Bric a brac, Tramtrack, 
Broad complex (BTB) domain, and recruit substrate via another protein- protein 
interaction domain at the C terminus (Figure 4.1.1.) (Stogios et al., 2005).  
131 
 
 
Figure 4.1.1. Schematic of a CUL3-BTB protein complex 
CUL3 RING ligase complexes consist of a CUL3 scaffold which binds to the 
RING domain protein RBX1 at the c terminus. RBX1 binds the ubiquitin 
charged E2 enzyme. Substrates are bound via a BTB domain containing 
adaptor protein which binds the N terminus of CUL3 via an N terminal BTB 
domain, and substrate via a second protein interaction motif at the C terminus.  
 
BTB domain containing proteins may dimerise via the BTB domain, and can therefore 
induce dimerization of CUL3 RING ligase complexes (Zhuang et al., 2009). There are 
approximately 350 BTB domain containing proteins in humans, though only around two 
thirds of these encode an additional protein- protein interaction domain. This suggests 
not all BTB proteins function as CUL3 adaptor proteins (Perez-Torrado et al., 2006). 
4.1.2 NEDD8 mediated regulation of CRL ubiquitin ligase 
activity 
The ubiquitin like protein NEDD8 is covalently linked to cullin proteins via an 
enzymatic cascade analogous to that of ubiquitin conjugation, termed neddylation 
(Gong and Yeh, 1999; Liakopoulos et al., 1998; Osaka et al., 1998). NEDD8 is first 
activated by a single E1 enzyme, NAE, which transfers NEDD8 to the catalytic cysteine 
residue of one of two E2 enzymes, UBE2M (UBC12) and UBE2F. These E2 enzymes 
CUL3
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U
U
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U
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catalyse neddylation of specific cullins; UBE2M catalyses neddylation of CUL1-4 and 
UBE2F neddylation of CUL5. These E2 enzymes work with separate E3 ligases; 
UBE2M with RBX1, and UBE2F with RBX2, to catalyse transfer of NEDD8 from the 
E2 to a conserved lysine residue in the C terminus of the target cullin (Huang et al., 
2009).  
Neddylation of cullins stimulates CRL ubiquitylation activity. Insight into the 
mechanism by which cullin neddylation brings about this enhanced ubiquitylation 
activity has been gained by examining the structure of both unmodified  and NEDD8 
modified cullin-RBX complexes (Duda et al., 2008). In CRL complexes not modified 
by NEDD8, the cullin adopts a closed conformation, and the RING domain of RBX1 is 
in contact with the cullin C terminal domain. NEDD8 modification of the acceptor 
lysine residue in the cullin C terminus results in marked structural changes, with the 
RBX1 RING domain released from interactions with the cullin into an open 
conformation. The RBX1 RING domain can then rotate into multiple different 
orientations (Duda et al., 2008). This open conformation enhances cullin ubiquitylation 
activity through increased recruitment of ubiquitin loaded E2, by improving ubiquitin 
transfer from the E2 active site and by bringing E2 and substrate into proximity (Saha 
and Deshaies, 2008).  
The process of cullin neddylation is inhibited by the protein CAND1, which 
binds to unmodified cullin-RBX1 complexes. The C terminal region of CAND1 binds 
to the cullin adaptor protein binding site preventing assembly of the CRL complex. The 
N terminal region of CAND1 binds to the RBX1 RING cullin interface that is present 
only when the cullin RBX1 complex is in the closed conformation. This locks the cullin 
in the closed conformation and obscures the NEDD8 acceptor lysine, preventing cullin 
neddylation (Duda et al., 2008; Goldenberg et al., 2004). 
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4.1.3 The role of DCUN1D1 in regulation of CRL activity 
DCUN1D1, like RBX1 and RBX2, functions as a NEDD8 E3 ligase, 
potentiating cullin neddylation (Kurz et al., 2008; Kurz et al., 2005; Scott et al., 2010). 
DCUN1D1 binds to components of the CRL complex (Kim et al., 2008) and is 
overexpressed in squamous cell carcinoma, in which cancer cells may become addicted 
to high DCUN1D1 levels (Sarkaria et al., 2006). Structural studies using the yeast 
homologue Dcn1 demonstrate Dcn1 to contain a ubiquitin associated (UBA) and a 
potentiating neddylation (PONY) domain, the latter of which is sufficient to potentiate 
neddylation (Kurz et al., 2008) both in vitro and in vivo. Further analyses have 
demonstrated that Dcn1 binds the E2 enzyme Ubc12 and the yeast CUL1 homologue 
Cdc53, reducing the distance between RBX bound, NEDD8 charged E2 and the 
acceptor lysine on the cullin, facilitating neddylation (Scott et al., 2010). Depletion of 
DCUN1D1 using siRNA demonstrates decreased, but not abolished neddylation of 
CUL1, suggesting despite its role in facilitating neddylation, DCUN1D1 is not essential 
for cullin neddylation (Kim et al., 2008). There are four other DCUN1D family 
members, DCUN1D2-5, each of which encode a C terminal PONY domain, but vary at 
the N terminus. DCUN1D3 has previously been shown to both interact with CUL3 and 
to influence its neddylation, with siRNA mediated depletion of DCUN1D3 decreasing 
CUL3 neddylation (Meyer-Schaller et al., 2009). 
4.1.4 Cullin 3 specific functions 
CUL3 CRL complexes are less extensively studied than CUL1 counterparts. As 
discussed above, proteins with a BTB domain mediate the interaction between CUL3-
RBX1 and substrate (Geyer et al., 2003; Pintard et al., 2004; Pintard et al., 2003). The 
BTB domain is a protein interaction domain which shares structural similarities with the 
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region of SKP1 which binds CUL1 (Schulman et al., 2000). BTB adaptor proteins may 
dimerize, thus inducing dimerization of CUL3 CRLs (Zimmerman et al., 2010). CUL3 
CRL complexes are implicated in the regulation of many diverse cellular processes. The 
first CUL3 CRL complex characterised was in C elegans. A complex involving the 
BTB domain containing protein MEL26 is required for degradation of MEI1, an event 
which allows proper formation of the mitotic spindle in early embryos (Furukawa et al., 
2003) . CUL3- BTB CRL complexes also play important roles in the control of mitotic 
progression and cytokinesis, where a complex involving CUL3 and KLHL9 and 
KLHL13 ubiquitylate the mitotic kinase Aurora B, controlling its proper localisation 
during mitosis (Sumara et al., 2007), and a KLHL21-CUL3 CRL complex is involved in 
Aurora B localisation during anaphase (Maerki et al., 2009). The transcription factor 
Nrf2 activates transcription of detoxifying enzymes in response to oxidative cell stress. 
Levels of Nrf2 are closely controlled by a CUL3 CRL complex which contains the BTB 
protein Keap1 (Zhang et al., 2004). Interestingly, a recent study described recurrent 
mutations in KLHL3, a BTB domain protein and CUL3  in patients with 
pseudohypoaldosteronism type II (PHA II), an inherited syndrome which results in 
hypertension, hyperkalaemia and metabolic acidosis, suggesting a CUL3- KLHL3 CRL 
complex plays a role in control of blood pressure, probably within the kidney (Boyden 
et al., 2012), though the substrate(s) affected remain so far uncharacterised. 
One previous study implicated a CUL3 CRL complex in the regulation of PML 
specifically under hypoxic conditions. Using prostate cancer cell lines, it was 
demonstrated that hypoxia induced expression of the BTB adaptor protein KLHL20, 
which forms a CUL3 CRL complex responsible for ubiquitylation and degradation of 
PML, a process dependent on the phosphorylation of PML (Yuan et al., 2011). In 
contrast to RNF4 mediated degradation of PML, this process was not dependent on 
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SUMO modification of PML, because a PML mutant which could not be sumoylated 
was efficiently ubiquitylated by the CUL3-KLHL20 complex. 
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4.2 Results 
4.2.1 siRNA screening data demonstrates Cullin 3 depletion 
results in PML accumulation 
As discussed in detail in Chapter 3 of this thesis, an siRNA screen using a 
library of siRNAs to target various components of the ubiquitome was performed to 
identify gene knockdowns which affected the size of PML bodies either in the presence 
or absence of arsenic treatment. The most striking phenotype noted in the siRNA screen 
performed in the absence of arsenic was identified when Cullin 3 (CUL3) was depleted. 
Cells transfected with CUL3 siRNA contained numerous large, bright PML bodies 
(Figure 4.2.1., panel A). Analysis of these images using the automated screening assay, 
demonstrated a 2.4 fold increase in the PML body total area when CUL3 and control 
siRNA transfected cells were compared (Figure 4.2.1., panel B). 
These data suggested that PML may be a substrate for a CUL3 ubiquitin E3 
ligase complex. In the absence of CUL3, it would be anticipated that substrates of a 
CUL3 E3 ligase complex would fail to be ubiquitylated, and thus accumulate. This is 
consistent with the phenotype identified in the siRNA screen. In support of this 
hypothesis, siRNA mediated depletion of DCUN1D1, a protein which is required for 
the neddylation and therefore activation of cullins, resulted in a 1.5 fold increase in the 
total area of the nucleus occupied by PML bodies.  
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Figure 4.2.1. siRNA screen data for CUL3 siRNA 
(A) Representative images of YFP-PML HeLa cells transfected with either 
control, non-targeting siRNA (left panels) or CUL3 siRNA (right panels) in the 
primary ubiquitome siRNA screen, as discussed in section 3.2.8. Cells were 
imaged with a 10x lens using an IN Cell 1000 automated microscope. Images 
represent individual z sections. 
(B) The sum of the area of all PML bodies in a given cell nucleus were 
analysed using the automated analysis protocol described in section 3.2.7.1.. 
The values for all cells transfected with non- targeting siRNA (6890 cells 
analysed) or CUL3 siRNA (6317 cells analysed) were averaged, and 
normalised to the NT siRNA result, to give the data shown on the graph. 
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4.2.2 Confirmation of CUL3 siRNA phenotype 
The data obtained in the initial siRNA screen used a pool of four siRNAs to 
target each test gene. Each of the four siRNA duplexes were then tested individually. 
This aimed to confirm that the phenotype identified in the primary screen was due to 
CUL3 depletion, and not due to an off target effect of an individual siRNA duplex. 
Cells were transfected with a non- targeting siRNA duplex, the previously tested 
pool of siRNAs targeting CUL3, or one of four individual siRNA duplexes targeting 
CUL3. Western blotting of cells transfected with non targeting control siRNA with an 
anti CUL3 antibody demonstrated two CUL3 species. The higher molecular weight 
species represented neddylated CUL3, and the lower, unmodified CUL3 (Figure 4.2.2., 
NT lane). 
 
Figure 4.2.2. CUL3 depletion results in accumulation of PML 
YFP PML HeLa cells were transfected with non-targeting, control siRNA or 4 
individual siRNA duplexes targeting CUL3, or a pool of all 4 duplexes. 72 hours 
later cells were lysed and analysed by western blotting with antibodies specific 
for PML, CUL3, RNF4 and actin. 
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Transfection with the pool of CUL3 siRNAs, or any of the four individual duplexes 
reduced CUL3 protein to undetectable levels (Figure 4.2.2., CUL3 siRNA 
lanes).CUL3 depletion resulted in accumulation of primarily high molecular weight 
YFP-PML and endogenous PML species. RNF4 expression was unaffected by CUL3 
depletion.  
To quantify the accumulation of PML noted by western blotting, cells were 
cultured on coverslips prior to transfection with non targeting siRNA, a pool of CUL3 
siRNAs or one of four individual siRNAs targeting CUL3. These cells were then 
imaged by deconvolution microscopy and YFP PML fluorescence quantified. Images 
demonstrated an increase in the number and size of PML nuclear bodies for cells 
transfected with the pool of CUL3 siRNAs or any of the four individual duplexes 
(Figure 4.2.3., panel A). The most pronounced increase in YFP PML fluorescence was 
noted in images of cells transfected with the pool of CUL3 siRNAs and the first 
individual siRNA duplex. Quantification of YFP PML fluorescence was then 
performed. Transfection of all four siRNA duplexes targeting CUL3 resulted in an 
increase in the PML body total area. The most pronounced effects were observed in 
cells transfected with oligo siRNA 1, for which an eight fold increase was noted 
(Figure 4.2.3., panel B). There was also an increase in the number of PML nuclear 
bodies detected, with transfection with any of the four individual CUL3 siRNAs 
increasing the number of PML bodies per cell two fold compared with control cells 
(Figure 4.2.3., panel C). This demonstrates that the increase in PML body total area 
noted in Figure 4.2.3., panel B is due to a combination of an increase in the number of 
PML bodies per nucleus and an increase in the size of these PML nuclear bodies. To 
investigate whether the increase in PML body number and size was due to redistribution 
of PML from the nucleoplasm to PML bodies, or whether there was an increase in the 
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total amount of PML present, the YFP PML fluorescence of the whole nucleus was 
quantified.  
 
Figure 4.2.3. Quantification of YFP PML fluorescence following CUL3 
depletion 
(A) YFP PML HeLa cells were transfected with non- targeting control siRNA, a 
pool of 4 siRNAs targeting CUL3, or each of the individual duplexes in the pool. 
72 hours later, cells were fixed with paraformaldehyde, stained with DAPI and 
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imaged using deconvolution microscopy. Immunofluorescence images 
represent maximal projections of multiple z sections.  
(B) YFP PML HeLa cells were transfected with non-targeting, control siRNA or 
4 individual siRNA duplexes targeting CUL3. Cells were fixed, stained with 
DAPI and imaged using deconvolution microscopy. Maximal intensity 
projections were prepared from multiple z sections, and quantitation of YFP 
PML fluorescence was performed to evaluate the size of PML nuclear bodies. 
The total area of PML nuclear bodies was calculated for each cell, and 
averaged for all cells analysed in each condition. Values were normalised to 
that found for NT siRNA transfected cells. 
(C) YFP PML HeLa cells were transfected and imaged as described in (B). 
Maximal intensity projections were prepared from multiple z sections and the 
number of PML bodies per nucleus quantified. Data presented represents the 
average number of PML bodies per cell, normalised to the number of PML 
bodies present in NT siRNA transfected cells. 
(D) YFP PML HeLa cells were transfected with control, non targeting 
(NT) siRNA or a pool of 4 siRNAs targeting CUL3. 72 hours later, cells 
were fixed and stained with DAPI prior to imaging using deconvolution 
microscopy. Maximal intensity projections of multiple z sections were 
prepared and the total YFP PML fluorescence per nucleus was 
calculated. This value was then divided by the area of the nucleus to 
normalise for nuclear size. Data presented is the average of all cells 
analysed for each condition, normalised to the value for NT siRNA. 
 
This demonstrated a 1.3 fold increase in whole nuclear YFP PML fluorescence for cells 
transfected with CUL3 siRNA compared to control cells (Figure 4.2.3., panel D). This 
indicated an increase in the total amount of YFP PML present in the nucleus. This 
increase was modest compared to the increases noted in PML body total area and 
number, suggesting both accumulation and redistribution of YFP PML to PML-NBs 
take place in response to CUL3 depletion. 
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4.2.3 DCUN1D1 depletion results in decreased neddylation of 
CUL3 and accumulation of PML 
As mentioned in section 4.2.1, DCUN1D1, a protein required for the 
neddylation and therefore activation of cullins was identified as a putative hit in the 
siRNA screen. To exclude the possibility that the phenotype identified in the screen was 
due to an off target effect of one of the siRNAs included in the pool of four tested, cells 
were transfected with each of the individual siRNA duplexes and the effects analysed 
by deconvolution microscopy. The resulting images revealed an increase in the number 
and size of PML nuclear bodies for all four of the individual duplexes tested (Figure 
4.2.4., panel A). Quantification of YFP PML fluorescence was then performed. This 
confirmed an increase in the PML body total area for each of the DCUN1D1 siRNA 
duplexes tested. The most pronounced effects were observed in cells transfected with 
the first oligosiRNA, in which a five fold increase in total PML body area was noted 
compared to that of control cells (Figure 4.2.4., panel B). These data confirmed the 
phenotype identified in the screen was recapitulated for each of the individual siRNA 
duplexes tested and was therefore unlikely to be due to an off target effect. 
To investigate whether the effects of DCUN1D1 depletion were mediated by 
effects of this depletion on CUL3, cells were transfected with a non targeting control 
siRNA duplex or a pool of four siRNAs targeting DCUN1D1. Western blotting analysis 
with an antibody specific for PML demonstrated accumulation of high molecular weight 
PML species in cells depleted of DCUN1D1 (Figure 4.2.4., panel C), similar to that 
identified in cells depleted of CUL3 (Figure 4.2.3). Analysis using a CUL3 specific 
antibody revealed a decrease in the high molecular weight, neddylated CUL3 species 
following DCUN1D1 depletion, and accumulation of the lower molecular weight CUL3  
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Figure 4.2.4. DCUN1D1 depletion results in decreased CUL3 
neddylation and PML accumulation 
 (A) YFP PML HeLa cells were transfected with a non- targeting siRNA duplex 
or 4 individual siRNAs targeting DCUN1D1. 72 hours later, cells were fixed 
with paraformaldehyde and stained with DAPI. Cells were then imaged by 
deconvolution microscopy. Immunofluorescence images presented are 
maximal intensity projections of multiple z sections. 
(B) YFP PML HeLa cells were transfected and imaged as in (A). YFP PML 
fluorescence in maximal intensity projections was quantified to calculate the 
total area of each cell nucleus occupied by PML bodies. This was then 
averaged for all cells analysed for each condition. Data presented represents 
the mean total PML body area per cell for each condition, normalised to the 
result for NT siRNA transfected cells. 
(C) YFP PML HeLa cells were transfected with a non- targeting siRNA duplex 
or a pool of 4 siRNAs targeting DCUN1D1. 72 hours later, cells were lysed and 
analysed by western blotting with antibodies specific for PML, CUL3 and actin. 
 
species (Figure 4.2.3. panel C). This demonstrates that DCUN1D1 is required, at least 
in part, for proper neddylation and therefore activity of CUL3. This suggests that the 
effects of DCUN1D1 depletion on PML identified in Figures 4.2.4., panels A-C are 
due to the resulting decrease in CUL3 CRL ubiquitin ligase activity. There is still a 
proportion of neddylated CUL3 present in cells depleted of DCUN1D1 (Figure 4.2.4. 
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panel C), which is likely to be why the accumulation of PML in cells depleted of 
DCUN1D1, maximally a five fold increase in PML body total area (Figure 4.2.4., 
panel B), is less than that observed in cells completely depleted of CUL3, in which up 
to an eight fold increase was identified (Figure 4.2.3., panel B). 
4.2.4 MLN4924 treatment results in accumulation of PML 
MLN4924 is a potent inhibitor of NEDD8 activating enzyme (NAE), and 
therefore prevents neddylation of cullins decreasing cullin-RING ligase activity leading 
to accumulation of their substrates (Soucy et al., 2009). If indeed PML is a substrate of 
a CUL3 ubiquitin ligase complex, it would therefore be expected that PML should 
accumulate in the presence of MLN4924. In order to test this hypothesis, YFP PML 
HeLa cells were incubated with MLN4924 for various periods of time, and the effects 
on PML monitored by western blotting and immunofluorescence. Western blotting with 
a CUL3 specific antibody confirms the loss of the high molecular weight CUL3 species 
and accumulation of the lower molecular weight CUL3 species following 24 hours of 
MLN4924 treatment, confirming the drug has inhibited neddylation of CUL3, and 
therefore inhibited its activity (Figure 4.2.5., panel A). An increase in total PML 
species is noted after MLN4924 treatment, with a particular increase in high molecular 
weight PML species (Figure 4.2.5., panel A). When assessed by deconvolution 
microscopy, an increase in the number and size of PML nuclear bodies is noted after 
twenty- four hours of MLN4924 treatment (Figure 4.2.5., panel B), and this phenotype 
persists after forty-eight hours of treatment. A change in phenotype was seen after 72 
hours of MLN4924 treatment, with the accumulation of PML in numerous small PML 
nuclear bodies (Figure 4.2.5., panel B).  
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Figure 4.2.5. MLN 4924 treatment results in accumulation of PML 
(A) YFP PML HeLa cells were treated with 5µM MLN 4924 and cells lysed at 0, 
24, 48 and 72 hours. Whole cell extracts were then analysed by western 
blotting with antibodies specific for PML, CUL3 and actin. 
(B) YFP PML HeLa cells were treated with 5µM MLN 4924 and cells fixed with 
paraformaldehyde at 0, 24, 48 and 72 hours. Cells were then stained with 
DAPI and imaged using deconvolution microscopy. Immunofluorescence 
images presented are maximal intensity projections of multiple z sections. 
 
These data demonstrated that inhibition of neddylation resulted in accumulation of 
PML, and are consistent with the hypothesis that PML is a substrate of a CUL3 CRL 
ligase, but don’t exclude that PML may be a substrate for other CRLs which would also 
be inhibited by MLN4924. 
4.2.5 Cell cycle analysis following CUL3 depletion 
The number and composition of PML nuclear bodies and posttranslational 
modifications of PML are reported to change throughout the cell cycle. An increase in 
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the number of PML bodies is identified in cells during S phase (Dellaire et al., 2006a), 
with a fall in the number of PML bodies as cells enter mitosis (Dellaire et al., 2006b).  
 
Figure 4.2.6. Cell cycle analysis following CUL3 depletion 
(A) YFP PML HeLa cells were transfected in triplicate with either a non- 
targeting siRNA duplex or a pool of 4 siRNAs targeting CUL3. 72 hours later, 
cells were fixed in ethanol and DNA stained with propidium iodide. The cellular 
DNA content was then assessed by flow cytometry to determine cell cycle 
stage. Data demonstrates the average percentage of cells in G1, S or G2 
phase of the cell cycle for NT siRNA and CUL3 siRNA transfected cells, ± the 
standard error of the mean.  
(B) Whole cell extracts from cells transfected with siRNA as in (A) were 
analysed by western blotting with a CUL3 antibody. 
 
CUL3 ubiquitin E3 ligase complexes have previously been demonstrated to 
regulate mitosis via ubiquitylation of key regulatory proteins (Maerki et al., 2009; 
Sumara and Peter, 2007; Sumara et al., 2007). Given the cell cycle dependent changes 
in PML and the potential disruption of mitosis secondary to CUL3 depletion, the cell 
cycle profile of YFP PML HeLa cells was determined in cells transfected with siRNA 
targeting CUL3. Cells were harvested and stained with propidium iodide 72 hours after 
siRNA transfection, the same time point that the accumulation of PML was noted after 
CUL3 depletion in the siRNA screen. CUL3 depletion was confirmed by western 
blotting of an aliquot of cells from each condition (Figure 4.2.6.). Flow cytometry 
147 
 
analysis of DNA content of the two populations of cells was performed by Dr Rosie 
Clarke, University of Dundee. Data obtained demonstrates only a slight increase in the 
percentage of cells in G2 phase of the cell cycle, with a corresponding decrease in G1 
and S phase population (Figure 4.2.6). These results suggest the accumulation of PML 
identified following CUL3 depletion is not due to the accumulation of cells in a certain 
phase of the cell cycle leading to PML accumulation. 
4.2.6 Attempts to identify BTB adaptor protein  
As discussed in the introduction to this chapter, CUL3 ubiquitin ligases rely on a 
substrate specific BTB domain containing protein to bring substrate into proximity with 
the CUL3 ligase complex (Furukawa et al., 2003; Geyer et al., 2003; Xu et al., 2003). It 
was therefore important to attempt to identify the BTB domain containing protein 
involved in a CUL3 ligase complex responsible for the ubiquitylation of PML.  
4.2.6.1 Investigation of the role of LZTR1 in PML stabilisation 
Data from the original siRNA screen was re-examined to ascertain if any of the 
putative hits identified in the non drug treated dataset were BTB domain containing 
proteins (Table II). LZTR1 is a protein with six N-terminal kelch repeats and two BTB 
domains at the C- terminus (Nacak et al., 2006). This makes it an atypical BTB domain 
containing protein because the BTB domain is usually located at the N- terminus 
(Petroski and Deshaies, 2005). LZTR1 is commonly deleted in the congenital Di 
George syndrome (Kurahashi et al., 1995). Depletion of LZTR1 with a pool of four 
siRNAs in the initial siRNA screen resulted in a 1.5 fold increase in the total area of the 
nucleus occupied by PML bodies (Table II).  
LZTR1 was also investigated in the deconvolution screen described in section 
3.2.5 of this thesis. Four individual siRNAs targeting LZTR1 were transfected into YFP 
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PML HeLa cells and the total area of PML bodies measured 72 hours later. Only one of 
the four siRNA duplexes used recapitulated the phenotype identified in the primary 
screen (Table XIV). This initially led to the phenotype being disregarded as an off 
target effect, however given the increased interest in proteins containing a BTB domain, 
further investigations were performed. 
Table XIV. Deconvolution screen: results for LZTR1 
 
Gene 
Symbol 
Fold change compared to NT siRNA control 
Oligo 1 Oligo 2 Oligo 3 Oligo 4 
LZTR1 0.62 2.50 0.91 1.01 
 
To assess whether all of the four individual siRNAs were effective in targeting 
LZTR1 mRNA for degradation, RT qPCR was employed to assess LZTR1 mRNA 
levels following siRNA knockdown with each of the four individual siRNA duplexes. 
Parallel samples were prepared for immunofluorescence analysis, to allow correlation of 
the degree of mRNA knockdown achieved with effects on YFP PML fluorescence. All 
four of the siRNA duplexes examined reduced LZTR1 mRNA to 50% or less than the 
level identified in control cells (Figure 4.2.7., unfilled bars). However, the degree of 
knockdown did not correlate with the degree of PML accumulation identified by 
immunofluorescence (Figure 4.2.7., grey bars). These results did not correspond to the 
data produced from the siRNA screen either, in which the most pronounced phenotype 
was identified in cells transfected with the second siRNA duplex (Table XIV). 
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Figure 4.2.7. The effects of siRNA mediated LZTR1 depletion 
YFP PML HeLa cells were transfected with either a non targeting control 
siRNA duplex or one of 4 individual siRNA duplexes targeting LZTR1. 72 hours 
later cells were lysed in RNA lysis buffer or fixed with paraformaldehyde. 
LZTR1 mRNA levels were then analysed by RT qPCR to assess knockdown 
efficiency of each LZTR1 duplex (unfilled bars) relative to control. Cells fixed in 
PFA were stained with DAPI  and imaged using deconvolution microscopy. 
Maximal intensity projections of multiple z sections were prepared and YFP 
PML fluorescence of PML bodies was analysed to measure the total area of 
the nucleus occupied by PML bodies. Results were averaged for all cells in 
each condition and normalised to the result obtained for NT siRNA transfected 
cells (grey bars).  
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4.2.6.2 Targeted siRNA screen: BTB domain containing proteins 
To attempt to identify BTB domain containing proteins that may be involved in 
a CUL3 ubiquitin ligase complex responsible for PML ubiquitylation, a repeat high 
content siRNA screen was performed, using 160 pools of siRNA targeting BTB domain 
containing proteins which are within the SCILLS ubiquitome siRNA library to transfect 
YFP PML HeLa cells. To widen the scope for hit identification, the screen was 
performed at two time points, with cells fixed at either 72 or 96 hours after transfection. 
Because the CUL3 siRNA phenotype was identified in cells not treated with arsenic, 
cells were not arsenic treated. The screen consisted of a total of four test plates, two at 
each time point, with non targeting and RNF4 siRNA controls on each plate as 
previously.  Plates were imaged using an automated microscope and analysed using the 
same protocol as for the previous siRNA screens to identify the PML body total area for 
a given cell, averaged for all cells analysed for a particular siRNA.  
The Z’ factor was calculated for each of the assay plates, and the results are 
shown in Figure 4.2.8.. The Z’ factor for plate 1 was satisfactory at over 0.6, but for the 
remaining plates was lower at 0.2. This is similar to the Z’ factors calculated for the 
non- drug treated plates in the previous siRNA screens.  
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Figure 4.2.8. Quality control for BTB domain siRNA screen 
The Z’ factor was calculated for each plate in the siRNA screen using results 
from wells containing the negative control, non targeting siRNA and the 
positive control, RNF4 siRNA. 
 
Due to the low number of siRNAs screened, slightly different criteria were 
adopted for hit identification, with siRNAs scoring as a hit if the total area of PML 
nuclear bodies was outwith 1.3 standard deviations of the mean. This resulted in an 
initial list of fourteen siRNA targets, which was further reduced following image 
analysis. A list of putative hits identified in this screen, and selected for further 
investigation is shown in Table XV. ABTB2 is included because although there was not 
significant accumulation of PML in cells transfected with ABTB2 siRNA, when 
reviewing the images, it was noted the cells contained numerous, small PML bodies, 
which was an interesting phenotype. LZTR1 was not further investigated because the 
experiments described in section 4.2.6.1 had already been performed. 
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Table XV. BTB domain siRNA primary screen: putative hits 
Gene Symbol 
Fold change 
compared to NT 
siRNA control 
LZTR1 3.11 
KCNC1 1.26 
ABTB2 0.84 
ANKFY1 1.09 
KLHL25 1.39 
 
4.2.6.3 Deconvolution siRNA screen- BTB domain containing proteins 
Four individual siRNA duplexes targeting each of KCNC1, KLHL25, ANKFY1 
and ABTB2 were ordered to allow deconvolution of the pools of siRNA tested in the 
primary screen. YFP PML HeLa cells were transfected with these siRNAs, and also 
with four siRNA duplexes targeting each of DCUN1D1 and CUL3 as positive controls, 
and to allow comparison of the phenotype observed in the images following depletion 
of the BTB domain containing proteins with those depleted of CUL3 or DCUN1D1.  
The data from the deconvolution screen was inconclusive. Only one siRNA 
duplex targeting each of KCNC1, ANKFY1 and KLHL25 resulted in a PML body total 
area higher than that identified in control, non target siRNA transfected cells (Table 
XVI, highlighted by red text).  
Table XVI. BTB domain siRNA deconvolution screen: results 
Gene Symbol 
Fold change compared to NT siRNA control 
Oligo 1 Oligo 2 Oligo 3 Oligo 4 
ABTB2 0.645 0.78 0.75 0.905 
ANKFY1 0.875 0.84 0.83 1.19 
KCNC1 0.88 1.145 0.785 0.64 
KLHL25 1.235 0.615 0.915 0.955 
CUL3 2.05 1.955 2.005 2.02 
DCUN1D1 1.94 1.15 1.295 1.07 
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Transfection with positive control siRNAs targeting CUL3 and DCUN1D1 
resulted in accumulation of YFP PML to a similar extent as previously identified in the 
high content screening assay.  
4.2.6.4 Further experiments with siRNA 
Rather than discount the phenotypes identified in the primary siRNA screen as 
off target effects following the deconvolution screen, attempts were made to correlate 
the degree of mRNA knockdown achieved for each of the siRNAs tested with the PML 
phenotype observed by immunofluorescence. Cells were transfected with the individual 
siRNA duplexes, and subsequent mRNA levels assessed using RT qPCR with specific 
primers for each gene target. Parallel samples were prepared for deconvolution 
microscopy, to allow quantification of PML body total area for each of the siRNAs 
tested.  
Each of the siRNAs transfected targeting KCNC1 reduced KCNC1 to less than 
50% of control levels (Figure 4.2.9., panel A, unfilled bars). Accumulation of PML 
was however only detected by immunofluorescence for the first siRNA tested, and this 
accumulation was only marginal (Figure 4.2.9., panel A, grey bars). The siRNAs 
targeting ABTB2 showed varying efficiency at reducing mRNA levels (Figure 4.2.9., 
panel B, unfilled bars), which did not correlate with the accumulation of PML. Three 
of the four siRNA duplexes targeting ANKFY1 resulted in accumulation of PML 
(Figure 4.2.9., panel C, grey bars).However, siRNA duplex 3 which resulted in the 
greatest mRNA knockdown did not lead to accumulation of PML (Figure 4.2.9., panel 
C, unfilled bars). All four of the siRNA duplexes targeting KLHL25 resulted in 
efficient mRNA knockdown (Figure 4.2.9., panel D, unfilled bars), but again, this 
degree of knockdown did not correlate with the degree of PML accumulation observed 
in the microscopy images (Figure 4.2.9., panel D, grey bars). 
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Figure 4.2.9. Analysis of knockdown efficiency and effects on PML of 
siRNAs targeting BTB domain containing proteins. 
(A) YFP PML HeLa cells were transfected with either a non targeting control 
siRNA duplex or one of 4 individual siRNAs targeting KCNC1. 72 hours later 
cells were lysed with RNA lysis buffer or fixed with paraformaldehyde. KCNC1 
mRNA levels were analysed by RT qPCR to assess KCNC1 siRNA knockdown 
efficiency relative to control siRNA (unfilled bars). Cells fixed in PFA were 
stained with DAPI and imaged by deconvolution microscopy. Maximal intensity 
projections of multiple z sections were prepared from the resulting images and 
YFP PML fluorescence of PML bodies was analysed to measure the total area 
of the nucleus occupied by PML bodies. Data were averaged for all cells 
analysed in each condition and normalised to the result obtained for NT siRNA 
transfected cells (grey bars). 
(B) YFP PML HeLa cells were transfected with either a non targeting control 
siRNA duplex or one of 4 individual siRNAs targeting ABTB2. Cells were then 
analysed as in (A). 
(C) YFP PML HeLa cells were transfected with either a non targeting control 
siRNA duplex or one of 4 individual siRNAs targeting ANKFY1. Cells were then 
analysed as in (A). 
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(D) YFP PML HeLa cells were transfected with either a non targeting control 
siRNA duplex or one of 4 individual siRNAs targeting KLHL25. Cells were then 
analysed as in (A). 
 
Unfortunately, these data did not isolate a BTB domain containing protein as a 
likely component of a CUL3 ligase complex responsible for PML ubiquitylation. 
Further experiments were performed to assess the effect of overexpression of these 
proteins on PML stability (data not shown). These failed to demonstrate decreased 
stability of PML in the presence of the overexpressed BTB domain containing protein, 
nor did any of these proteins colocalise at PML nuclear bodies by immunofluorescence 
(data not shown). 
4.2.6.5 GFP IP and mass spectrometry to identify YFP PML 
interaction partners 
Following the limited success in identifying a BTB domain containing adaptor 
protein using siRNA to investigate loss of function phenotypes, a different approach 
was employed to attempt to identify components of an endogenous CUL3-PML 
complex by mass spectrometry.  
Large scale cultures of YFP PML HeLa cells and control HeLa cells expressing 
YFP were lysed, and immunoprecipitation of YFP or YFP PML was performed using 
agarose beads coupled to a single chain, recombinant camelid anti GFP antibody. Eluted 
proteins were separated by SDS-PAGE, and in gel tryptic digestion was performed by 
Dr Mike Tatham, who also performed the mass spectrometry analysis. Approximately 
3000 proteins which had intensity data in both the YFP and YFP PML samples were 
identified, and of these, 37 were found to be enriched in the YFP PML dataset, 
suggesting they were specific interaction partners of PML (Figure 4.2.10.).  
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Figure 4.2.10. Mass spectrometry analysis of YFP PML interacting 
proteins 
Control HeLa cells expressing YFP, and YFP PML HeLa cells were cultured in 
10, 15cm tissue culture plates each, and lysed under non denaturing 
conditions when confluent. Lysates were then subjected to 
immunoprecipitation using agarose beads coupled to a single chain, 
recombinant, camelid antibody specific for GFP. Proteins eluted from the YFP 
and YFP PML immunoprecipitations were separated by SDS PAGE, and the 
gel excised into 5 slices, which were then subjected to tryptic digestion and 
peptide extraction. Samples were analysed by mass spectrometry and 
analysed using MaxQuant software. Intensity data for each protein identified 
were used to calculate the relative abundance of each protein in control YFP 
and YFP PML samples. The scatter plot displays ratios for all proteins 
identified, with proteins significantly enriched in the YFP PML sample 
highlighted in red. 
 
Of the proteins enriched in the YFP PML IP (Table XVII), none have a BTB 
domain. Neither CUL3 nor known interaction partners of PML, for example SUMO, 
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Daxx or Sp100 were identified, which suggests the immunoprecipitation conditions may 
not have preserved these protein- protein interactions. Alternatively, it may be that the 
conditions used were not sufficient to extract PML from PML nuclear bodies which are 
relatively insoluble.  
Table XVII. Proteins found to specifically interact with YFP PML by 
immunoprecipitation and mass spectrometry 
Proteins enriched in YFP PML IP 
PML RPL14 
SYNE2 EMG1 
EIF3A PRPF31 
CLPP ARHGDIA 
MYPN RPL10A 
NNMT TRPS1 
DROSHA PRDX6 
EXOSC5 FAM3C 
KIAA1033 HIST2H2AA3 
BCAP31 RPL19 
DFFA AK3 
BAZ1A EXO3CL1 
TATDN1 AK2 
TSN PSMA3 
IFI30 LAMTOR1 
C1orf135 POLR3B 
PSMA6 RPL13 
GRPEL1 ANKRD5 
HDHD3  
 
4.2.7 MLN4924 treatment of leukaemia cell lines 
Recent publications have documented the sensitivity of leukaemia cell lines and 
primary leukaemia cells to treatment with the NEDD8 activating enzyme inhibitor 
MLN4924 (Swords et al., 2010; Tan et al., 2011). To assess whether accumulation of 
PML may contribute to the induction of apoptosis induced by MLN4924, leukaemia cell 
lines were examined by immunofluorescence after treatment with a therapeutically 
relevant concentration of MLN4924.  
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The myeloid leukaemia cell lines HL60 (Gallagher et al., 1979) and P39 (Nagai 
et al., 1984) were kindly gifted by Mary Hepburn and Sudhir Tauro, Department of 
Haematology, University of Dundee. Both of these cell lines consist of suspension cells 
which grow easily under standard tissue culture conditions. Initial experiments sought 
to characterise the sensitivity of these cells to MLN4924 treatment. Cells were exposed 
to various concentrations of MLN4924 for 72 hours and cell viability assayed using an 
ATP based viability assay. The surviving fraction was calculated for each cell line at 
each drug concentration and IC50 curves and values calculated using GraphPad Prism 
software  (Figure 4.2.11., panel A). The IC50 for HL60 cells was found to be 170nM 
after 72 hours of MLN4924 treatment, with P39 cells more sensitive to MLN4924 
treatment with an IC50 of 130nM.  
Subsequent experiments were performed to assess the effects of MLN4924 
treatment on PML in these cell lines. Using the data obtained from the IC50 calculations, 
a concentration of 150nM MLN4924 was used in subsequent experiments. HL60 and 
P39 cells were treated with MLN4924, using the same cell density as examined in the 
experiments performed to determine the IC50. Following 72 hours of drug or control 
exposure, cells were cytospun onto microscopy slides and stained with antibodies 
specific for PML and SUMO2/3 and examined by deconvolution microscopy (Figure 
4.2.11., panel B). PML bodies are present in control cells of both cell lines examined 
(Figure 4.2.11., panels B and C, DMSO treated cells). In control HL60 cells, the 
SUMO2/3 antibody identified diffuse nuclear staining with punctate accumulations of 
SUMO2/3 which colocalise with PML-NBs, suggesting PML, or other PML-NB 
components are SUMO2/3 modified in these cells (Figure 4.2.11, panel B).  
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Figure 4.2.11. MLN4924 treatment of leukaemia cell lines 
(A) HL60 and P39 leukaemia cell lines were treated with concentrations of 
MLN4924 varying from 50nM to 1µM for 72 hours in multiple replicates and cell 
viability assessed using an ATP based cell viability assay. The surviving 
fraction for each MLN4924 concentration was calculated and the IC50  for 
each cell line calculated using GraphPad Prism software. 
(B) HL60 cells were treated with 150nM MLN4924 for 72 hours. Cells were 
cytospun onto microscope slides, fixed and incubated with anti PML and anti 
SUMO2/3 primary antibodies followed by fluorescently labelled secondary 
antibodies and DAPI staining. Immunofluorescence images presented are 
maximal intensity projections of multiple z sections, PML is shown in red, 
SUMO2/3 in green. 
(C) P39 cells were treated and imaged as described in panel (B). 
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In contrast, very little nuclear SUMO2/3 was identified in P39 cells (Figure 4.2.11., 
panel C). Following MLN4924 treatment, HL60 cell nuclei enlarge and large, bright 
PML bodies are present, which demonstrate SUMO2/3 colocalisation (Figure 4.2.11., 
panel B). The number of PML nuclear bodies in P39 cells is increased after 72 hours of 
MLN4924 treatment, and there is increased diffuse nuclear SUMO2/3 staining, but only 
occasional colocalisation of SUMO2/3 at PML nuclear bodies (Figure 4.2.11., panel 
C). These results confirm that the localisation of PML is altered in leukaemia cell lines 
following MLN4924.  
4.2.8 Conclusions 
Through the use of a high content siRNA screen, CUL3 depletion was noted to 
result in significant accumulation of PML. Further experiments using four individual 
siRNA duplexes to target CUL3 mRNA for degradation demonstrated the same 
accumulation of PML as identified in the primary screen, and quantification of YFP 
PML fluorescence revealed CUL3 depletion resulted in an increase in total cell PML, 
primarily due to accumulation in PML nuclear bodies. 
Depletion of DCUN1D1, a protein required for the neddylation of cullins, was 
also noted to result in accumulation of PML in the primary siRNA screen. Further 
experiments confirmed this to be a true phenotype, with all of four siRNA duplexes 
tested reproducing the phenotype identified in the screen. Western blotting analysis of 
cells depleted of DCUN1D1 revealed decreased neddylation of CUL3, demonstrating 
the effects of DCUN1D1 depletion on PML are likely to be mediated by the reduction 
in neddylated CUL3 capable of forming CRLs. This in turn suggests the ubiquitin ligase 
activity of CUL3 is required for PML accumulation, and a model is proposed in which, 
under basal conditions, PML is ubiquitylated by a CUL3 ubiquitin E3 ligase complex, 
targeting PML for degradation by the proteasome. Thus, the accumulation of PML 
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identified in the absence of CUL3 is due to decreased ubiquitylation of, and therefore 
stabilisation of PML. 
Attempts to identify the BTB adaptor protein component of the CUL3 complex 
responsible for PML ubiquitylation have been so far unsuccessful. A targeted siRNA 
screen of BTB domain containing proteins yielded a list of putative hits which could not 
be confirmed in subsequent experiments. The use of immunoprecipitation of YFP PML 
plus mass spectrometry to attempt to identify BTB domain containing proteins which 
interact with PML was also unsuccessful, probably because PML was inadequately 
purified from cells, given that well characterised PML interaction partners were not 
identified either.  
The inhibitor of neddylation, MLN4924 was identified to alter PML expression 
in both YFP PML HeLa cells and the leukaemia cell lines HL60 and P39. In all three 
cell lines, an increase in the number and size of PML nuclear bodies was identified in 
cells treated with MLN4924, which is likely to be, at least in part, due to the inhibition 
of CUL3 function by this inhibitor. PML is known to sensitise cells to apoptotic stimuli, 
and therefore this accumulation of PML may increase the susceptibility of leukaemia 
cells to MLN4924 induced apoptosis. 
4.3 Discussion 
4.3.1 CUL3 depletion leads to PML accumulation 
The siRNA screen described in Chapter 3 of this thesis identified CUL3 as a 
potential regulator of PML. Deconvolution of the pool of siRNAs used in the siRNA 
screen confirmed that PML accumulated following CUL3 depletion with four different 
siRNA duplexes targeting CUL3 (Figures 4.2.2 and 4.2.3.), suggesting that indeed the 
phenotype identified was due to CUL3 depletion rather than an off target effect. In 
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support of this finding, depletion of DCUN1D1, a NEDD8 E3 ligase responsible for 
neddylation and therefore activation of cullins also resulted in accumulation of PML. 
Further experiments confirmed this effect to be independent of the siRNA sequence 
used to target DCUN1D1 (Figure 4.2.4.), and demonstrated decreased neddylation of 
CUL3 following DCUN1D1 depletion. CUL3 is therefore identified as a substrate of 
DCUN1D1. It is likely that the accumulation of PML identified following DCUN1D1 
depletion is due to decreased activity of a CUL3 RING ligase complex. Of note, RBX1, 
a RING domain containing protein which confers E3 ligase activity to CRL complexes 
was also identified as a hit in the primary siRNA screen (Table II), though was not 
further validated.  
CUL3 depletion results in marked accumulation of PML, which is 
predominantly of higher molecular weight than PML present in control cells (Figures 
4.2.2. and 4.2.4.). This suggests that the PML which accumulates may be post 
translationally modified, and raises the possibility that a CUL3 CRL complex may 
specifically regulate post translationally modified forms of PML. PML is SUMO 
modified at three major sites (Kamitani et al., 1998). It may be that SUMO modification 
at one or more of these residues is required to recruit a CUL3 complex. This could be 
tested using a cell line stably expressing a PML mutant which cannot be sumoylated. If 
SUMO modified PML is the substrate of the CUL3 CRL, this PML mutant would not 
be expected to accumulate in the absence of CUL3. If confirmed, this SUMO specificity 
of the CRL complex would be similar to the SUMO specific recruitment of RNF4 to 
SUMO modified PML following arsenic treatment (Geoffroy et al., 2010; Lallemand-
Breitenbach et al., 2008; Tatham et al., 2008). Post translational substrate modification, 
for example phosphorylation, of the CRL binding site on substrates has been previously 
demonstrated to regulate CRL binding (Wu et al., 2003). CUL3 CRL complexes interact 
with substrate via a BTB domain containing protein (Geyer et al., 2003). If SUMO 
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modified PML is a substrate of such a CRL, it is possible that this specificity for 
sumoylated PML may be conferred by SIM domains in the BTB domain containing 
protein. Thus the CUL3 CRL complex would be recruited to SUMO modified PML via 
SIM domain(s) located in the BTB adaptor protein. A bioinformatics analysis of BTB 
domain containing proteins could be undertaken to identify proteins with putative SIM 
domains. Any identified could then be tested experimentally using an in vitro system to 
test ubiquitylation activity of the resulting CUL3 CRL complex towards PML, or in 
vivo where overexpression of the BTB containing protein would be expected to result in 
PML degradation. 
4.3.2 Attempts at rescue experiments 
The gold standard method for validation of siRNA mediated phenotypes is 
demonstration that expression of an siRNA resistant version of the target gene rescues 
the siRNA mediated phenotype. To this end, attempts were made to create cell lines 
stably expressing an siRNA resistant version of CUL3. Two strategies were employed. 
In the first, YFP PML HeLa cells were transfected with constructs expressing either 
FLAG tagged wild type CUL3 or a version of CUL3 rendered resistant to one of the 
siRNA duplexes tested by virtue of three silent point mutations in the siRNA target 
sequence. In the second, parental HeLa cells were transfected with the same constructs. 
Each of these constructs was designed to express CUL3 at low levels, using the HSV-1 
gD promoter to achieve this (Cuchet et al., 2011). Unfortunately, no colonies stably 
expressing these constructs were isolated following antibiotic selection. This may be 
due to toxicity conferred by CUL3 overexpression. It may therefore be possible to 
create stable cell lines expressing an inducible, siRNA resistant version of CUL3 for use 
in rescue experiments. Attempts were made to demonstrate rescue using transient 
transfections of DNA along with siRNA (data not shown). It proved extremely difficult 
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to achieve satisfactory expression of the siRNA resistant construct at the same time as 
achieving adequate siRNA mediated knockdown of endogenous CUL3.  
Compounds which induced the same effect as siRNA depletion of a gene 
product can be used to validate siRNA mediated phenotypes (Mohr et al., 2010). The 
compound MLN4924 is a potent inhibitor of the NEDD8 activating enzyme. MLN4924 
treatment therefore inhibits cullin neddylation, resulting in accumulation of the 
substrates of CRLs (Soucy et al., 2009). Treatment of YFP PML HeLa cells with 
MLN4924 resulted in inhibition of neddylation of CUL3 and accumulation of PML 
(Figure 4.2.5.). This supports the hypothesis that PML is a substrate of a CUL3 CRL 
complex. Of note, the phenotype identified after 24 hours of MLN4924 treatment 
closely resembled that of CUL3 depletion, with PML accumulating in large PML-NBs. 
After 72 hours of MLN4924 exposure, the appearance of PML-NBs changes, and many 
small PML-NBs were observed. It may be that the later phenotype is due to perturbation 
of other cellular processes induced by long-term inhibition of neddylation. 
4.3.3 BTB domain adaptor protein identification 
Unfortunately, this study failed to identify the BTB domain containing adaptor 
protein component of a CUL3-PML complex. Of note, KLHL20, the substrate adaptor 
previously reported to form part of a CUL3 CRL complex which ubiquitylates PML in 
response to hypoxia (Yuan et al., 2011) was not identified as a hit in the primary screen, 
nor in the rescreen of BTB domain containing proteins. This suggests that this CRL 
complex does not regulate PML under normoxic conditions.  There may be redundancy 
between BTB adaptor proteins which may account for the failure to identify an adaptor 
using siRNA to screen loss of function phenotypes.  
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In a second approach to attempt to identify a BTB domain containing adaptor 
protein, YFP PML and interaction partners were immunoprecipitated from cells and 
subjected to mass spectrometric analysis. This yielded only a small list of interaction 
partners of PML (Table XVII) which did not include well characterised PML-NB 
components, SUMO or ubiquitin. CUL3 depletion results in accumulation of PML in 
PML-NBs, which suggests that CUL3 CRL mediated PML degradation may take place 
within PML-NBs. It may therefore be expected that CUL3 would be found associated 
with PML-NB located PML. Since other PML-NB components were not identified, it is 
possible that PML-NB PML was not extracted under the conditions used. Attempts to 
use increased concentrations of detergents to solubilise PML resulted in loss of all PML 
interacting proteins, when samples were analysed by mass spectrometry (data not 
shown). An alternative approach may be to attempt to purify intact YFP PML bodies 
using differential centrifugation followed by immunoprecipitation using the anti-GFP 
antibody used in this study. This would hopefully allow identification of all elements of 
a CUL3 CRL complex found at PML-NBs, but also provide information regarding other 
proteins present at PML-NBs. 
4.3.4 PML, CUL3 and disease 
CUL3 expression correlates with tumour stage in breast cancer, with increasing 
levels of CUL3 expression found as tumours progress (Haagenson et al., 2012). It 
would be interesting to assess PML expression in such samples. The data presented in 
this chapter suggests PML is a substrate of a CUL3 CRL complex. If this is indeed the 
case, one would anticipate PML expression to be reduced in tumours with high CUL3 
expression. PML has tumour suppressor activities (Gang Wang et al., 1998), and 
therefore the increased CUL3 identified in tumours may drive tumour growth through 
loss of PML. Equally, it would be interesting to assess CUL3 expression in tumours 
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which have been demonstrated to have lost PML expression (Gurrieri et al., 2004) to 
confirm the reciprocal effects. Therapeutic agents that increase PML expression may be 
useful in the treatment of cancers in which PML expression is lost, and this study 
identifies MLN4924 as such a compound. The treatment of leukaemia cells with 
MLN4924 resulted in accumulation of PML in PML-NBs (Figure 4.2.11.) when 
MLN4924 was used at a concentration demonstrated to reduce cell viability by half. 
This accumulation of PML may contribute to the pro-apoptotic effects of MLN4924 
previously described (Swords et al., 2010) by enhancing PML-p53 interactions. The 
contribution of PML accumulation to the cytotoxic effect of MLN4924 could be 
investigated  in PML-/- mice. 
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5 Degradation characteristics of PML isoforms in 
response to arsenic 
5.1 Introduction 
PML is expressed as various isoforms due to alternative splicing. These 
isoforms share a common N terminus, encoded by exons 1-6, but vary at the C terminus 
due to varied expression of exons 7-9 (Jensen et al., 2001a). To assess the role of this 
variable C-terminal region in the response of an individual PML isoform to arsenic 
treatment, a series of cell lines expressing only one of the six major PML isoforms, 
PML I- VI, were treated with arsenic and the response monitored by western blotting, 
immunofluorescence and high content imaging. The post translational modifications of 
the isoforms were characterised by immunoprecipitation, and the effects of depletion of 
RNF4 analysed using RNA interference. 
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5.2 Results 
5.2.1 PML isoforms degrade at different rates in response to 
arsenic treatment 
It is now well established that PML undergoes SUMO dependent, ubiquitin 
mediated degradation in response to arsenic treatment (Geoffroy et al., 2010; 
Lallemand-Breitenbach et al., 2008; Tatham et al., 2008). When assessed by western 
blotting, PML is identified as multiple species representing the different isoforms and 
their post translationally modified forms (Figure 5.2.1). Following arsenic treatment at 
a therapeutically relevant concentration, PML rapidly accumulates as high molecular 
weight species (Figure 5.2.1, 1 hour time point). Previous work has demonstrated this 
to represent modification with SUMO (Geoffroy et al., 2010; Lallemand-Breitenbach et 
al., 2001) and ubiquitin (Geoffroy et al., 2010; Lallemand-Breitenbach et al., 2008; 
Tatham et al., 2008). At later time points, total PML species are reduced due to their 
proteasomal degradation (Figure 5.2.1, 24 and 30 hour time points). However, some 
PML species persist (Figure 5.2.1, arrowhead), indicating that not all forms of PML 
degrade at the same rate in response to arsenic treatment. 
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Figure 5.2.1. PML isoforms appear to respond differently to arsenic 
treatment. 
HepaRG hepatocytes were treated with 1µM arsenic trioxide and lysed after 0, 
1, 4, 12, 24 and 30 hours. Whole cell extracts were analysed by western 
blotting with chicken anti PML and anti tubulin antibodies.  
 
5.2.2 PML and the PML-RARα oncoprotein degrade at 
similar rates in response to arsenic treatment 
The NB4 acute promyelocytic leukaemia (APL) cell line expresses the PML-
RARα fusion (Lanotte et al., 1991) and is a useful model system for investigating the 
effects of therapeutic agents used to treat APL, including all trans retinoic acid (Lanotte 
et al., 1991) and arsenic trioxide (Chen et al., 1996; Chen et al., 1997). The PML-RARα 
fusion product represents a unique PML isoform in which truncated PML is present at 
the N-terminus, with exons 3-9 of RARα forming the C-terminus of the oncoprotein. 
NB4 cells were treated with arsenic trioxide to compare the rates of degradation of 
PML-RARα and endogenous PML (Figure 5.2.2.). Western blotting performed with 
antibodies specific for PML and RARα demonstrated that both PML and the PML-
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RARα fusion are post translationally modified at similar rates following arsenic 
treatment (Figure 5.2.2., 0, 1, 4 hour time points). Analysis after prolonged exposure 
to arsenic reveals similar degrees of degradation of endogenous PML isoforms and 
PML-RARα (Figure 5.2.2., 12 hour time point) which suggests that arsenic induced 
degradation of PML is not absolutely dependent on a sequence within the differentially 
spliced C- terminus of PML. 
 
Figure 5.2.2. PML-RARα and PML degrade at similar rates following 
arsenic treatment 
The NB4 acute promyelocytic leukaemia cell line which contains the PML- 
RARα fusion was treated with 1µM arsenic for 0, 1, 4, 8 and 12 hours prior to 
lysis. Whole cell extracts were analysed by western blotting with chicken anti 
PML, anti RARα and anti actin antibodies. The PML- RARα fusion protein is 
indicated by arrowheads. 
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5.2.3 Characterisation of cell lines expressing only a single 
PML isoform 
To assess the role of the variable C- terminus of PML in determining response to 
arsenic treatment, six cell lines expressing only a single PML isoform were used. These 
cell lines were a kind gift from Roger Everett, MRC- University of Glasgow Centre for 
Virus Research, Glasgow, UK and were previously used to investigate the role of the 
various PML isoforms in repression of herpes virus replication (Cuchet et al., 2011). 
These cell lines were created using HepaRG hepatocytes (Gripon et al., 2002) which 
stably express a short hairpin RNA (shRNA) to deplete endogenous PML (Everett et al., 
2008). Expression of a single eYFP PML isoform was then reconstituted at low levels 
using lentiviral transfection of a eYFP PML construct with expression from the HSV-1 
gD gene promoter (Cuchet et al., 2011).  
Initial experiments sought to characterise PML expression in these cell lines. 
Western blotting with an anti PML antibody demonstrated a different profile of PML 
species for each cell line, representing the expression of the various isoforms and their 
post translationally modified forms (Figure 5.2.3., top panel). Comparison of the PML 
antibody signal in the HALL lane with the HALP lane confirms the specificity of the 
chicken anti PML antibody, because HALP cells are depleted of PML.  There was some 
variation in expression levels of the different isoforms, but none were hugely 
overexpressed when compared to endogenous PML expression (Figure 5.2.3., cf. 
HALL with PML I- PML VI). The profile of SUMO1 and SUMO2/3 conjugates did 
not vary significantly between cell lines (Figure 5.2.3.).  
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Figure 5.2.3. Western blotting of HepaRG cells expressing a single 
PML isoform 
HepaRG cells stably expressing eYFP plus a control shRNA (HALL), eYFP 
plus an anti PML shRNA (HALP) or an anti PML shRNA plus a single shRNA 
resistant eYFP PML isoform fusion (PML I-PMLVI), were lysed and whole cell 
extracts analysed by western blotting with anti PML, anti SUMO1, anti 
SUMO2/3 and actin antibodies. 
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Figure 5.2.4. Fluorescence microscopy of HepaRG cells expressing a 
single PML isoform 
HepaRG cells stably expressing an anti PML shRNA plus a single shRNA 
resistant eYFP PML isoform fusion were fixed and DNA stained with DAPI. 
Cells were then imaged by deconvolution microscopy. Images presented are 
maximal projections of multiple z- sections. eYFP PML is shown in green, 
DAPI in blue. 
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Cells were then examined by deconvolution microscopy (Figure 5.2.4.). Images 
obtained confirmed that all PML isoforms form PML nuclear bodies in the absence of 
other isoforms, presumably due to interaction between PML molecules of the same 
isoform. These images also demonstrated the differences in PML expression noted by 
western blotting in Figure 5.2.3. Cells expressing PML I had numerous, bright PML 
bodies, whereas cells expressing PML V had fewer, smaller PML bodies (Figure 
5.2.4.). There were also some differences in the structure of PML nuclear bodies formed 
by the different PML isoforms. Analysis of cells expressing PML II revealed frequent 
cells displaying thread like structures of eYFP PML II (Figure 5.2.4. arrowheads), 
whereas cells expressing the other PML isoforms displayed punctate, round PML 
bodies. These data suggested that the variable C-terminus of PML influences 
interactions between PML molecules in the formation of PML nuclear bodies which in 
turn influences the structure of the PML bodies formed. 
5.2.4 Characterisation of the response of individual PML 
isoforms to arsenic treatment 
To assess the response of the different PML isoforms to arsenic treatment, cells 
expressing a single eYFP PML isoform were exposed to arsenic for various periods of 
time and whole cell extracts analysed by western blotting (Figure 5.2.5.). All of the 
PML isoforms analysed appeared to be post translationally modified in response to 
arsenic treatment, as demonstrated by a change in electrophoretic mobility of PML after 
one hour of arsenic exposure, with the appearance of high molecular weight PML 
species (Figure 5.2.5.). After twenty- four hours of arsenic treatment, some PML 
isoforms had degraded more than others. Treatment of PML IV resulted in the 
accumulation of high molecular weight PML species, but little or no apparent 
degradation. Conversely, PML V was efficiently degraded following arsenic treatment,  
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with almost no PML species identified after twenty- four hours arsenic exposure. PML 
I, II and VI displayed very similar patterns of response to arsenic treatment: they were 
initially modified, and these modified species were degraded, but there was 
reappearance of a major species that may represent the newly synthesised unmodified 
material that accumulates after twenty- four hours of treatment (Figure 5.2.5.). 
 
Figure 5.2.5. Western blotting of PML isoform expressing cells treated 
with arsenic 
HepaRG cells stably expressing an anti PML shRNA plus a single shRNA 
resistant eYFP PML isoform fusion were treated with 1µM arsenic for 0, 1 or 24 
hours prior to lysis. Whole cell extracts were analysed by western blotting with 
anti PML antibody and anti actin antibodies. 
 
By exploiting the fact that these cells express a eYFP- linked PML isoform, 
deconvolution microscopy was employed to evaluate the subcellular localisation of the 
PML isoforms in response to arsenic. Immunofluorescence microscopy using an anti 
SUMO2/3 antibody reveals that SUMO2/3 colocalised with PML nuclear bodies in all 
cell lines in untreated cells (Figure 5.2.6., panels A-F, 0 hour time point). The initial 
response of all isoforms to arsenic treatment was similar.  
250 -
150 -
100 -
75 -
50 -
0 1 24 0 1 24 0 1 24 0 1 24 0 1 24 0 1 24
kD
PML I PML II PML III PML IV PML V PML VI
Hours of 1uM arsenic
PML
actin
176 
 
 
Figure 5.2.6. Immunofluorescence analysis of PML isoform 
expressing cells treated with arsenic 
(A-F) HepaRG cells stably expressing an anti PML shRNA plus a single 
shRNA resistant eYFP-PML isoform fusion (PML I-PML VI) were treated with 
1µM arsenic for 0, 1 or 24 hours prior to fixation with paraformaldehyde. Cells 
were then analysed by immunofluorescence using an anti SUMO2 antibody. 
eYFP PML is shown in green, SUMO2/3 in red and DAPI in blue. Images 
presented are maximal projections of multiple z- sections.  
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Following 1 hour of arsenic treatment, there was an increase in the number of PML 
nuclear bodies, and an increase in the amount of SUMO2/3 present at these PML bodies 
(Figure 5.2.6., panels A-F, 1 hour time point). This is consistent with the data 
presented in Figure 5.2.5. where an increase in high molecular weight PML species was 
demonstrated after 1 hour of arsenic treatment and suggests that at least part of this 
increase in molecular weight is due to SUMO modification. After 24 hours of arsenic 
treatment, differences in response became apparent. The number of PML bodies present 
was reduced following prolonged treated with arsenic, but PML I appeared to 
accumulate in fewer, larger PML bodies (Figure 5.2.6., panel A). PML I, II and VI 
accumulated in the cytoplasm following prolonged arsenic treatment. This cytoplasmic 
PML did not colocalise with SUMO2/3 suggesting that it had either been desumoylated 
or was newly synthesised and yet to be SUMO modified (Figure 5.2.6., panels A, B 
and F, 24 hour time point). It is possible that the reappearance of an apparently 
unmodified PML species noted in Figure 5.2.5. represents this non- SUMO modified 
cytoplasmic fraction. PML III and PML V appear to be efficiently degraded following 
prolonged arsenic treatment, with a decrease in the number and size of PML nuclear 
bodies observed, and no accumulation of PML in the cytoplasm (Figure 5.2.6., panels 
C and E). Consistent with the observation in Figure 5.2.5., PML IV was not 
significantly degraded following arsenic treatment and accumulated in bright PML 
bodies which colocalise with SUMO2/3 (Figure 5.2.6., panel D).  
5.2.5 High content imaging and quantification of YFP PML 
fluorescence 
To quantify the differences identified in the response of the PML isoforms to 
arsenic, a high content imaging assay was developed to enable automated imaging and 
analysis of eYFP PML fluorescence. Cells were cultured in 96 well plates and treated 
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with arsenic for various lengths of time as indicated previously. Following fixation, 
cells were stained with DAPI and imaged using an IN Cell 2000 automated microscope. 
Resulting images were then analysed using an automated protocol designed to quantify 
the size, number and location of eYFP PML nuclear bodies or cytoplasmic inclusions 
(Figure 5.2.7.). This protocol identified clusters of pixels when eYFP intensity 
exceeded a given threshold above background intensity, and assigned these pixel 
clusters to the nucleus or cytoplasm based on whether they lay within the nucleus as 
defined by DAPI staining.  
 
Figure 5.2.7. Screenshot of high content imaging analysis protocol 
Cells cultured in 96 well plates were imaged using an IN Cell 2000 automated 
microscope, capturing images of eYFP and DAPI signal. Images were then 
analysed using IN Cell Investigator software with a protocol designed to 
identify PML nuclear bodies (yellow outlines) and PML cytoplasmic inclusions 
(pink outlines). 
 
Analysis of the size of PML nuclear bodies and cytoplasmic inclusions 
demonstrated that the total area of the nucleus occupied by PML bodies decreased for 
all PML isoforms analysed except PML IV (Figure 5.2.8., panels A-F, focus on panel 
D). This decrease in PML body total area following 24 hours of arsenic treatment was 
statistically significant for isoforms PML I, II, V and VI. These data also confirmed the 
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cytoplasmic accumulation of PML noted in Figure 5.2.6., with a two to four fold 
increase in the total area of cytoplasmic inclusions noted for PML I, II and VI over the 
course of a 24 hour arsenic treatment. PML V was readily degraded following arsenic 
treatment, with the nuclear PML body total area decreasing by two thirds following 
prolonged arsenic treatment (Figure 5.2.8., panel E), with no appearance of 
cytoplasmic PML. 
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Figure 5.2.8. High content imaging and quantification of eYFP PML 
fluorescence following arsenic treatment: analysis of PML body size 
(A-F) HepaRG cells stably expressing an anti PML shRNA plus a single 
shRNA resistant eYFP-PML isoform fusion (PML I-PML VI) were cultured in 
clear bottomed, black, 96 well plates prior to arsenic treatment for 0, 1 or 24 
hours. Cells were then fixed and stained with DAPI prior to automated, high 
content imaging. Resulting images were analysed using an automated protocol 
(Figure 5.2.7.) to quantify the area of PML nuclear bodies or cytoplasmic 
inclusions. The sum of the area of all PML nuclear bodies or cytoplasmic 
inclusions per cell were averaged for all cells analysed at each time point. Data 
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was then normalised to the amount of nuclear or cytoplasmic PML present in 
untreated cells. Data presented represents the mean normalised total area of 
PML in the nucleus (grey bars, left y axis) or cytoplasm (unfilled bars, right y 
axis) at each time point, ± standard error of the mean. * p<0.05, ** p<0.02 
students t test comparing 0 and 24 hour time points. 
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Figure 5.2.9. High content imaging and quantification of eYFP PML 
fluorescence following arsenic treatment: analysis of number of PML 
bodies per cell 
(A-F) Cells were cultured, arsenic treated and imaged as in Figure 5.2.8.. Data 
were analysed using an automated protocol to count the number of PML 
nuclear bodies and cytoplasmic PML inclusions per cell, which was then 
averaged for all cells analysed for each time point. Data was then normalised 
to the number of PML nuclear bodies or cytoplasmic inclusions in untreated 
cells. Data presented represent the normalised mean number of PML nuclear 
bodies (grey bars, left y axis) and cytoplasmic inclusions (unfilled bars, right y 
axis) for each time point, ± standard error of the mean. * p<0.05, ** p<0.02 
students t test comparing 0 and 24 hour time points 
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The number of PML nuclear bodies and cytoplasmic inclusions were also altered 
by arsenic treatment. Statistically significant decreases in the number of PML nuclear 
bodies present following 24 hours of arsenic treatment were quantified for PML I, II 
and V (Figure 5.2.9., panels A, B and E). Conversely, there was a statistically 
significant increase in the number of PML nuclear bodies present in cells expressing 
PML IV following the same treatment, again confirming PML IV to be the isoform 
most resistant to arsenic mediated degradation (Figure 5.2.9., panel D). Interestingly, 
the number of cytoplasmic inclusions in cells expressing PML I did not increase 
following arsenic treatment (Figure 5.2.9., panel A), demonstrating the increase in total 
area of cytoplasmic PML noted in Figure 5.2.8., panel A is due to the accumulation of 
a limited number of large cytoplasmic inclusions. On the other hand, the number of 
cytoplasmic inclusions counted in cells expressing PML II and PML VI increased two 
fold following arsenic treatment (Figure 5.2.9., panel B and F), suggesting the three 
fold increase in total cytoplasmic PML area noted in Figure 5.2.8., panel B and F was 
due to a combination of an increase both number and size of cytoplasmic inclusions.  
5.2.6 Super resolution imaging reveals differences in PML 
body structure 
As demonstrated in Figure 5.2.4. and 5.2.6., the individually expressed PML 
isoforms form PML nuclear bodies, and these are associated with SUMO modification. 
Previous work has investigated the structure of PML nuclear bodies. Electron 
microscopy with immunolabelling revealed PML bodies to be ring shaped (Boisvert et 
al., 2000; Koken, 1994; Lallemand-Breitenbach et al., 2001) and more recent work 
using high resolution microscopy (Hattersley et al., 2011; Lang et al., 2010) confirmed 
PML bodies to consist of a spherical shell of PML, with SUMO1 and SUMO2/3 found  
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Figure 5.2.10. Super- resolution imaging of PML isoform expressing 
cells treated with arsenic 
(A-F) HepaRG cells stably expressing an anti PML shRNA plus a single 
shRNA resistant eYFP-PML isoform fusion (PML I-PML VI) were treated with 
1µM arsenic for 0, 1 or 24 hours prior to fixation with paraformaldehyde. Cells 
were immunolabelled using an anti SUMO2/3 antibody and a fluorescently 
labelled anti sheep secondary antibody. Cells were then analysed by 
structured illumination. eYFP PML is shown in green, SUMO2/3 in red and 
DAPI in blue. Images presented are progressive z sections though a 
representative PML nuclear body. 
 
predominantly interspersed within the PML shell and in the central core of the PML 
body respectively. The structure of the PML bodies formed by the individual isoforms 
and the changes in structure induced by arsenic treatment was investigated using 3-
dimensional structured illumination microscopy (3D SIM) to obtain super- resolution 
images. The images confirmed that all PML isoforms form nuclear bodies consisting of 
hollow, near spherical shells of PML and that SUMO2/3 is associated with these shells 
(Figure 5.2.10., panels A-F). However, the location of SUMO2/3 in relation to PML 
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differed between isoforms. In untreated cells, SUMO2/3 was found in the central core 
of PML bodies formed by PML I, II and V consistent with previous reports, but 
SUMO2/3 was incorporated into the PML outer shell of the nuclear bodies formed by 
PML III (Figure 5.2.10., panel C). PML VI nuclear bodies had SUMO2/3 in both 
locations (Figure 5.2.10., panel F). Following 1 hour of arsenic treatment, there was an 
increase in SUMO2/3 associated with all PML isoforms, but this was particularly 
marked in cells expressing PML I and V, where there was accumulation of SUMO2/3 
associated with the outer shell of PML as well as in the central core (Figure 5.2.10., 
panels A and E). The most dramatic changes in nuclear body structure were seen after 
24 hours of arsenic treatment. Nuclear bodies were still visible as essentially spherical 
structures consisting of PML and SUMO2/3, but the well defined outer shell of PML 
was no longer seen in cells expressing PML I, II, IV or VI. Rather, PML was present 
both in the outer part of and within the central area of the nuclear body and was seen to 
closely localise with SUMO2/3. Interestingly, in cells expressing PML V, the PML was 
efficiently degraded after twenty four hours of arsenic treatment but the remnants of 
PML nuclear bodies could be identified by a spherical hollow shell of SUMO2/3. This 
may represent a tiny fraction of very heavily SUMO2/3 modified PML, below the limit 
of detection of eYFP- fluorescence or SUMO modification of another component of the 
nuclear body, for example SP100. 
When structured illumination was used to analyse the cytoplasmic inclusions of 
PML I following twenty four hours of arsenic treatment, it was apparent that these did 
not have the spherical structure of PML nuclear bodies (Figure 5.2.11.). Rather, these 
appeared to consist of a disordered mass of eYFP PML with no associated SUMO 2/3.  
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Figure 5.2.11. Super resolution imaging of cytoplasmic PML 
inclusions following arsenic treatment 
(A) HepaRG cells stably expressing an anti PML shRNA plus an shRNA 
resistant eYFP-PML I fusion were treated with arsenic for 24 hours prior to 
fixation and immunolabelling with an SUMO2/3 antibody. Cells were analysed 
by structured illumination. eYFP PML Is shown in green, SUMO2/3 in red and 
DAPI in blue.  
(B) Magnification of area outlined by white box in (A). Images presented are 
progressive z sections through a representative cytoplasmic PML I inclusion.  
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5.2.7 All PML isoforms are SUMO and ubiquitin modified 
following arsenic treatment 
The appearance of high molecular weight PML species following arsenic 
treatment seen for all isoforms examined (Figure 5.2.5.) suggested that all are post- 
translationally modified in response to arsenic treatment. Immunofluorescence 
experiments confirmed an increase in co-localisation of PML and SUMO2/3 following 
arsenic treatment (Figure 5.2.6.), suggesting each isoform is SUMO modified in 
response to arsenic treatment. To biochemically characterise the post- translational 
modifications of the PML isoforms, eYFP PML and its conjugates were 
immunoprecipitated from each of the isoform expressing cell lines after varying 
exposures to arsenic trioxide. The data presented in Figure 5.2.12. demonstrates that all 
isoforms were modified with SUMO1, SUMO2/3 and ubiquitin in response to arsenic 
treatment, although substantial differences between isoforms were noted. While it was 
difficult to compare the amount of SUMO modification between isoforms due to 
differences in PML expression levels, it was possible to analyse the differences in 
modification for any given isoform at different time points after arsenic treatment. 
While PML I, II and V showed a low level of SUMO2/3 modification (Figure 5.2.12., 
panels A, B and E), PML III, IV and VI were essentially unmodified prior to arsenic 
treatment (Figure 5.2.12., panels C, D and F). In untreated cells, SUMO1 and 
SUMO2/3 modification of PML I and II was manifest as a number of distinct species, 
whereas SUMO modification of PMLV was apparent as a high molecular weight smear, 
suggesting it may be modified with polymeric SUMO chains. 
There was a marked increase in SUMO1, and even more substantial increase in 
SUMO2/3 modification of PML I after one hour of arsenic treatment (Figure 5.2.12. 
panel A). 
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Figure 5.2.12. GFP immunoprecipitation confirms all PML isoforms are 
SUMO and ubiquitin modified in response to arsenic 
(A-F) HepaRG cells stably expressing an anti PML shRNA plus a single 
shRNA resistant eYFP-PML isoform fusion (PML I-PML VI) were treated with 
1µM arsenic for 0, 1 or 24 hours prior to lysis under conditions to maintain 
SUMO modification. eYFP PML was then immunoprecipitated from whole cell 
extracts and bound proteins eluted and analysed by western blotting with anti 
PML, anti SUMO1, anti SUMO2 and anti ubiquitin antibodies.  
 
  
A very similar pattern was seen for PML II and PML VI (Figure 5.2.12. panels 
B and F). The increase in SUMO modification appeared slower for other isoforms, with 
the most marked SUMO1 and SUMO2/3 modification of PML III and PML IV taking 
place after 24 hours of arsenic treatment (Figure 5.2.12. panels C and D). Given that 
there was a decrease in the amount of eYFP PML I, II and III immunoprecipitated after 
24 hours of arsenic treatment, the fact there was substantially more SUMO1 and 
SUMO2/3 co-immunoprecipitated at this time point suggests that this small amount of 
PML is extensively SUMO modified (Figure 5.2.12. panels A, B and C).  Data in 
Figures 5.2.5., 5.2.6. and 5.2.8. identified PML IV as relatively stable in the presence of 
arsenic trioxide. The GFP- IP data (Figure 5.2.12. panel D) demonstrated that PML IV 
is modified by both SUMO1 and SUMO2/3 in response to arsenic. There was an 
increase in ubiquitin modification of PML IV after twenty four hours of arsenic 
treatment, but no decrease in the amount of eYFP PML IV immunoprecipitated, 
suggesting that despite ubiquitin modification, the protein is not efficiently degraded by 
the proteasome.  
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5.2.8 The effect of RNF4 depletion on arsenic mediated 
degradation of PML isoforms I-VI 
Having confirmed that all PML isoforms studied are SUMO and ubiquitin 
modified in response to arsenic treatment, the effects of depletion of the SUMO specific 
ubiquitin E3 ligase RNF4 on the response of the different isoforms to arsenic was 
investigated. A pool of siRNAs was used to efficiently deplete cells of RNF4, prior to 
arsenic treatment. The fate of each PML isoform was then monitored by western 
blotting and immunofluorescence, and eYFP PML fluorescence was quantified using a 
high content imaging assay, modified such that cells were transfected with siRNA in 96 
well plates prior to arsenic treatment. High content imaging was performed as described 
previously in the siRNA screening experiments discussed in Chapters 3 and 4 of this 
thesis. 
RNF4 depletion prior to arsenic treatment resulted in the accumulation of high 
molecular weight PML species for all isoforms examined (Figure 5.2.13., panels A 
and D, Figure 5.2.14., panels A and D, and Figure 5.2.15., panels A and D), which 
suggests that, indeed, RNF4 is required for ubiquitylation and subsequent degradation 
of each of the PML isoforms. When cells were examined by fluorescence microscopy, it 
was apparent that this accumulation of PML was within PML nuclear bodies, which are 
demonstrated to be larger and brighter following RNF4 depletion and arsenic treatment 
(Figure 5.2.13., panels B and E, Figure 5.2.14., panels B and E, and Figure 5.2.15., 
panels B and E). This was confirmed by quantification of eYFP PML fluorescence 
(Figure 5.2.13., panels C and F, Figure 5.2.14., panels C and F, and Figure 5.2.15., 
panels C and F).  
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Figure 5.2.13. Effect of RNF4 depletion on the response of PMLI and PML 
II to arsenic treatment 
(A, D) HepaRG cells stably expressing an anti PML shRNA plus either eYFP 
PML I (A) or eYFP PML II (D) were transfected with a pool of 4 siRNAs 
targeting RNF4 or a non targeting control siRNA. 48 hours after transfection 
cells were treated with arsenic for 0 or 24 hours. Whole cell extracts were then 
separated by SDS-PAGE and analysed by western blotting. RNF4 depletion 
was confirmed by immunoblotting with an anti RNF4 antibody. 
(B, E) HepaRG cells stably expressing an anti PML shRNA plus either eYFP 
PML I (B) or eYFP PML II(E)  were transfected with a pool of 4 siRNAs 
targeting RNF4 or a non targeting control siRNA. 48 hours after transfection 
cells were treated with arsenic for 0 or 24 hours. Cells were fixed and stained 
with DAPI prior to imaging by deconvolution microscopy. Representative 
mages are  presented  as maximal intensity projections of multiple z- sections. 
(C, F) HepaRG cells stably expressing an anti PML shRNA plus either eYFP 
PML I(C) or eYFP PML II(F) were transfected with a pool of 4 siRNAs targeting 
RNF4 or a non targeting control siRNA in 96 well plates. 48 hours later, cells 
were treated with arsenic for 0 or 24 hours prior to fixation and DAPI staining. 
High content imaging was then performed and the resulting images were 
analysed using an automated protocol to quantify the size of PML nuclear 
bodies. The sum of the area of all nuclear bodies per cell was averaged for 
each condition and normalised to control siRNA transfected cells at the 0 hour 
time point. Normalised data are presented as the mean ± the standard error of 
the mean of data from two experiments. 
PML I
PML PML
PML PML
DAPIDAPI
DAPI DAPI
30uM
NT siRNA
RNF4 siRNA
0 24
Hours 1uM arsenic
0 24 24
NT siRNA
RNF4 siRNA
Hours of arsenic treatment
R
el
at
ive
nu
cl
ea
r
PM
L
ar
ea
0.0
0.5
1.0
1.5
2.0
250 -
150 -
100 -
75 -
50 -
50 -
37 -
25 -
0 24 0 24
N
T 
si
R
N
F4
 s
i
hours of
arsenickD
PML
RNF4
actin
PML II
30uM
NT siRNA
RNF4 siRNA
0 24
Hours 1uM arsenic
PML PML DAPIDAPI
PML PML DAPIDAPI
0
NT siRNA
RNF4 siRNA
R
el
at
ive
nu
cl
ea
r
PM
L
a r
ea
0.0
0.5
1.0
1.5
2.0
Hours of arsenic treatment
kD
250 -
150 -
100 -
75 -
50 -
50 -
37 -
25 -
0 24 0 24
N
T 
si
R
N
F4
 s
i
hours of
arsenic
PML
RNF4
actin
A B
C
D E
F
193 
 
 
Figure 5.2.14. Effect of RNF4 depletion on the response of PML III and 
PML IV to arsenic treatment 
(A- F) Experiments were performed as in Figure 5.2.13, but cells expressing 
eYFP PML III or eYFP PML IV were used. 
 
 
Figure 5.2.15. Effect of RNF4 depletion on the response of PML V and 
PML VI to arsenic treatment 
(A- F) Experiments were performed as in Figure 5.2.13, but cells expressing 
eYFP PML V or eYFP PML VI were used. 
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The most striking observations were made when cells expressing PML V were 
depleted of RNF4 prior to arsenic treatment. Marked accumulation of PML V was 
observed following RNF4 depletion alone (Figure 5.2.15, panels A-C), which suggests 
PML V is subject to ubiquitylation by RNF4 and subsequent proteasomal degradation 
under basal conditions. This may account for the relatively low levels of PML V 
expression seen in untreated cells, and is also consistent with the observation that PML 
V is the most efficiently degraded isoform in response to arsenic treatment, because it 
appears to be a particularly good substrate for RNF4. 
5.2.9  Conclusions 
The contribution of the variable C- terminus of the various PML isoforms to the 
response of an individual PML isoform to arsenic trioxide treatment was investigated 
using a series of cell lines which express only a single PML isoform, thus allowing 
evaluation of the response of a single isoform in isolation. Western blotting 
demonstrated an accumulation of high molecular weight PML species for all isoforms 
shortly after arsenic treatment, suggesting all are post translationally modified in 
response to arsenic exposure. Following longer arsenic treatment, PML V was 
confirmed to be readily degraded whereas PML IV was not. Immunofluorescence 
experiments confirmed that all isoforms form PML nuclear bodies in the absence of 
other isoforms, and that SUMO2/3 colocalises with these PML nuclear bodies. 
Following arsenic treatment, this colocalisation was increased, suggesting all isoforms 
are modified with SUMO2/3 following arsenic treatment. PML I, II and VI were 
demonstrated to accumulate in the cytoplasm following arsenic treatment. 
Quantification of changes in YFP PML fluorescence after arsenic treatment was 
performed using a high content imaging assay, which confirmed degradation of nuclear 
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PML for all isoforms except PML IV, and a two to four fold increase in cytoplasmic 
PML following arsenic treatment for PML I, II and VI.  
Immunoprecipitation of YFP PML isoforms and their conjugates following 
arsenic treatment demonstrated that all are SUMO1, SUMO2/3 and ubiquitin modified 
after arsenic treatment, but that there is variation in the kinetics of this response. Finally, 
the effect of RNF4 depletion on the response to arsenic of the PML isoforms was 
evaluated using RNA interference. These experiments confirmed the requirement of 
RNF4 for arsenic induced degradation of each of the PML isoforms tested, because in 
the absence of RNF4, PML accumulated in large PML nuclear bodies following arsenic 
treatment. These accumulated PML species were confirmed to be high molecular weight 
species by western blotting, consistent with accumulation of SUMO modified PML. 
Cells expressing PML V showed a particularly dramatic phenotype following RNF4 
depletion, with accumulation of PML V in the absence of arsenic treatment, suggesting 
PML V is constantly degraded in an RNF4 dependent manner in cells under basal 
conditions. 
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5.3 Discussion 
5.3.1 Characterisation of the response of the major PML 
isoforms to arsenic treatment 
SUMO dependent, ubiquitin mediated proteolysis of the PML-RARα fusion 
protein is responsible for cure in Acute Promyelocytic Leukaemia (Lallemand-
Breitenbach et al., 2008; Tatham et al., 2008). Six major nuclear PML isoforms, PML I-
VI are expressed as a result of alternative splicing of the primary PML transcript. These 
isoforms share a common N- terminal region, encoded by exons 1-6, but express unique 
C- termini (Jensen et al., 2001a). The response of  endogenous PML isoforms II, III, IV 
and V to arsenic was assessed using isoform specific antibodies (Condemine et al., 
2006). All isoforms were identified to degrade to similar extent following arsenic 
treatment. By examining endogenous PML isoforms, the response of a single isoform to 
arsenic cannot be clearly ascertained, because interactions between different isoforms 
may influence this process. To avoid such inter-isoform interactions, and allow 
investigation of the role of the unique C- terminal region in the response of individual 
PML isoforms to arsenic treatment, cell lines expressing only a single YFP- linked PML 
isoform (Cuchet et al., 2011) were treated with arsenic. The fate of PML isoforms was 
then monitored using western blotting, fluorescence microscopy and super resolution 
microscopy. The data presented in this thesis therefore represents the first 
comprehensive characterisation of the response of the individual PML isoforms to 
arsenic treatment.  
5.3.2 Susceptibility to arsenic mediated degradation 
It is now well established that PML undergoes proteasomal degradation in 
response to arsenic treatment (Lallemand-Breitenbach et al., 2008; Tatham et al., 2008). 
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The NB4 cell line examined in this study expresses the longest PML-RARα isoform, 
bcr1 (Figure 1.4.1.). The PML breakpoint in this PML-RARα isoform is within intron 6 
and therefore exons 1-6 are encoded. This is equivalent to the common N-terminal 
region expressed by all PML isoforms examined in this study. Like PML VI, PML-
RARα lacks the PML SIM domain. The C terminal region of PML-RARα is encoded by 
exons 3- 9 of RARα. This region includes the DNA binding, hormone binding and RXR 
binding motifs. PML-RARα was efficiently degraded in response to arsenic (Figure 
5.2.2.). This demonstrates that none of the elements encoded within the RARα portion 
of PML-RARα interfere with this process, and also that no single element encoded 
within exons 7-9 of PML is absolutely required for arsenic induced degradation to take 
place.  
Western blotting of endogenous PML after arsenic treatment revealed PML 
species that were relatively resistant to arsenic induced degradation, suggesting that 
different PML isoforms may respond differently to arsenic treatment (Figure 5.2.1.).  
Subsequent arsenic treatment of cells expressing only an individual PML isoform 
confirmed this hypothesis. PML IV was found to be relatively resistant to arsenic 
treatment, while PML V was very readily degraded (Figures 5.2.5.). Western blotting 
analysis of PML IV after prolonged arsenic treatment demonstrates the accumulation of 
high molecular weight PML species. This suggests PML IV is SUMO modified in 
response to arsenic treatment but that this modification fails to trigger degradation. 
Fluorescence microscopy demonstrates PML IV to accumulate in PML-NBs after 
arsenic treatment (Figure 5.2.6.). This is consistent with previous reports that 
degradation of PML takes place in PML-NBs (Geoffroy et al., 2010; Lallemand-
Breitenbach et al., 2001). Immunoprecipitation analysis demonstrates PML IV is 
SUMO and ubiquitin modified following arsenic treatment (Figure 5.2.12., panel D). It 
is not therefore clear why degradation does not take place. One explanation is that 
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PML-NBs formed by PML IV may fail to recruit proteasomal subunits demonstrated to 
be recruited to PML-NBs after arsenic treatment (Lallemand-Breitenbach et al., 2001), 
thus preventing degradation. This would not be identified using a system in which PML 
IV was expressed with a background of endogenous PML expression (Condemine et al., 
2006). Alternatively, PML IV may be ubiquitylated with ubiquitin chains other than 
Lys48 linked chains, for example Lys63 chains which would not target PML IV for 
degradation. 
5.3.3 Localisation of PML after arsenic treatment 
High content imaging was used to quantify YFP-PML fluorescence for each 
isoform after arsenic treatment (Figure 5.2.8.). PML is rapidly targeted to PML-NBs 
after arsenic treatment, where it accumulates in large PML-NBs if RNF4, the ubiquitin 
E3 ligase required for arsenic induced degradation of PML is depleted (Geoffroy et al., 
2010; Lallemand-Breitenbach et al., 2008; Tatham et al., 2008). An assay was therefore 
developed to measure the size of PML-NBs as a measure of degradation, and also the 
size of any cytoplasmic inclusions of PML. This confirmed the differences in 
susceptibility of the different isoforms to arsenic treatment, with PML IV the least 
degraded after 24 hours of arsenic (Figure 5.2.8., panel D). The localisation of PML 
following arsenic treatment also differs between isoforms, with PML I, II and VI 
accumulating in the cytoplasm after prolonged arsenic treatment (Figure 5.2.8., panels 
A, B and F). A recent report (Lång et al., 2012) described the formation of cytoplasmic 
accumulations of PML and nucleoporins (CyPNs) following arsenic treatment in cells 
overexpressing PML I, both on a background of endogenous PML and in cells depleted 
of PML. Here, we identify formation of PML cytoplasmic inclusions for three of the six 
PML isoforms examined (Figure 5.2.6. and Figure 5.2.8., panels A, B and F). PML I, 
II and VI found in cytoplasmic foci following arsenic treatment did not appear to be 
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SUMO modified, because immunofluorescence analysis shows no colocalisation of 
SUMO2/3 with PML in these foci (Figure 5.2.6.). This was described for CyPNs 
reported previously (Jul-Larsen et al., 2009; Lång et al., 2012). The sequence of PML 
VI is common to all isoforms (Jensen et al., 2001a). It is therefore interesting that it 
localises differently to PML III, IV and V in response to arsenic treatment. This 
suggests that elements encoded by the C- terminal regions of PML III, IV and V 
preclude CyPN formation, whereas the C- terminal regions of PML I and II do not. 
The function of CyPNs is not currently clear. In untreated cells, CyPNs appear 
following mitosis and gradually disappear as PML-NBs are reformed in G1 phase. This 
suggests PML is recycled from one generation to the next via storage in CyPNs. In 
contrast, when cells are treated with arsenic these CyPNs are stabilised and PML-NBs 
do not reform (Lång et al., 2012). This suggests PML translocation from cytoplasm to 
nucleus is impaired following arsenic treatment. The cytoplasmic PML isoform, PML 
VII, has previously been demonstrated to be required for transforming growth factor 
beta (TGFβ) signalling (Lin et al., 2004). A proportion of PML localises to the 
endoplasmic reticulum and mitochondrial associated membranes where it regulates cell 
survival by modulating calcium ion transport, thus regulating apoptosis (Giorgi et al., 
2010). It is not clear whether arsenic induced cytoplasmic accumulation of PML I, II 
and VI contributes to these cytoplasmic functions of PML, or whether the sequestration 
exerts effects by preventing nuclear PML functions which are specific to these isoforms.  
5.3.4 Differences in PML body structure 
The structure of PML-NBs has previously been investigated using electron 
microscopy (Boisvert et al., 2000; Koken, 1994; Lallemand-Breitenbach et al., 2001) 
and more recently using high resolution microscopy (Hattersley et al., 2011; Lang et al., 
2010). These studies demonstrated PML to form a spherical shell around a central core 
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which contains SUMO2. In contrast, in APL, the structure of PML-NBs is disrupted and 
vast numbers of small nuclear speckles are identified by immunofluorescent staining 
with an anti PML antibody (Daniel et al., 1993). Each of the individually expressed 
PML isoforms examined in this thesis formed PML-NBs. Differences in the structure of 
these PML-NBs was observed using deconvolution microscopy. PML II was noted to 
form thread like structures as well as punctate PML-NBs. This is in keeping with a 
previous report in which PML II was stably expressed in PML-/- cells (Condemine et 
al., 2006). The other PML isoforms formed punctate PML-NBs, all of which 
colocalised with SUMO2 by immunofluorescence. PML body formation was previously 
demonstrated to require both sumoylation of PML (Lallemand-Breitenbach et al., 2001) 
and the SIM domain of PML (Shen et al., 2006), which is encoded within exon 7a, and 
is therefore present in PML I-V but not PML VI. The current data therefore suggest the 
SIM is dispensable for PML-NB formation because PML VI forms PML-NBs which 
appear structurally similar to those formed by the other isoforms examined, with a near 
spherical outer shell of PML. The presence or absence of other PML-NB constituent 
proteins at PML-NBs formed by PML VI has not been assessed by this study but 
previous work reported robust Sp100, Daxx and ATRX colocalisation at PML-NBs 
formed by PML VI (Cuchet et al., 2011). A number of PML body components have 
SIM domains, and PML VI is sumoylated (Figure 5.2.12.). PML-NB formed by PML 
VI may therefore rely on interactions between the SIM of PML-NB components with 
SUMO modified PML VI. 
To further investigate the structure of PML-NBs, 3D structured illumination 
microscopy was employed to obtain high resolution images of PML-NBs before and 
after arsenic treatment. This demonstrated that nuclear bodies formed by all isoforms 
consist of a spherical shell of PML, and are associated with SUMO2. The distribution of 
SUMO2 differed between isoforms. Consistent with previous reports (Hattersley et al., 
201 
 
2011; Lang et al., 2010), SUMO2/3 was found in the central core of PML-NBs formed 
by PML I, II and V. However SUMO2/3 was incorporated into the outer PML shell of 
PML-NBs formed by PML III.  A number of PML isoform specific interactions have 
been described (Fogal et al., 2000; Yu et al., 2010) and it is likely that isoform specific 
differences observed in PML-NB structures are due, at least in part, to differences in 
interacting proteins recruited to PML-NBs by the different isoforms. The difference in 
SUMO2/3 modification state of each PML isoform is also likely to influence the 
structure of PML-NBs.  
It would be very interesting to use a quantitative proteomics approach to 
investigate PML isoform specific interactions using these cell lines. This would allow 
identification of isoform specific interactions and overcome the problem associated with 
inter-isoform interactions present in cells in which a single isoform is overexpressed on 
a background of endogenous PML. This would help define the contribution of the 
various isoforms to cellular processes in which PML has been implicated. This 
approach could be extrapolated to include assessment of PML isoform interaction 
partners before and after arsenic treatment, which may help confirm the identity of, for 
example, the SUMO E3 ligase(s) responsible for PML sumoylation after arsenic 
treatment. The single chain, recombinant, camelid, anti GFP antibody used in the 
present study provides an excellent method for immunoprecipitating YFP linked PML 
from cells, however previous problems in extracting PML adequately under conditions 
which maintain PML- interaction partner interactions would need to be addressed. One 
option may be purify intact YFP-PML-NBs from cells using the previously mentioned 
antibody. 
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5.3.5 RNF4 is required for degradation of all PML isoforms 
The ubiquitin E3 ligase RNF4 is required for arsenic induced degradation of all 
six PML isoforms examined in this thesis, as siRNA mediated depletion of RNF4 prior 
to arsenic treatment blocks degradation and results in accumulation of high molecular 
weight PML species (Figures 5.2.13., 5.2.14 and 5.2.15). When RNF4 depleted cells 
were examined by fluorescence microscopy, it was apparent that each PML isoform 
accumulated in PML-NBs after arsenic treatment. This is consistent with previous 
reports (Geoffroy et al., 2010; Tatham et al., 2008)(this thesis) in which the localisation 
of endogenous PML or PML overexpressed on a background of endogenous PML was 
examined after RNF4 depletion and arsenic treatment. 
An intriguing finding of this study was the dramatic effect of RNF4 depletion on 
PML V expression under basal conditions (Figure 5.2.15., panel A). RNF4 has been 
previously proposed to ubiquitylate PML under basal conditions because an increase in 
PML expression was identified following RNF4 depletion (Lallemand-Breitenbach et 
al., 2008). While there is a slight increase in expression of PML III following RNF4 
depletion (Figure 5.2.14, panel A), there is marked accumulation of high molecular 
weight PML V species under basal conditions, which are increased further following 
arsenic treatment (Figure 5.2.15., panel A). This suggests PML V is a particularly good 
substrate for RNF4, and may account for the low levels of PML V observed in this 
(Figure 5.2.3.), and other studies (Bernardi and Pandolfi, 2007; Cuchet et al., 2011) . 
This is also consistent with the observation that PML V is the PML isoform most 
readily degraded in response to arsenic treatment (Figures 5.2.5, 5.2.6., panel E and 
5.2.8., panel E). RNF4 is recruited to PML modified with polymeric SUMO chains in 
PML-NBs following arsenic treatment via four SUMO interaction motifs in the N- 
terminal region of the protein (Geoffroy et al., 2010; Lallemand-Breitenbach et al., 
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2008; Tatham et al., 2008). PML V appears to be a particularly good substrate for RNF4 
which suggests that PML V may be more SUMO modified when compared to other 
isoforms. This hypothesis is supported by the observation that when analysed by 
western blotting, PML V is identified as a high molecular weight smear (Figure 5.2.3.), 
and that immunoprecipitation of PML V and analysis of post- translational 
modifications revealed a similar smear of SUMO1 modification, suggesting PMLV is 
modified by multiple SUMO1 molecules (Figure 5.2.12., panel E). PML V has 
previously been suggested to act as a scaffold in PML-NBs, because it is particularly 
stable in PML-NBs when analysed by fluorescence recovery after photobleaching 
(FRAP) (Weidtkamp-Peters et al., 2008). Interestingly, PML mutants which cannot be 
sumoylated at Lys160 and Lys490 have dramatically reduced residence time in PML-
NBs (Weidtkamp-Peters et al., 2008), and therefore the increased residence times 
observed for PML V may be due to its high levels of SUMO modification at one or both 
of these residues. PML V is one of only two PML isoforms conserved from mouse to 
humans (Condemine et al., 2006), which suggests functions dependent on the unique C- 
terminal region of PML V may be particularly important, perhaps including this 
potential function as a scaffold component for PML-NBs. The importance of this region 
of PML V is further supported by the observation that the C-terminal region of PML V 
is capable of forming punctate nuclear structures in the absence of other PML isoforms, 
and recruits other PML-NB components to these structures (Geng et al., 2012). 
5.3.6 Implications for treatment of APL? 
In APL, PML and PML-RARα interact via the PML coiled coil domain. This 
domain is encoded within the common N terminal region of all PML isoforms examined 
in this study, as well as all PML-RARα isoforms (Figures 1.3.1. and 1.4.1.),(Jensen et 
al., 2001a; Melo et al., 2006). This suggests that PML-RARα can interact with all PML 
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isoforms. Interactions between PML-RARα and PML  result in the disruption of PML-
NBs in APL (Daniel et al., 1993). This implies that these interactions interfere with the 
normal functions of the PML isoforms and PML-NBs, events which contribute to the 
pathogenesis of APL.  
 PML-RARα in NB4 cells is rapidly degraded following arsenic treatment 
(Figure 5.2.2.) (Muller et al., 1998). While the degradation of PML-RARα is important 
for cure of APL, it is not sufficient to induce cure, because single agent ATRA 
treatment, which induces degradation of PML-RARα, often results in only short term 
remissions (Huang et al., 1988). ATRA treatment does however result in the 
reformation of PML-NBs, but no degradation of PML. This is in contrast to arsenic 
treatment, following which PML-NBs are reformed prior to degradation of PML 
(Geoffroy et al., 2010; Zhu et al., 1997). Following treatment of the APL derived NB4 
cell line, or cells engineered to overexpress PML-RARα with arsenic, PML and PML-
RARα are rapidly redistributed from the characteristic nuclear speckles associated with 
APL into PML-NBs (Zhu et al., 1997). This also recruits other PML-NB components, 
for example Sp100, to PML-NBs. The reformation of PML-NBs has been postulated to 
contribute to arsenic induced cure of APL, because PML-NBs exert functions in control 
of apoptosis and induction of cellular senescence (de The et al., 2012). The work 
presented in this thesis demonstrates PML I- VI are recruited to PML-NBs following 
arsenic treatment (Figure 5.2.6.), but not all are then degraded. These data therefore 
raise the possibility that differential degradation of PML isoforms in response to arsenic 
treatment may contribute to disease response. PML V is very readily degraded in 
response to arsenic when expressed in isolation (Figures 5.2.5. and 5.2.6., panel E). It 
is therefore unlikely that PML V functions would contribute to cure, because PML V is 
almost completely degraded after 24 hours of arsenic treatment. Perhaps instead the lack 
of PML V results in activation of cellular processes which contribute to cure. 
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Alternatively, other factors recruited to PML-NBs by PML V may dissociate following 
PML V degradation and they may be important for disease response. Conversely, PML 
isoforms which are not readily degraded are likely to continue to function after arsenic 
treatment has been instituted. PML IV is the isoform identified as most resistant to 
arsenic induced degradation. It is therefore likely that the functions of PML IV and 
PML IV specific interactions would persist following arsenic treatment. PML IV has 
been previously shown to directly interact with p53 (Fogal et al., 2000). This interaction 
was dependent on the unique C terminal region of PML IV and resulted in increased 
p53 transactivation (Fogal et al., 2000). The persistence of this PML IV- p53 interaction 
may therefore contribute to arsenic induced apoptosis of leukaemia cells. This may be 
particularly important in leukaemic stem cells, which are relatively resistant to 
conventional chemotherapeutic agents.  
This study therefore implicates differential degradation of PML isoforms, and 
the resulting effects on isoform specific interactions in the cure of APL following 
arsenic treatment. A comprehensive study of PML isoform specific interactions and 
functions as discussed in section 5.3.3 would help delineate the functional effects of 
differential degradation of the various PML isoforms in response to arsenic treatment. 
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